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ABSTRACT
The major allergen of mugwort pollen, Art v 1, is a significant contributor to hay fever in
Europe and North America. A notable motif in Art v 1 – characterized by clusters of contiguous
β-arabinosides of hydroxyproline – was found to be a key recognition element for antibodies
generated in response to the natural protein. This dissertation details the synthesis of oligomers
of β-arabinosides of hydroxyproline and the search to establish the minimal carbohydrate
epitope of Art v 1.
The key issue pertaining to the formation of glycosidic bonds is the α/β selectivity at the
anomeric carbon. To this end, using a 2,3,5-O-benzyl-1-thio-α-L-arabinofuranoside donor, we
were able to obtain the Ara-Hyp monomer in 60% yield with 4:1 β:α selectivity using silver
triflate and N-iodosuccinamide as activators.
A dimer of β-Ara-Hyp was prepared by deprotection of the N- and C- termini of the βAra-Hyp monomer respectively, after which peptide coupling of the two compounds was
performed using HATU as coupling reagent to give the product, Boc-([β-L-Araf]Hyp) 2 -OAll, in
60% yield. Similar approaches were employed using a [2+1] or [1+2] fragment condensation
strategy to produce the trimer, Boc-([β-L-Araf]Hyp) 3 -OAll, in 35% yield. The tetramer, Boc-([β-LAraf]Hyp) 4 -OAll was produced using a [2+2] strategy in 49% yield.
We’ve installed terminal amides on the oligomers to best mimic the extended peptide
found in the natural allergen.

Production of oligomer-specific building blocks (Ac-([β-L-

Araf]Hyp)-OMe, Boc-([β-L-Araf]Hyp)-NHMe) allowed a more convergent synthesis towards the
end-capped oligomers.

With this strategy, end-capped dimer, trimer, and tetramer were

synthesized by fragment condensation in 48%, 35%, and 15% respectively. The end-capped
glycopeptides could then be fully deprotected by global debenzylation to give the final products
in quantitative yield.

xvi

Nuclear magnetic resonance and circular dichroism spectra were obtained for all
synthetic glycopeptides.

Analysis of the CD spectra showed that the glycosylated proline

oligomers exhibit a polyproline type II helical conformation.

While CD spectrum of the

monomer showed that it was unordered, the elliptical curve of dimer, trimer, and tetramer all
exhibited significant PPII characteristics. Spectra obtained from 1H,

13

C, and various 2D NMR

was used for comparison with NMR data taken from the natural allergen.

xvii

CHAPTER 1: INTRODUCTION
1.1 Carbohydrates in Biology
It has been shown over the past couple of decades that carbohydrates play a more
important role in biology1 than previously appreciated.
nature as biopolymers.

Sugars are found in abundance in

Sugars can exist as oligosaccharides, polysaccharides, and/or

glycosides in natural products, many of which display important biological activity.

Many

carbohydrates have specific roles in biological processes ranging from signal transduction2 to
immune response3.
The functions of carbohydrates in living organisms are diverse. For example, heparan
sulphate (Figure 1.1), a linear polysaccharide in proteoglycans, is found on the plasma
membrane of all animal cells and regulates a wide variety of biological activities.4

Gene

mutation leading to the expression of modified proteoglycans has been implicated in conditions
including rib malformations, craniofacial defects, and eye and lens defects.

Figure 1.1 Structure of heparan sulfate subunit
Over 500 N-acetylglucosamine (Figure 1.2) protein conjugates are involved in almost all
aspects of cellular function.5 Both hypo-and hyper-glycosylation of these proteins have been
associated with disease. For example, altered glycosylation of proteins due to nutrient excess
and/or stress has been associated with glucose toxicity,6 a.k.a. type-2 diabetes.

Reduced

glycosylation leading to the hyperphosphorylation of tau proteins may also affect neuronal

1

function. The hyperphosphorylated tau proteins aggregate into neurofibrillary tangles, one of
the proposed mechanisms in the onset of Alzheimer’s disease.7

Figure 1.2 N-acetyl glucosamine (GlcNAc)
Advances in glycobiology and glycochemistry have enabled the development of
carbohydrate-based experimental therapeutics for a variety of diseases, including HIV and
cancer.8 Carbohydrate-based tumor antigens that induce only weak immunological responses
have been successfully conjugated to carrier proteins to illicit a more powerful immune
response.9 Advances in glycopeptide assembly have led to synthetic antitumor vaccines such
as GD3 (Figure 1.3) that are conjugated to keyhole limpet hemocyanin (KLH), a well-known
carrier protein.

Figure 1.3 GD3-Protein conjugate vaccine for melanoma
Various pathogenic bacteria are coated with polysaccharides, glycoproteins, and/or
glycolipids which can be targeted by carbohydrate-rich protein-conjugated antibacterial
vaccines.10

Vaccines against Streptococcus pneumonia, Neisseria meningiditis, and

Salmonella typhi are now commercially available.

2

Carbohydrate-based antiparasitic vaccines are also in development based on the unique
glycoconjugates found on the surface of many parasites.11

Plasmodium falciparum is the

pathogenic parasite responsible for malaria, a disease which kills more than two million people
per year.12 P. falciparum expresses large amounts of glycosylphosphatidylinositol (GPI) on the
surface of its cells. This glycolipid is responsible for the activation of the inflammatory nature of
malaria.

A synthetic hexasaccharide GPI (Figure 1.4) conjugated to a carrier protein was

administered to malaria-infected mice. The mortality rate of the infected mice was reduced to
ten percent.13

Figure 1.4 Synthetic hexasaccharide GPI
1.2. Hydroxyproline-Rich Glycoproteins
The focus of this dissertation, Art v 1, is a hydroxyproline-rich glycoprotein (HRGP).
Glycosides of hydroxyproline (Hyp) in the plant cell wall matrix were originally discovered by
Lamport and co-workers in the 1960s.14 These glycoproteins and proteoglycans are widely
distributed in the plant kingdom15 with functions associated with growth, cell differentiation, and
plant defense.16 The HRGPs can be divided into four groups:

3

1) Extensins - Hyp-rich glycoproteins with repeating sequences such as Ser(Hyp)4 and
are highly glycosylated with oligosaccharides of arabinose.
2) Arabinogalactan proteins (AGPs) - typically contain arabinogalactan (Ara-Gal) chains
that are attached to the protein via a Gal-Hyp linkage.
3) Solanaceous lectins - Hyp-rich lectins that consist of a carbohydrate-binding domain
and an extensin-like domain.
4) proline-rich proteins (PRPs) - a broad classification of molecules that are rich in
Pro/Hyp, but which cannot be classified as any of the previous three groups.
While the HRGP can be divided into groups, there are no distinct boundaries between them. In
fact, Art v 1 draws characteristics of all four HRGP groups.
1.3 Art v 1: the Major Allergen of Mugwort
Artemisia vulgaris (Figure 1.5) is a widespread weed that belongs to the Asteraceae
family. The plant is native to temperate Europe, Asia, parts of North Africa, and has been
naturalized in North America. This species is known by several common names, amongst them
are chrysanthemum weed, wild woodworm, felon herb, and mugwort, and typically blooms from
July to September.

The pollen of this plant is a major contributor to hay fever (allergic rhinitis)

in late summer to early fall. Art v 1, the major allergen of mugwort, is recognized by up to 95%
of mugwort pollen-sensitized patients.17 In Europe, mugwort pollen affects up to 14% of all
patients with pollinosis.18

In industrialized countries of the world, Immunoglobulin E (IgE)

mediated allergy affects more than 40% of the population.19

4

Figure 1.5 Artemisia vulgaris plant
A modular glycoprotein, Art v 1 has a tadpole-like structure that is comprised of two
major domains known as the “head” and “tail” domains. The head domain is similar to protein
sequences found in plant defensins. This globular domain, comprised of amino acids residues
1-55 (Table 1.1), is cysteine-rich and stabilized by disulfide bonds. The tail domain, comprised
of amino acid residues 56-108 (Table 1.2), is the proline-rich domain. This section contains
about 20 proline residues and is heavily hydroxylated and glycosylated. The prolyl domain
facilitates protein folding20 and influences the conformation of the globular domain.21
Table 1.1 Amino acid residues in the “Head” domain
1-10
AGSKLCEKTS

11-20
KTYSGKCDNK

21-30
KCDKKCIEWE

31-40
KAQHGACHKR

41-50
EAGKESCFCY

51-55
FDCSK

Table 1.2 Amino acid residues in the “Tail” domain
56-60
SPPGA

61-70
TPAPPGAAPP

71-80
PAAGGSPSPP

81-90
ADGGSPPPA

.
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91-100
DGGSPPVDGG

100-108
SPPPPSTH

1.4 Natural Versus Recombinant Art v 1
During the primary post-translational modification (PTM) of the polyproline domain of
HRGPs, most of the proline residues are hydroxylated by a prolyl-4 hydroxylase (Scheme 1.1).
The hydroxyprolines are further modified by subsequent O-glycosylation with some type of
carbohydrate molecule(s) during the secondary PTM. The carbohydrates in natural Art v 1
constitute about 30-40% of the mass of the molecule.

Scheme 1.1 Two sequential post translational modifications
The cDNA sequence of the Art v 1 glycoprotein was determined.17 Natural Art v 1 (nArt
v 1) was characterized and expressed in Escherichia coli and produced as the recombinant
allergen (rArt v 1). The major difference between the natural and recombinant allergen is that
rArt v 1 lacks the post translational modifications of the proline rich domain. Any differences
found in biological reactivity of the two allergens could be attributed to the carbohydrate moiety
of the natural versus recombinant allergen.
1.5 Two Novel O-Glycans in the Polyproline Domain
The hydroxyproline-rich domain of Art v 1, also known as the tail section, contains amino
acid residues 56-108. Post translational modification of the tail section gives rise to two novel
O-glycans that have been described by Leonard et al.22 Through the use of high field NMR, in
conjunction with chemical and enzymatic degradation and mass spectrometry, Leonard reported
the existence of a new carbohydrate determinant in Art v 1. The three major peaks of the gel
filtration chromatogram of alkali-degraded nArt v 1 are shown in Figure 1.6.
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Figure 1.6 Gel filtration chromatogram of alkali-degraded nArt v 1. Reprint with permission from
Journal of Biological Chemistry
The first and smallest peak (I) of the gel filtration chromatogram was attributed to
incompletely digested material (Figure 1.6).
attributed

to

hydroxyproline-linked

The second peak (II) was most intense and

arabinogalactan,

which

the

authors

termed

Hyp-

polysaccharide (Hyp-PS). Natural Art v 1 was found to contain an 11.4:1 ratio of arabinose and
galactose residues. Analysis of Hyp-PS showed that it contained arabinose and galactose
residues in a 5.5:1 ratio, about half of all arabinose residues in the glycoprotein. Limited acid
hydrolysis of Hyp-PS saw cleavage of the arabinose units while leaving the trigalactosyl-Hyp
intact with a calculated [M+Na]+ ion mass of 640 Da. When Hyp-PS was treated with α-Larabinosidase, similar results were found indicating that Hyp-PS composed of a galactosyl-core
with α-L-arabinose residues attached. Hyp PS has a β-1,3-linked galactan backbone with side
chains of β-1,6-linked units similar to type II arabinogalactans (arabino-3,6-galactan),23 but with
differing patterns of substituted arabinose residues. Leonard et al. proposed that this be termed
a type III arabinogalactan polysaccharide (AGP). Mass spectrometry indicated that Hyp-PS has
isoforms that contain 5-28 α-linked arabinofuranose residues in the positions indicated in Figure
1.7. β-Glucosyl Yariv reagent (Figure 1.8), a synthetic phenyl glycoside that specifically binds to
arabinogalactan polysaccharides (AGP),24 was used to precipitate natural Art v 1. This positive
test confirms that Hyp-PS is an AGP.
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.
Figure 1.7 The unusual arabinogalactan (Hyp PS); arrows indicate potential sites for further
arabinosylation

Figure 1.8 β-glucosyl Yariv reagent
Type II arabinogalactans have known to be immunogenic with monoclonal antibodies
binding to arabinose-containing epitopes.25

Surprisingly, Hyp-PS bound very weakly to

antibodies from the sera of mugwort-allergic patients.22 A similar glycoprotein from Phleum
pratense also disappointed investigators by its insignificant binding to IgE of patients.26
The final peak (III) in the gel filtration chromatogram of alkali degraded nArt v 1
represents β-L-arabinoside of hydroxyproline (β-L-Araf-Hyp) (Figure 1.6).

Initially, it was

thought that the carbohydrate domain of Art v 1 comprised only of α-arabinose and β-galactose
residues. However, upon treatment of nArt v 1 with α-arabinofuranosidase and β-galactosidase,
8

the product had a calculated mass much larger than the total peptide mass of the carbohydrate
region of nArt v 1 (Figure 1.9). The authors calculated that about 2.5 kDa of unaccounted mass
still remained in the enzymatically treated glycoprotein. This mass was eventually attributed to
16-17 arabinose residues that were resistant to the α-arabinosidase.

-arabinofuranosidase

-Ara

-galactosidase

nArtv1
15 kDa
isoform
13 kDa
isoform

-Gal
-Ara

Figure 1.9 Enzymatic degradation of Art v 1.
Proton and two dimensional NMR data suggested that the 16-17 residues of “dark
matter” were single β-arabinofuranosides linked to hydroxyproline (Figure 1.10a). This novel Oglycan does occur as a monomer, but anywhere from two to four adjacent β-arabinosylated
prolines may be present (Figure 1.10b, 1). Unlike other well-known HRGPs having the Ser-Hyp4
motif, no oligo-arabinosides were found in Art v 1. This second new type of O-glycan did react
with antibodies from the sera of mugwort-allergic patients. As reported earlier, comparison of
the recombinant and natural allergen showed that a number of patients responded only to the
natural Art v 1.27

This means that the post translational modifications, namely proline

hydroxylation and subsequent β-arabinosylation, are influencing the conformation of the
epitopes of the mugwort allergen. While the exact mechanism of the stabilizing effects of
arabinoglycosylated prolines are yet unclear, it has been implicated that β-arabinosides in the
polyproline-domain does influence the allergenicity of Art v 1.21
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Figure 1.10 a) The single β-L-Ara-Hyp motif, b) Tetramer of Hyp-β-arabinofuranoside
1.6 Immunological Studies
1.6.1 In vitro and in vivo testing of Art v 1
T-cells, or T-lymphocytes, are a specialized type of white blood cell that play a central
role in cell-mediated immunity. Initial testing showed that the post-translational modifications
did not influence T-cell recognition of Art v 1.17 In a related study by Jahn-Schmid et al.,
peripheral blood from eighteen mugwort pollen-sensitized patients was collected based on case
history and positive in vitro and in vivo tests. These patients were found to have IgE that
recognized both nArt v 1 and rArt v 1. For this patient group, the nArt v 1 and its recombinant
form elicited similar T-cell responses in peripheral blood mononuclear cells (PBMC) and in
allergen-specific T-cell lines (TCL).28
T-cell epitopes were determined by TCL against both the natural and recombinant
allergen. The T cell proliferation assays utilized thirty-three overlapping 12-mer peptides that
spanned the entire amino acid sequence of rArt v 1.

Out of seventeen patients, fourteen

recognized an Art v 1 epitope at amino acids 22-36 in the cysteine rich region of Art v 1. Five
patients recognized an epitope at amino acids 43-54, also in the cysteine domain. Only two of
seventeen patients exhibited multiple dispersed epitopes, a rather low number in comparison to
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known epitopes of other pollen allergens. A follow up study by this group reported that the
single T cell epitope Art v 122-36 is associated with the expression of HLA-DRB1*01.1*, 29
In the first clinical study of mugwort allergens, Schmid-Grendelmeier and co-workers
investigated the allergenicity of nArt v 1 and rArt v 1 by both in vitro and in vivo experiments.30
Thirty-two patients with mugwort pollen allergy (17 female, 15 male; 16-43 years old) and 10
control subjects (7 female, 3 male; 21-41 years old) were included in this study. The thirty-two
mugwort allergic patients were selected based on having a clinical history of recurrent rhinitis, a
positive skin prick test (SPT) response to mugwort extracts, and increased IgE levels to
mugwort pollen.
The in vitro results agreed with the findings of Jahn-Schmid and co-workers. It was
reported that both nArt v 1 and rArt v 1 alone were able to induce T-cell proliferation in mugwortsensitized patients.

The proliferative responses of PBMCs to rArt v 1 and nArt v 1 were

comparable, the only difference being that the recombinant form required longer incubation
periods to induce lymphocyte proliferation.
The in vivo tests, however, showed that the recombinant allergen elicits a lower SPT and
nasal provocation test (NPT) reactivity than the natural allergen. While rArt v 1 was still able to
elicit positive SPT and NPT, the amount of rArt v 1 required was significantly higher than that for
nArt v 1. The recombinant allergen showed a decrease in the size of the wheals induced in the
SPT, while having a reduced response compared to that of its natural counterpart in the NPT.

1

*Human Leukocyte Antigen (HLA) is the name of the major histocompatibility complex (MHC) in
humans. MHC mediates the interaction of leukocyte (white blood cells) with other leukocytes or body
cells.
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1.6.2 IgE recognition of Art v 1
Immunoblots, radioallergosorbent tests (RAST), and enzyme-linked immunosorbent
assays (ELISA) were used to evaluate the IgE binding properties of natural and recombinant Art
v 1.17 Immunoblots and RAST showed that two groups of patients exist: one group that exhibits
similar IgE recognition of nArt v 1 and rArt v 1, and a second group that showed significantly
lower or no reactivity to the recombinant allergen. ELISA experiments showed that rArt v 1 only
caused a partial (30%) inhibition of IgE binding to nArt v 1.
Oberhuber and co-workers published a paper in 2008 detailing the analysis of IgE
binding profiles in a group of mugwort-allergic patients.27 Sera from 100 pediatric mugwort
allergic patients (62 males, 38 females; 1-19 years old) were tested.

Patients all showed

hypersensitivity to mugwort based on a SPT from mugwort pollen extract and a positive RAST.
In order to evaluate IgE binding activity, ELISA experiments were performed with purified
nArt v 1 and rArt v 1. The natural allergen was recognized by the serum of 79 of the 100
patients. As for the recombinant allergen, only 39 patients’ sera recognized the protein, a 50%
drop in allergen recognition as compared to nArt v 1.
More recent work has shown that glycosylation of the natural Art v 1 protein contributes
to the thermal stability of the allergen in that it aids in the complete refolding of the glycoprotein
after heat denaturization, something that the recombinant allergen could not replicate.20
Razzera and co-workers reported, after comparing NMR chemical shifts of the recombinant and
naturally glycosylated Art v 1, that the carbohydrates in the polyproline domain affect the
defensin domain in the natural molecule (Figure 1.11).21 These results, in combination with the
findings of Himly and Oberhuber et al.,17,

27

strongly suggest that, for a significant group of

patients, the involvement of post-translational modification and the resulting carbohydrates are
crucial in the formation of IgE binding epitopes of Art v 1.
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Figure 1.11 NMR solution structure of Art v 1. a) Defensin domain in dark blue, intermediate
region in blue, and polyproline domain in light blue. b) Ribbon illustration of Art v 1. Reprinted
with permission from Elsevier.
1.7 A Related Allergen from Ambrosia
Altmann and coworkers recently characterized a new allergen, Amb a 4 (Figure 1.12),
from ragweed (Ambrosia artemisiifolia).31 The isolated ragweed pollen protein consisted of a
defensin-like domain with a 50% homology to Art v 1 (Table 1.3).

The C-terminal

hydroxyproline-rich domain contained small amounts of the single hydroxyproline-linked βarabinoside residues also found in Art v 1. The recombinant ragweed protein reacted with the
sera of more than 30% of weed pollen allergic patients.

Figure 1.12 Cartoon representations of Art v 1 and Amb a 4
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Table 1.3 Proline-rich domains of Art v 1 and Amb a 4.

Art v 1
Amb a 4

56
SPPGA
-NPGP

61
TPAPPGAAPP
PPGAPKGKAP

71
PAAGGSPSPP
APSPPSGGGA

81
ADGGSPPPPA
PPPSGGEGGD

91
DGGSPPVDGG
GPPPPEGGEGG

101
SPPPPSTH
GGDGGGE

1.8 Arabidopsis CLV3 Glycopeptide: Another β-L-Arabinoside of Hyp
CLAVATA3 (CLV3) is a glycopeptide gene secreted from Arabidopsis thaliana plants.32
The CLV3 gene is expressed in the shoot apical meristem (SAM), which continuously produces
organs for the plants, and is a key component in the regulation of stem cell renewal and
differentiation.33 Overexpression in the CLV3 gene can lead to developmental retardation.32 It
has been reported that the mature CLV3 peptide found in CLV3-overexpressing Arabidopsis
plants feature a 13 amino acid peptide.34 This peptide features a trans-4-hydroxyproline at the
seventh residue (Hyp7) that is attached to three L-arabinose residues via β-1,2-linkages (Figure
1.13). In testing the restrictions of stem cell activity by synthetic peptides varying in the number
of carbohydrates attached to Hyp7, it was found that the biological activity increased with the
length of the arabinose chain.

Figure 1.13 CLV3

14

1.9 Closing Comments
Small amounts of Art v 1 have been isolated from the pollen of Artemisia vulgaris. The
isolation and chemical characterization of the allergenic epitope of Art v 1, however, is not
practical through extraction and partial degradation of the natural protein.

There is much

difficulty in obtaining pure compounds due to the heterogeneous nature of the glycoprotein.
Chemical degradation techniques typically lead to a complex mixture of amino acids. In order to
clearly identify the carbohydrate motif that contributes to the epitopes of Art v 1, homogenous
compounds of monomer, dimer, trimer, and tetramer must be obtained by way of chemical
synthesis.

This dissertation describes our efforts to synthesize homogenous oligomers of

hydroxyproline β-arabinosides.

The following chapters will present the synthetic methods,

challenges, and triumphs we’ve endured upon our path to this goal.
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CHAPTER 2: SYNTHESIS OF A MONOMER OF 4-O-[β-L-ARABINOFURANOSYL]-(2S,4R)4-HYDROXYPROLINE

2.1 Importance of Arabinosides
Both enantiomers of arabinose exist in nature. β-Linked homopolymers of D-arabinose
can be found in the cell wall of Mycobacterium tuberculosis and Mycobacterium leprae (Figure
2.1),35 while the L-form is an important component of plant cell walls.36 As described in Chapter
1, we are specifically interested in contiguous β-L-arabinofuranosides of hydroxyproline, a motif
that is found in mugwort pollen. We believe this constitutes a significant allergenic epitope of
the Art v 1 glycoprotein. The chemical synthesis of arabinosides, to further investigate their
biological significance, has therefore become an important endeavor.

Figure 2.1 Arabinofuranosyl residues found in the cell wall of mycobacterium
2.2 Challenge of β-Arabinoside Synthesis
Methods for the stereoselective introduction of furanosides are not as well developed as
for their pyranoside counterparts.37 The key issue pertaining to the formation of glycosidic
bonds is the α/β selectivity at the anomeric carbon.
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Two major factors that influence this

stereochemistry are highlighted in Figure 2.2 and will be discussed in more detail in the
following sections.

Figure 2.2 Factors that influence stereochemistry in glycosylation. a) The anomeric effect,
although strong for pyranoses, offers little selectivity for its furanose counterpart.
b)
Neighboring group participation favors the 1,2-trans-glycoside.
2.2.1 The anomeric effect
The anomeric effect is a stereoelectronic effect that describes the tendency of incoming
substitutents on the anomeric carbon of a pyranose ring to prefer the axial orientation. This
effect is typically used by carbohydrate chemists to control the stereoselectivity of a
glycosylation reaction.
The anomeric effect is well understood and controlled for pyranoses that have a strong
conformational preference for a chair (Scheme 2.1),38 but the effect is weak for furanoses and
by itself is not sufficient to influence α/β selectivity.39 Furanoses may have up to 20 low energy
twist and envelope conformations, while able to adopt an infinite number of conformations
differing slightly from those ideal conformations.40 These numerous low energy conformations
can lead to many different transition states during glycosylation that does not bias the anomeric
selectivity.

If the conformations were more rigid, it might be possible to have more

stereocontrol.

Scheme 2.1 Stereoselectivity utilizing the anomeric effect
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The Magnusson group published a paper in 1994 detailing the anomeric effect in
conformationally restricted furanosides.39 They chose a furanose that was fused, at C-3 and C4, with a norbornane ring system (Scheme 2.2). The rigidity of the norbornane ring restricts the
conformational flexibility of the furanose ring. With all the carbons in one plane, the only two
conformations allowed would be those with the oxygen either above (oE) or below (Eo) the plane
of the ring.

Upon O- and S-furanosylation of this fused ring system, they found that the

anomeric substituent did indeed favor what they called the “pax” conformation, which is the
pseudo-axial conformation.

This work showed that with strict conformational control of the

furanose ring, one can control the stereoselectivity of the furanosylation by invoking the
anomeric effect.

Scheme 2.2 Conformational restriction leading to increased anomeric effect in furanoside
2.2.2 Neighboring group participation
Neighboring group participation (Scheme 2.3), a phenomenon widely used to good
advantage by carbohydrate chemists to control stereoselectivity at the anomeric carbon, heavily
favors the formation of the 1,2-trans product. Scheme 2.4 shows the glycosylation of Fmocprotected hydroxyproline allyl ester (4) with a sulfoxide donor 7 having a participating pivaloyl
group at C-2 giving the only the trans product 8.38
formation of the α-arabinoside.
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Unfortunately for us, this would lead to the

Scheme 2.3 Neighboring group participation

Scheme 2.4 Stereocontrol via neighboring group participation
2.3 Previous Efforts to Produce β-Arabinosides
Amongst some of the earliest work in the effort to obtain 1,2-cis-arabinosides,
Claudemans and coworkers employed glycosyl halides (e.g., 10) which were masked at C-2 by
a nonparticipating group, viz a benzyl ether, for the synthesis of 9-β-D-arabinofuranosyladenine
(11) (Scheme 2.5).41 They later reported that, mechanistically, the glycosylation exhibited both
SN1- and SN2-type properties and, regardless of the configuration of the C-1 halide, having a
nonparticipating group at C-2 gave the more stable trans ion pair which would yield the cisproduct.42

Furthermore, the rate of glycosylation was increased with each hydroxyl group

having been protected as an “armed”43 benzyl ether as opposed to a more electron withdrawing
species.44

Scheme 2.5 Early efforts to obtain 1,2-cis-arabinosides
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Prandi and coworkers published papers in 2000 showcasing 1,2,5-orthoester 13 in the
synthesis of a penta-arabinofuranoside of the mycobacterial cell wall (Scheme 2.6).45

The

orthoester intermediate 13 can be converted to either a glycosidic donor 12 or acceptor 14. The
stereoselectivity of the subsequent glycosylation reaction is controlled by the protecting group at
C-2. α-Arabinosidic linkages (viz, 15) could be made with a participating C-2 acetate, while βlinkages (viz, 16) are accessed through a para-methoxybenzyl (PMB) ether at C-2.

Scheme 2.6 Use of 1,2,5-orthoester as donor and acceptor
Intramolecular aglycon delivery (IAD) is a more recent approach to synthesize 1,2-cisglycosides (Scheme 2.7). In this method, the glycosyl acceptor is first tethered to the protecting
group at C-2. Activation of the anomeric leaving group, along with subsequent formation of the
oxacarbenium ion, allows for the delivery of the tethered nucleophile from the same face to form
the new glycosidic bond.

Prandi’s use of a PMB ether (Scheme 2.6) at C-2 to facilitate an

intramolecular aglycon delivery to give only the β-linked polysaccharides is an example of this
strategy.
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Scheme 2.7 Intramolecular aglycon delivery
More recently, Shinohara et al. reported on the synthesis of Arabidopsis CLV3
glycopeptide utilizing IAD for the installation of its β-arabinofuranosidic linkages.34 The CLV3
peptide is a 13 amino acid glycopeptide containing a β-L-triarabinosylated hydroxyproline
(Scheme 2.8, 22). The three arabinose residues are linked to one another via β-1,2-linkages.
Nα-Fmoc hydroxyproline benzyl ester (18) and thioglycoside donor 17 were treated with DDQ to
give the mixed acetal 19 in 74% yield. Activation of the anomeric thio leaving group gave the βglycoside 20 in 82% yield. This process is repeated twice more to give the protected Hyp
triarabinofuranoside 22. Incorporation of the synthetic glycopeptide into the 13 amino acid chain
was done by solid phase peptide synthesis.

Comparison of the mono-, di-, and

triarabinosylated CLV3 peptides showed that increased arabinosylation corresponded to
increased biological activity.

Scheme 2.8 Synthesis of CLV3 glycopeptide utilizing IAD
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Lowary’s group showed that β-arabinofuranosides could be made with high
stereoselectivity through a 2,3-anhydro sugar intermediate 24 (Scheme 2.9).46 Transformation
of a thioglycoside triol 23 into a 5-benzoyl-2,3-epoxide donor 24 was achieved in one step.
Subsequent activation of the leaving group and addition of an alcohol nucleophile gave
glycosides 25 with good β-selectivity.

However, increasing the steric bulk of the alcohol

nucleophile led to lower β-selectivity. Acceptors bearing electron withdrawing protecting groups
also suffered a slight loss in selectivity. Nonetheless, upon treatment of the epoxide 26 with
LiOBn in benzyl alcohol and sparteine (27), the β-arabinoside 28 could be obtained in desired
regioselectivity and great yield.

Scheme 2.9 stereoselective β-arabinosylation through a 2,3-anhydro sugar intermediate
Boons and co-workers devised a practical approach to the stereoselective synthesis of
β-L-arabinofuranosides.47

Bearing in mind that furanosides have many low energy

conformations, the Boons group sought to lock the thioglycoside donor into a conformation that
would favor nucleophilic attack from the β-face. Using density functional theory (DFT) quantum
mechanical calculations, the optimized geometries of the arabinofuranosyl oxacarbenium ion
were found to be the 3E and E3 conformations (Figure 2.3a). The E3 conformation permits a
staggered relative orientation of the substituents for the 1,2-cis attack and thus would favor the
formation of a β-glycoside. In order to apply the principle of conformational restraint, they
employed a 3,5-O-di-tert-butylsilane protecting group that gave a [6,5] bicyclic molecule (Figure
22

2.3b), in which the 6-membered ring would be a chair, locking the furanose ring in the desired
E3 conformation.

Figure 2.3 a) In the 3E conformation, the C-2 substituent is axial, resulting in steric interactions
that favor alpha attack. The E3 conformation allows the C-2 substitutent to be in a pseudoequatorial orientation, favoring a beta attack at the anomeric carbon. b) C-3 and C-5 alcohols
protected as a silyl acetal.
With the thioglycoside donor 29 in-hand, Boons’ group investigated several different
glycosyl acceptors (Table 2.1, Entries 1-3). For most pyranose derivatives with a free primary
alcohol at C-6 (Entries 1 and 2), activation of the donor with NIS/AgOTf provided excellent
selectivity ranging from 15:1 β/α to 100% β, along with good chemical yields, ranging from
82% to 95%. In the one case where the overall yield was only 69%, β-selectivity was 100% (not
shown). Pyranoses with a secondary C-3-OH acceptor (e.g., Entry 3) were also studied under
the same activation conditions. Stereoselectivity in these reactions slipped to 8:1 β/α, while the
yields were in the mid-80’s.
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Table 2.1 Selected examples of glycosylation with L-arabinosyl donors. Reagents and
conditions: NIS/AgOTf, DCM, -30 °C

DONOR

β/α ratio /
YIELD

ACCEPTOR

GLYCOSIDE

β/α = 15/1
91%

1
29

30

31

β only
94%

2
29

32

33

β/α = 8/1
82%

3
29

34

35

β/α = 3/1

4

88%
36

37

30

β/α = 2/1

5

85%
36

32

38
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In order to prove that the conformationally restricted donor 29 was responsible for the
excellent β-selectivity, the same primary alcohols mentioned above were reacted with a 2,3,5tri-O-benzylated thioglycoside donor 36 (Entries 4 & 5). Although the chemical yield remained
good, as expected, the β/α ratio dropped significantly (Entries 1 vs 4, 2 vs 5). This provides
empirical proof of the effectiveness of conformational control in the synthesis of βarabinofuranosides.
Crich and co-workers simultaneously developed a similar approach to assemble the β-Darabinofuranothioglycosyl donor, but first investigated a 3,5-O-benzylidene protected donor (39,
Figure 2.4) since the six membered ring had provided good conformational control in the case of
pyranoses (e.g., glycosylations with 40).48 Unfortunately, in the case of furanosides, donor 39
was difficult to synthesize and found to not be as stable as the silylene protected donor.

In

addition to being less stable, the benzylidene-protected thioglycoside 39 gave rise to lower
β:α selectivity and typically poor yields.49

Figure 2.4 Benzylidene method adapted for β-D-arabinofuranoside formation

Since a more robust protecting group was needed, Crich and coworkers chose to move
ahead with the 3,5-O-(di-tert-butyl-silane) arabinofuranoside donor 29 (Scheme 2.10). The list
of acceptors they employed included methanol, cyclohexanol, and pyranoses with free primary
or secondary alcohols. Based on their success with the synthesis of β-thiomannopyranosides,50
they also decided to investigate the sulfoxide method51 for the formation of βarabinofuranosides. It was interesting that activation of the thioglycoside donor 29 (Scheme
2.10) with NIS/AgOTf and reaction with cyclohexanol provided a β/α ratio of only 1.5:1 (41),
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while activation of the corresponding sulfoxide donor 42 with Tf2O

and reaction with

cyclohexanol provided a β/α ratio of 10:1.

Scheme 2.10 Sulfide and sulfoxide donors. a) cyclohexanol, NIS/AgOTf, CH2Cl2 -30 °C  RT,
b) Tf2O -78°C, 30 min, then cyclohexanol
Other activators were also employed, but in the end the NIS/AgOTf combination
employed by Boons and co-workers still gave the best β/α ratio when it came to using the Larabinofuranothioglycoside as donor. Other methods of activation that did not prove useful
were believed to be less successful because the activators did not completely convert the
donors into glycosyl triflates, a hypothesis that was supported by low-temperature NMR
experiments.49

A point to bear in mind is that only L-arabinosides were activated with

NIS/AgOTf. The D-thioarabinosides in this study were activated in other ways.
Crich concurred with Boons’ hypothesis that the intermediate in the glycosylation is most
likely the oxacarbenium ion in the E3 conformation. Since the publication of these two key
papers, Lowary and co-workers have reported a crystal structure of a 3,5-O-(di-tert-butyl-silane)
arabinofuranoside derivative in which the furanose ring is in an E4 conformation (Figure 2.5).52

Figure 2.5 Crystal structure of 3,5-O-(di-tert-butyl-silane) arabinofuranoside derivative. Reprint
with permission from IUCr.
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Zhu, the first author on the 2007 paper from the Boons group, is now at University
College, Dublin. The Zhu Group’s goal, in a more recent paper, was to directly compare the
NIS/AgOTf activation for glycosylation with L- and D-arabinofuranosyl donors (Table 2.2),
something that neither the Boons nor Crich groups had done.53 3,5-O-(Di-tert-butyl-silane)-Darabinothiofuranoside (ent-29) was used as the donor while several sugars with free primary
and secondary alcohols were used as acceptors. Some of these acceptors were a lot like the
ones that were used by Crich. Glycosylation of the primary alcohols proceeded in good yields
(78% to 90%), with β/α ratios in the range of 2:1 to as high as 6:1. Glycosylation of secondary
alcohols gave comparable β/α ratios, but the yield dropped slightly (not shown). Zhu concluded
that, given the state-of-the-art for the synthesis of β-D-arabinosides, this can still be regarded as
an efficient glycosylating agent.
Table 2.2 Selected comparisons of L- vs D-arabinofuranosyl donors.17
DONOR

ACCEPTOR

β:α ratio /
YIELD

GLYCOSIDE

β:α = 15:1
91%
29

30

31

β:α = 8:1
83%
ent-29

30
43
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(Table 2.2 continued)
DONOR

ACCEPTOR

β:α ratio /
YIELD

GLYCOSIDE

β only
95%
29

44
45

β:α = 5:1
90%
ent-29

45

44

2.4 Current Investigation
Scheme 2.11 shows a tetramer of hydroxyproline-β-arabinoside (1).

Retrosynthetic

analysis shows that we must first prepare the monomer, which in turn requires us to prepare a
donor and acceptor for glycosylation. In light of published results described above, we chose to
adopt the Crich/Boons approach of using a conformationally restricted donor for the synthesis of
our β-glycosides.

Scheme 2.11 Retrosynthetic analysis of tetramer
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The synthesis of the donor begins with a variation on the Guthrie-Smith method54 for the
synthesis of peracylated arabinofuranose (Scheme 2.12).55 This “general” method was also
adopted by Crich.

Commercially available L-arabinose (46) is present in solution as an

equilibrium mixture of the linear and cyclic (both furanose and pyranose) forms.

Low

concentrations of HCl are generated in situ with acetyl chloride and methanol; these reaction
conditions lock the arabinose into the methyl furanoside form. In order to obtain this kinetic
product, the reaction must be stopped at three hours to prevent equilibration to the unwanted
methyl pyranosides. The triol 47 was esterified with acetic anhydride in pyridine to give the
2,3,5-O-acylated methyl furanoside 48. Treatment of the methyl glycoside in acetic anhydride
with acetic acid, followed by sulfuric acid, gave the anomeric acetate 49. Work up with several
washes of NaHCO3 is crucial as the excess acetic acid side product is extremely hard to
remove.

We believe compound 49 to be mostly α-furanoside due to neighboring group

participation of the C-2 acetate. Unfortunately, due to the many low energy conformations of
this compound,37 the NMR spectra were complex and thus an α:β ratio was not determined.

Scheme 2.12 Peracylated arabinofuranoside synthesis
With compound 49 in hand, the next step was to form the thioglycoside donor (Scheme
2.13).

Upon coordination of boron trifluoride to the oxygen of the anomeric acetate, an

oxacarbenium ion is formed that undergoes nucleophilic attack by thiocresol to give
thioglycoside 50. The apparent singlet assigned to the anomeric proton confirms the formation
of the α-anomer, the major product. The β-anomer (not shown in scheme) is hardly visible in
NMR spectra, suggesting <10%. Temperature control during this glycosylation is crucial to limit
the formation of unwanted side products. It is also important that BF3.OEt2 is added slowly to
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the reaction mixture over a span of 10 to 15 minutes. The median yield for this reaction, under
these optimal conditions, is 66% and reproducible on multigram scale.

Scheme 2.13 Preparation of bicyclic silyl acetal donor
Methanolysis of the acetate esters, followed by work-up with an acidic resin, afforded
compound 51.

The triol was dissolved in a 5:1 ratio of CH2Cl2/DMF with 2,6-lutidine as

base/buffer. The dimethylformamide is essential to fully dissolve the very polar triol. After
cooling to 0 °C, di-tert-butylsilyl-bis-triflate was added slowly and the reaction was allowed to
warm up to room temperature overnight. While the 54% yield of silyl acetal 52 is modest, the
purity of the compound obtained is evidenced by the NMR spectra.
We originally attempted benzylation of the C-2 alcohol in compound 52 with sodium
hydride and benzyl bromide according to Crich/Boons (Scheme 2.14),47, 49 but this combination
of reagents gave us product mixtures in which most components were more polar than the
starting material. Upon isolation of these side products, it was apparent that the tert-butyl silyl
group was being cleaved from one of the oxygens, presumably due to adventitious sodium
hydroxide. Around this time, a new paper was published by the Zhu group.53 Interestingly, a
change was noted in the procedure for the benzylation reaction.

Silver(I) oxide in

dichloromethane is now used as the reagent/solvent in place of NaH in THF.

When we

contacted Zhu about the new procedure, he also cited problems with the cleavage of the silyl
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acetal as the reason for the change. In this improved strategy, the silver polarizes the C-Br
bond of the benzyl bromide, facilitating nucleophilic attack by the secondary alcohol of the
arabinoside without subjecting the silyl protecting group to harsh, basic conditions. Compound
29 was the first glycosyl donor prepared in our lab for hydroxyproline arabinosylation.

Scheme 2.14 Benzylation of C-2 alcohol
Synthesis of the glycosyl acceptor was accomplished in one step from commercially
available Boc-L-trans-4-hydroxyproline (53). The carboxylic acid functionality was converted to
the corresponding cesium salt, which reacts with allyl bromide to give the allyl ester 54 (Scheme
2.15). We chose these protecting groups based on how we would like to deprotect them
downstream.

The Boc carbamate would be easily removed by trifluoroacetic acid and is

orthogonal to the allyl ester, which could be removed in a mild manner by palladium (0).56

Scheme 2.15 Preparation of hydroxyproline acceptor
While synthesis of the hydroxyproline acceptor is straightforward, we anticipated that it
would likely give us problems in glycosylation due to its poor nucleophilicity.

Aside from the

secondary alcohol being hindered, the pyrrolidine ring is in a Cγ-exo conformation due to
gauche interactions between the substituents (Figure 2.6).57

This places the hydroxyl

functionality in a pseudo-axial orientation, favored by a hyperconjugative interaction between
the axial hydrogens at Cβ and Cδ and the alcohol at Cγ.58 These effects contribute to the
overall poor nucleophilicity of the alcohol.
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Figure 2.6 Hyperconjugation via σσ* interaction
2.4.1 Glycosylation with the conformationally-restricted glycosyl donor
In our first attempt at the glycosylation of hydroxyproline we followed the procedure
published by Crich, wherein the glycosyl donor was ent-29 (derived from D-Ara) and the
glycosyl acceptor was cyclohexanol (Scheme 2.16).

N-Iodosuccinimide was used as the

activator to form the oxacarbenium ion, followed by the addition of silver triflate to form the
anomeric triflate. The six-membered silyl acetal ring should serve to lock the furanose into the
conformation that favors β-attack. The reaction is messy, however, with a plethora of side
products. Monitoring of the reaction and separation of compounds is also hampered by the fact
that product 55 is not very UV active.

Due to low concentrations of analyte in the test tubes

after flash chromatography, anisaldehyde staining, which is generally used to detect sugar
molecules, is not sufficiently sensitive. Portions of α- and β-anomers collected, even after flash
chromatography, are still rather crude.

We have isolated pure β-glycoside in milligram

quantities by normal phase HPLC that has enabled 1H,

13

C, COSY, HSQC, and HMBC NMR

spectra to be acquired. While we do believe that there is a slight preference for the formation of
the β-glycoside, the poor overall yield (~12% after HPLC) and stereoselectivity ultimately led us
to investigate other glycosidic donors. We were, however, able to fully assign all protons and
carbons in the NMR spectra (Table 2.3).
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Scheme 2.16 Glycosylation of hydroxyproline with silyl acetal donor
NMR resonance assignments are based on the information obtained from one-pulse

13

C

and 1H experiments as well as COSY, double-quantum filtered COSY, 135° DEPT, TOCSY, and
HSQC. These assignments are summarized in Table 2.3.

(a) The Proline Domain
Due to the rotational isomerization of the molecule, a 2:1 ratio of rotamers can be seen
in the 13C and 1H NMR spectra. The 13C resonances at 118.7 (118.3) ppm correlate to a single
carbon, which is secondary according to the 135 ° DEPT spectrum. Correlation between this
carbon and resonance 5.21-5.35 ppm leads to assignment of these signals to the terminal =CH2
of the allyl ester. The COSY spectrum shows correlation of the signals arising from these
olefinic CH2 to a multiplet at 5.85-5.96 ppm, which was therefore assigned as the C-H of the
monosubstituted alkene. This proton is further coupled to two protons of signals 4.55-4.69 ppm
in the COSY 1H spectrum, which is the allylic CH2, as supported also by the

13

C 135 ° DEPT

spectrum. The TOCSY spectrum shows correlation between all five protons.
Multiplets at 2.08-2.15 ppm and 2.35-2.49 ppm can be attributed to a pair of
diastereotopic protons with rotational isomerization peaks identifiable by the HSQC spectrum.
The chemical shifts would suggest that they are the beta protons of the proline. As expected,
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the beta proton signals showed correlation with two other proton signals at 4.40 ppm and 4.29
ppm in the 1H-1H COSY spectrum, that were assigned to Hα (showed no other cross peak) and
Hγ respectively. The Hγ showed further correlation with a pair of diastereotopic protons (3.583.69 ppm) (who are also correlated with each other) assigned to Hδ. The HSQC spectrum
confirms that they are connected to a single carbon.

TOCSY spectrum shows correlation

between all six protons of the pyrolidine ring spin system.
The

13

C resonances at 172.7 (172.4) ppm can be assigned to the ester carbonyl

functionality of the Boc group. The quaternary carbon of the tert-butyl group can be assigned to
the 13C resonances at 80.2 (80.1) ppm, and 135° DEPT spectra shows those resonances to be
missing. The primary carbons of the tert-butyl group can be assigned to the

13

C resonances at

28.2 (28.4) ppm, and the HSQC spectra confirms that there are 3 protons connected to each at
1.38 (1.45) ppm on the 1H spectrum.
(b) The Arabinose Domain
The anomeric proton signal can be confidently assigned to the resonance at 4.97 (4.93)
ppm. The coupling constant here is 5.3 Hz, and is in the expected range for β-anomers of
arabinosides (c.f., 3J12= 1-3 Hz for α-arabinosides).10 There are two doublets for H1, as a
consequence of the rotational isomerization of the molecule.

The anomeric signal is in

correlation with one other proton at 3.90 ppm (COSY), which we assign as H2. The TOCSY
spectrum shows correlation between the anomeric proton, H2, and four other signals. Two of
these signals, 4.30 ppm and 3.88 ppm, show correlations to the same carbon in the

13

C-1H

HSQC spectrum; they are diastereotopic H5 protons of the arabinose ring. The remaining two
signals, 3.59 ppm and 4.28 ppm, are assigned to H4 and H3 respectively.
The aromatic protons can easily be assigned to the multiplet at 7.29-7.40 ppm. HSQC
data shows five distinct carbon peaks ranging from 127.7-128.3 ppm, along with a quaternary
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carbon at 137.7 ppm, that directly correlate to the aromatic carbons of the benzyl group. One of
the two benzyl CH2 signals can be seen clearly in the 1H NMR spectra with a coupling constant
of 12.2 Hz. TOCSY shows correlation between all aromatic protons and even long range cross
peaks with the benzyl CH2.
The two singlets at 0.99 ppm and 1.07 ppm, with a total of 18 Hs, can be assigned to the
protons of the two tert-butyl groups of the silyl acetal. The resonances 27.1 ppm and 27.5 ppm
in the

13

C spectra can be assigned to the primary carbons of the tert-butyl group, while the

quaternary carbons are at 20.1 ppm and 22.6 ppm.
Table 2.3 Chemical Shifts for β-Glycoside 55β.
L -Ara
H1
H2
H3
H4
H5
CH2Ph
SitBu2

1

CH2Ph

7.29-7.40

Hyp
Hα
Hβ

13

H ppm
4.97 (4.93)
3.90
4.31
3.59
3.88, 4.31
4.69-4.80
0.99, 1.07

C ppm
99.2 (100.0)
80.7
78.4
73.6 (73.4)
68.4
71.8 (71.9)
20.1 (4°), 22.6 (4°),
27.1 (1°), 27.5 (1°)
127.7, 127.8, 127.9,
128.0, 128.4, 137.7 (4°)

Hγ
Hδ
Boc (tert-butyl)

4.36-4.44
2.08-2.15,
2.35-2.42 (2.43-2.49)
4.30
3.64
1.38 (1.45)

COOR
CH2CH=CH2
CH2CH=CH2
CH2CH=CH2

4.55-4.69
5.85-5.96
5.21-5.35

58.1 (57.7)
37.6 (36.8)
75.2
51.1 (51.6)
80.2 (80.1) (4°)
28.2 (28.4) (1°)
153.7 (154.2), 172.7 (172.4)
65.5 (65.6)
131.7 (131.9)
118.7 (118.3)

*Values in parentheses relate to the minor rotamer about C(=O)N bond of the carbamate.
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Crich’s glycosylation of cyclohexanol with a sulfoxide donor (Scheme 2.10, 42) gave an
average yield but great diastereoselectivity.

With the Taylor Group’s past experience with

sulfoxide donors,38 this was the next logical approach. Developed by Kahne and coworkers in
1989,59 the sulfoxide method has proven useful in the glycosylation of sterically hindered
nucleophiles. The sulfoxide donor 42 was made by oxidation of the sulfide donor 29 with mCPBA, after which we were able to separate the pair of diastereomers (Scheme 2.17).
Unfortunately, the same problems that plagued the sulfide glycosylation still existed, and we
were not able to acquire better yields or selectivity under these conditions.

Scheme 2.17 Glycosylation of hydroxyproline with sulfoxide donor
We also briefly investigated a method that would give absolute β-selectivity in
glycosylation. Intramolecular aglycon delivery (IAD) allows for the tethering of the nucleophile to
the O-2 substitutent in a process that would only allow for the formation of a 1,2-cis-glycoside.
As described in Section 2.3, Prandi published a paper in 2000 that utilizes this method for the
construction of β-arabinofuranosides that used a para-methoxybenzyl ether as the tethering
agent (Scheme 2.18, vide supra).45a Efforts to synthesize 56 with para-methoxybenzyl bromide
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and sodium hydride in THF were unsuccessful due to silyl acetal cleavage.

A recent

publication by the Ito group gave us another avenue to explore the concept of IAD through the
formation of a 2-napthyl ether.60 Compound 57 has been synthesized in our lab in modest yield.
The bulkiness of the naphthylmethyl group makes for a difficult nucleophilic attack by the
secondary alcohol. We had synthesized enough of compound 57 that it was possible for us to
move on to the next step of tethering the hydroxyproline nucleophile with DDQ, although the
instability of the silyl acetal functionality concerned us relating to future reactions.

Scheme 2.18 Intramolecular aglycon delivery strategies
Ito and coworkers have shown that a 3,5-O-tetra-i-propyldisiloxanylidene protection was
optimal in giving β-selectivity when applied to arabinofuranosides.61 This method, much like the
silyl acetal employed by Boons and Crich, used the conformational restriction of the eight
membered disiloxane ring to promote the synthesis of the β-anomer. We decided to try this
method in the hope that the eight membered disiloxane ring would be more robust under both
basic and glycosylating conditions. Treatment of thioglycoside triol 51 in amine base and 1,3dichloro-1,1,3,3-tetraisopropyldisiloxane gave the bicyclic donor 58 in modest yield (Scheme
2.19). Much to our dismay, the eight membered disiloxane ring was no more stable than the
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six-membered silyl acetal ring. Subsequent exposure to sodium hydride again showed the
cleavage of the 3,5-O-protecting group and compound 59 was obtained in unsatisfactory yield.

Scheme 2.19 Preparation of disiloxane donor
2.4.2 Conformationally unrestrained donor
We decided to test a fully benzylated thioglycoside donor (compound 60, Scheme 2.20)
to confirm our suspicion that the labile silyl protecting groups were the cause of our low yields.
Compound 51 was transformed into the tri-O-benzyl arabinofuranothioglycoside 60 using
standard methods (benzyl bromide, NaH, DMF) in great yield. The success of this benzylation
reaction reinforced our hypothesis about the shortcomings of the 3,5-O-silyl protecting groups.
Just to be thorough, we also made the corresponding sulfoxide 61 in good yield.

Scheme 2.20 Preparation of two conformationally unrestrained donors
Lowary and coworkers, in their synthesis of a naturally-occurring, highly branched
arabinofuranosyl hexasaccharide, had reported a surprising highly stereoselective synthesis of
β-arabinofuranosides.62

Using N-iodosuccinimide and silver triflate as activator, the

hexasaccharide 63 was obtained in high yield and with 100% β-selectivity (Scheme 2.21). The
authors reported that careful control of temperature is critical as an increase in side products
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was observed when the reaction was run at -40 or 0 oC. We employed this procedure in the
hope of finding similar success for our purpose.

Scheme 2.21 Low temperature glycoysylation method
To our delight, reaction of thioglycoside 60 with our hydroxyproline acceptor gave a
reasonable yield (60%) with an average β:α ratio of 4:1 (Scheme 2.22), a significant
improvement relative to Scheme 2.16 in both aspects. Also important is the fact that we are
able to separate the α- and β-anomers by means of flash chromatography, an added bonus that
would save us much time and grief as compared to HPLC. Careful upscaling of this reaction
has allowed us to do the glycosylation on a multigram level, and we are able to obtain
spectroscopically pure β-glycoside up to a gram at a time. Further advantages of this route
include saving one linear step in the overall synthesis while also substituting for two reactions
that gave typical yields of ~35% (silyl acetal protection, benzyl ether protection) with a single
protection step that yields up to 90% (benzylation). The tri-O-benzylated arabinofuranosides are
robust and can withstand a variety of acidic and basic conditions.

Down the line, the

perbenzylated arabinosides can be deprotected by a single hydrogenolytic step to remove all
benzyl ethers.

39

Scheme 2.22 Glycosylation of hydroxyproline with benzylated sulfide donor
We also applied the sulfoxide method to making our β-arabinosides of hydroxyproline
(Scheme 2.23). The sulfoxide donor 61 is activated by triflic anhydride and a sterically hindered
amine base acts as a buffer for the reaction. The sulfoxide glycosylation gave similar yields but
offered far superior selectivity (25:1 β:α by integration of anomeric proton) than its sulfide
counterpart. However, the reaction was plagued by side products that are indistinguishable
chromatographically from our wanted compounds.

Moreover, the stability of the triflic

anhydride, even when left unopened, is a deterrent for this reaction compared to the relatively
stable NIS/AgOTf. This practical application, in combination with the extra step required to form
the sulfoxide, led us to favor the sulfide donor 60 for the large scale preparation of the βmonomer. β-Glycoside 64β has been fully characterized by mass spectromery, 1H,
D NMR spectra.

Scheme 2.23 Glycosylation of hydroxyproline with benzylated sulfoxide donor
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2.5 Experimental Section
General methods: All reactions were performed under a dry nitrogen atmosphere unless
otherwise noted. Reagents were obtained from commercial sources and used directly;
exceptions are noted. Diisopropylethylamine, triethylamine, and pyridine were dried and distilled
from CaH2 and stored over KOH pellets. Ethanol and methanol were distilled from Mg turnings
and stored over 3 Ǻ molecular sieves. Flash chromatography was performed using flash silica
gel (32-63 μ) from Dynamic Adsorbents Inc. Reactions were followed by TLC on precoated
silica plates (200 μm, F-254 from Dynamic Adsorbents Inc.). The compounds were visualized by
UV fluorescence or by staining with ninhydrin, KMnO4, or 10% sulfuric acid in ethanol stains.
NMR spectra were recorded on Bruker DPX-250, AV-400-liquid, or Varian 700 MHz
spectrometers. Proton NMR data is reported in ppm downfield from TMS as an internal
standard. Disodium 3-trimethylsilyl-1-propane-sulfonate (DSS) was used to reference 1H NMR
spectra run in D2O. High resolution mass spectra were recorded using either time-of-flight or
electrospray ionization.
2.5.1 Experimental procedures

(2.1)
Peracylated-α-L-Arabinoside (49). L-Arabinose (5.0 g, 33.3 mmol, 1 equiv.) was dissolved in
methanol (100 mL) and treated with a solution of acetyl chloride (2.5 mL) in methanol (30 mL) at
rt under N2. The mixture was stirred for 3 h, during which time the solid completely dissolved.
The reaction was quenched dropwise with pyridine. The solvent was evaporated, followed by
azeotroping with DCM to give the methyl arabinoside as a mixture of anomers. The crude
product was dissolved in pyridine (40 mL) and cooled to 0 °C, after which acetic anhydride (20
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mL) was added and the reaction was stirred overnight at rt.

The solvent was evaporated and

the mixture was diluted with CH2Cl2 (250 mL), washed with water (250 mL), 1 M HCl (250 mL),
sat. NaHCO3 (250 mL), and brine (250 mL). The organic phase was filtered through MgSO4
and concentrated to give the triacetate. The crude product was dissolved in acetic anhydride
(80 mL) and cooled to 0 °C. Acetic acid (20 mL) was added dropwise. After 15 min, sulfuric
acid (5 mL) was added dropwise. The mixture was warmed to rt while stirring for approximately
2 h. The solution was poured over a mixture of ice (50 g), CH2Cl2 (250 mL) and sat’d aq.
NaHCO3 (200 mL). The organic layer was separated and washed again with several volumes of
sat’d aq. NaHCO3, filtered through MgSO4, and concentrated to give the crude peracylated
furanoside as a light oil (9.071 g, 85%; 3 steps).

(2.2)
p-Cresyl 2,3,5-O-acetyl-1-thio-α-L-arabinofuranoside (50). A solution of 49 (4.47 g, 14 mmol,
1.0 equiv.) and p-thiocresol (2.64 g, 21 mmol, 1.5 equiv.) in dry CH2Cl2 (60 mL) was cooled to 0
°C under N2. Boron trifluoride diethyl etherate (1.0 mL, 1.17 g, 8.1 mmol, 0.5 equiv.) was added
dropwise and the mixture stirred for 5 h under N2 at 0 °C. The reaction was quenched with Et3N
(4 mL) and concentrated. The mixture was diluted with EtOAc (150 mL) and washed with H2O
(150 mL) and brine (150 mL). The organic layer was filtered through MgSO 4 and concentrated.
The residue was purified by flash chromatography eluting with 3:1 Hex/EtOAc to give 50 as a
light colored oil (3.54 g, 66 %). Rf 0.25 (3:1 Hexanes/EtOAc). [α]D25 -170.2 (c = 1, CH2Cl2). 1H
NMR (400 MHz, CDCl3) δ 2.10 (s, 3H), 2.11 (s 3H), 2.13 (s, 3H), 2.34 (s, 3H), 4.28 (dd, J = 12.1,
5.5 Hz, 1H), 4.39 (dd, J = 12.1, 3.6 Hz, 1H), 4.48 (app. q, J = 4.7 Hz, 1H), 5.07 (d, J = 5.5 Hz,
1H), 5.27 (s, 1H), 5.47 (s, 1H), 7.13 (d, J = 7.8 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H);

42

13

C NMR (100

MHz, CDCl3) δ 20.7 (3C), 21.1, 62.8, 77.2, 79.9, 81.4, 91.2, 129.6, 129.8, 132.7, 138.1, 169.6,
170, 170.5; HRMS (ESI) calcd for C18H21O7SNa (M+Na)+: 405.0978; obsd: 405.0985.

(2.3)
p-Cresyl

3,5-O-(Di-tert-butylsilylene)-1-thio-α-L-arabinofuranoside

(52).

Thioglycoside

triacetate 50 (694 mg, 1.8 mmol) was dissolved in MeOH (15 mL). Sodium methoxide (200 μL,
25% in MeOH) was added and stirred under N2 overnight. Amberlite® IR-120 acid resin was
added portionwise while stirring until solution was neutralized, after which it was filtered and
rinsed with MeOH, and concentrated. The crude triol 51 (363 mg, 1.4 mmol, 1.0 equiv.) was
suspended in a mixture of dry CH2Cl2 (13 mL) and DMF (2.5 mL) and cooled to 0 °C under N2.
2,6-Lutidine

(762

μL,

705

mg,

6.6

mmol,

4.7

equiv.)

and

di-tert-butylsilyl

bis-

(trifluoromethanesulfonate) (545 μL, 741 mg, 1.7 mmol, 1.2 equiv.) were then added
sequentially. The mixture was stirred overnight under N2 at room temperature. The mixture
was concentrated and the residue diluted with EtOAc (30 mL) and washed with H2O (30 mL)
and brine (30 mL). The organic layer was filtered through MgSO4 and concentrated. The
residue was purified by flash chromatography eluting with 15:1 Hex/EtOAc to give 52 as an
amorphous colorless solid (297 mg, 53%). Rf 0.49 (3:1 Hexanes/EtOAc). [α]D25 -181.0 (c = 1.0,
CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 1.00 (s, 9H), 1.08 (s, 9H), 2.33 (s, 3H), 3.58 (d, J = 4.2
Hz, 1H), 3.87-3.98 (m, 2H), 4.02 (app. t, J = 8.3 Hz, 1H), 4.14 (app. q, J ~ 5 Hz, 1H), 4.35 (dd, J
= 8.3, 4.2 Hz, 1H), 5.27 (d, J = 5.9 Hz, 1H), 7.12 (d, J = 7.8 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H);
13

C NMR (100 MHz, CDCl3) δ 20.1, 21.1, 22.7, 27.1, 27.5, 67.4, 73.7, 80.6, 77.4, 91.5, 129.8,

130.3, 132.3, 137.9; HRMS (ESI) calcd for C20H33O4SSi (M+H)+: 397.1863; obsd: 397.1856.
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(2.4)
p-Cresyl 2-O-Benzyl-3,5-O-(di-tert-butylsilylene)-1-thio-α-L-arabinofuranoside (29). Compound
52 (400 mg, 1.1 mmol, 1 equiv.) was dissolved in dry CHCl2 (11 mL) and stirred under N2.
Benzyl bromide (240 μL, 345 mg, 2.0 mmol, 2 equiv.) was added, followed by Ag 2O (714 mg,
3.1 mmol, 3 equiv.). The mixture was stirred for 3 d, filtered through an inch of silica and
washed with CHCl2, and concentrated.

The residue was purified by flash chromatography

eluting with 120:1 Hex/Ether  60:1 Hex/EtOAc to give 29 as a colorless solid (336 mg, 64%).
Rf 0.62 (3:1 Hexanes/EtOAc). [α]D25 -129.93 (c = 1, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 0.97
(s, 9H), 1.06 (s, 9H), 2.28 (s, 3H), 3.84-3.98 (m, 3H), 4.12 (app. t, J = 8.4 Hz, 1H), 4.31 (dd, J =
8.2, 4.1 Hz, 1H), 4.72 (d, J = 12.0 Hz, 1H), 4.81 (d, J = 12.0 Hz, 1H), 5.34 (d, J = 5.2 Hz, 1H),
7.05 (d, J = 7.9 Hz, 2H), 7.26-7.40 (m, 7H); 13C NMR (100 MHz, CDCl3) δ 20.2, 21.2, 22.7, 27.2,
27.6, 67.4, 72.2, 73.8, 81.4, 86.8, 90.3, 127.9, 128.1, 128.5, 129.8, 130.6, 132.3, 137.71,
137.74; HRMS (ESI) calcd for C27H39O4SSi (M+H)+: 487.2333; obsd: 487.2324.

(2.5)
p-Cresyl 2-O-Benzyl-3,5-O-(di-tert-butylsilylene)-1-thio-α-L-arabinofuranoside S-Oxide (42). A
solution of 3-chloroperoxybenzoic acid (63.5 mg, 77 wt %, 2.8 mmol, ~1.2 equiv.) in dry CH2Cl2
(1 mL) was added dropwise to a solution of compound 29 (116 mg, 0.24 mmol, 1 equiv.) in dry
CH2Cl2 (4 mL) at -80 °C under Argon and stirred. The reaction mixture was gradually warmed to
room temperature over 2 h. The solution was diluted with CH2Cl2 (30 mL), washed with sat’d aq
NaHCO3 (30 mL), filtered through MgSO4, and concentrated. The residue was purified by
column chromatography, eluting with 10:1 Hex/EtOAc to afford 42 as a colorless gel (68 mg,
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57%) and a mixture of diastereomers varying in their configuration at sulfur. Diastereomer A: Rf
0.42 (3:1 Hexanes/EtOAc). [α]D25 101.4 (c = 1, CHCl3).

1

H NMR (400 MHz, CDCl3) δ 1.00 (s,

9H), 1.05 (s, 9H), 2.40 (s, 3H), 3.89 (app. t, J = ~10 Hz, 1H), 3.99-4.05 (td, J = 10, 5.0 Hz, 1H),
4.22 (dd, J = ~10, 7.2 Hz, 1H), 4.30 (d, J = 11.4 Hz, 1H), 4.35 (dd, J = 9.0, 5.0 Hz, 1H), 4.574.59 (m, 1H), 4.58 (d, J = 11.4 Hz, 1H), 4.65 (d, J = 5.1 Hz, 1H), 6.98 (app. t, J = 3.6 Hz, 2H),
7.25-7.27 (m, 3H), 7.30 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H); 13C NMR (100 MHz, CDCl3)
δ 20.2, 21.4, 22.6, 27.1, 27.4, 67.4, 72.0, 77.0, 78.5, 82.0, 99.3, 124.4, 127.7, 127.9, 128.2,
129.9, 136.2, 137.3, 141.7; HRMS (ESI) calcd for C27H39O5SSi (M+H)+: 503.2282; obsd:
503.2298; Diastereomer B: Rf 0.33 (3:1 Hexanes/EtOAc). [α]D25 -178.6 (c = 1.35, CHCl3).

1

H

NMR (400 MHz, CDCl3) δ 0.95 (s, 9H), 1.05 (s, 9H), 2.40 (s, 3H), 3.78-3.84 (m, 1H), 3.86 (app.
t, J = ~9.4 Hz, 1H), 4.20 (app. t, J = 8.2 Hz, 1H), 4.30 (dd, J = 8.6, 4.5 Hz, 1H), 4.35 (app. t, J =
6.4 Hz, 1H), 4.58 (d, J = 11.7 Hz, 1H), 4.63 (d, J = 5.6 Hz, 1H), 4.76 (d, J = 11.7 Hz, 1H), 7.237.36 (app. m, 7H), 7.52 (d, J = 8.1 Hz, 2H);

13

C NMR (100 MHz, CDCl3) δ 20.0, 21.5, 22.6, 27.0,

27.4, 67.3, 72.3, 76.9, 81.1, 81.5, 98.2, 125.6, 128.0, 128.1, 128.4, 129.9, 136.4, 137.3, 142.3;
HRMS (ESI) calcd for C27H39O5SSi (M+H)+: 503.2282; obsd: 503.2294.

(2.6)
N-tert-Butoxycarbonyl-trans-4-hydroxy-L-proline allyl ester (54). To a suspension of Boc-HypOH (53) (1.77 g, 7.7 mmol, 1.0 equiv.) in dry MeOH (16 mL) was added cesium carbonate (1.37
g, 4.2 mmol, 0.55 equiv.). The mixture was stirred under N2 for 1.5 h during which time the
reaction mixture became a homogeneous solution.

The solvent was evaporated, and the

residue dissolved in dry DMF (10 mL) and treated immediately with allyl bromide (1.2 g, 0.86
mL, 9.9 mmol, 1.3 equiv.). The mixture was stirred overnight at RT under N2. The mixture was
diluted with EtOAc (150 mL) and washed with H2O (150 mL) and brine (150 mL). The organic
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layer was filtered through MgSO4 and concentrated. The residue was purified by flash column
chromatography, eluting with 2:1 EtOAc/Hex to give the ester 54 as a light oil (1.86 g, 89%). Rf
0.34 (2:1 EtOAc/Hex). [α]D25 -65.0 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 1.40 (1.46)* (s,
9H),

2.03-2.10 (m, 1H), 2.25-2.35 (m, 1H), 2.96 (s, 1H), 3.44-3.65 (m, 2H), 4.40-4.48 (m, 2H),

4.56-4.71 (m, 2H), 5.25 (app. t, J = ~11.3 Hz, 1H), 5.35 (dt, J = 17.1, 3.8, 1.2 Hz, 1H), 5.87-5.95
(m, 1H);

13

C NMR (100 MHz, CDCl3) δ 28.2 (28.3), 39.1 (38.3), 54.6, 58.0 (57.7), 65.6, 69.1

(69.8), 80.5 (80.2), 118.8 (118.3), 131.6 (131.8), 154.1 (154.6), 172.9 (172.6); HRMS (ESI)
calcd for C13H21NO5Na (M+Na)+: 294.1312, obsd: 294.1320.
* values in parentheses signifiy a second signal due to a minor rotamer

(2.7)
Nα-tert-Butyloxycarbonyl-trans-4-hydroxy-4-O-[2-O-Benzyl-3,5-O-(di-tert-butylsilylene)-Larabinofuranosyl]-L-proline Allyl Ester 55. A solution of compounds 29 (219 mg, 0.45 mmol, 1.0
equiv.) and 54 (250 mg, 0.92 mmol, 2.0 equiv.) in dry CH2Cl2 (30 mL) were added to a flask
containing activated 4 Å crushed molecular sieves under N2. The suspension was stirred for
~20 min at RT then cooled to -65 °C (ethylene glycol and dry ice). The temperature dropped to
-30 °C and NIS (173 mg, 0.68 mmol, 1.5 equiv.) was added, followed by a solution of AgOTf (57
mg, 0.22 mmol, 0.5 equiv) in toluene (0.6 mL) as the temperature continued to drop to -65 °C.
The suspension was stirred for 1 hr during which it was allowed to gradually warm to RT.
Solution continued to stir until room temperature was reached.

After ~20 mins at room

temperature, the reaction was quenched with Et3N, filtered, and concentrated. The residue was
diluted with EtOAc (50 mL) and washed with sat’d aq. Na2S2O3 (50 mL) and brine (50 mL),
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filtered through MgSO4, and concentrated.

The residue was purified by column

chromatography, eluting with 10:1 Hex/EtOAc to afford crude 55 as a colorless oil (147 mg,
51%) as a mixture of anomers and rotamers. Crude compound 55 was subjected to HPLC,
eluting with 20% EtOAc in Hexanes at 13.0 mL min-1 on a 21 mm silica column detecting with
UV at 254 nm. RT (α) = 13 min, RT (β) = 23 min; β-anomer: Rf 0.30 (3:1 Hexanes/EtOAc).

1

H

NMR (400 MHz, CDCl3) δ 0.99 (s, 9H), 1.07 (s, 9H), 1.38 (1.45)* (1 s, 9H), 2.08-2.15 (m, 1H),
2.35-2.42 (2.43-2.49) (m, 1H), 3.58-3.69 (m, 3H), 3.86-3.91 (m, 2H), 4.26-4.32 (m, 3H), 4.364.44 (m, 1H), 4.56-4.73 (m, 3H), 4.79 (d, J = 12.2 Hz, 1H), 4.97 (4.93) (d, J = ~5.3 Hz, 1H), 5.24
(app. t, J = 11.6 Hz, 1H), 5.32 (ddd, J = 17.2, 5.9, 1.3 Hz, 1H), 5.85-5.96 (m, 1H), 7.29-7.40 (m,
5H); 13C NMR (100 MHz, CDCl3) δ 20.1, 22.6, 27.1, 27.5, 28.2 (28.4), 37.6 (36.8), 51.1 (51.6),
58.1 (57.7), 65.5 (65.6), 68.4, 71.8 (71.9), 73.6 (73.4),

75.2, 78.4, 80.2 (80.1), 80.7, 99.2

(100.0), 118.7 (118.3), 127.7, 127.8, 127.9, 128.0, 128.4, 131.7 (131.9), 137.7, 153.7 (154.2),
172.7 (172.4); HRMS (ESI) calcd for C33H52NO9Si (M+H)+: 634.3406; obsd: 634.3408.
* values in parentheses signifiy a second signal due to a minor rotamer

(2.8)
p-Cresyl 2,3,5-O-Benzyl-1-thio-α-L-arabinofuranoside (60).

Triol 51 (1.91 g, 7.5 mmol, 1.0

equiv.) was dissolved in dry DMF (15 mL) and cooled to 0 °C under N2. Benzyl bromide (5.3
mL, 7.61 g, 44.5 mmol, 6.0 equiv.) and NaH (1.78 g, 60% dispersion, 44.5 mmol, 6.0 equiv.)
were added sequentially. The reaction mixture was allowed to warm to RT while it stirred under
N2 for 3 h. The reaction was quenched with sat’d NaHCO3 (150 mL) and extracted with CH2Cl2
(150 mL). The organic layer was washed with H2O (150 mL) and brine (150 mL), filtered
through MgSO4, and concentrated. The residue was purified by flash chromatography eluting
with 20:1  10:1  1:2 Hex/EtOAc to give 60 as a clear gel (3.26 g, 84%; 2 steps). Rf 0.46 (3:1
47

Hexanes/EtOAc). [α]D25 -107.9 (c = 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 2.32 (s, 3H),
3.63 (dd, J = 10.8, 4.7 Hz, 1H), 3.68 (dd, J = 10.8, 3.9 Hz, 1H), 4.03 (app. q, J = 3.3 Hz, 1H),
4.11 (t, J = 2.9 Hz, 1H), 4.36-4.38 (m, 1H), 4.48-4.65 (m, 6H), 5.53 (d, J = 2.0 Hz, 1H), 7.10 (d, J
= 7.8 Hz, 2H), 7.26-7.35 (m, 15H), 7.41 (d, J = 7.8 Hz, 2H);

13

C NMR (100 MHz, CDCl3) δ 21.2,

69.1, 72.7, 72.3, 73.4, 80.5, 83.5, 88.4, 90.6, 127.6, 127.7, 127.8, 127.9, 127.9, 128.0, 128.3,
128.4, 128.5, 129.7, 131.0, 132.0, 137.4, 137.8, 138.2; HRMS (ESI) calcd for C33H34NaO4S
(M+Na)+: 549.2070; obsd: 549.2067.

(2.9)
p-Cresyl

2,3,5-O-Benzyl-1-thio-α-L-arabinofuranoside

S-Oxide

61.

A

solution

of

3-

chloroperoxybenzoic acid (283 mg, 77 wt %, 1.3 mmol, 1.2 equiv.) in dry CH2Cl2 (4 mL) was
added dropwise to a solution of compound 60 (555 mg, 1.1 mmol, 1.0 equiv.) in dry CH2Cl2 (16
mL) at -78 °C under N2 and stirred. The reaction mixture was gradually warmed to RT over 1.5
h. The solution was diluted with CH2Cl2 (70 mL), washed with sat’d NaHCO3 (70 mL), filtered
through MgSO4, and concentrated.

The residue was purified by column chromatography,

eluting with 3:1 Hex/EtOAc to afford 61 as a colorless gel (429mg, 75%) and essentially a single
diastereomer (uneven mixture in which the amount of minor isomer is negligible).
diastereomer: Rf 0.19 (3:1 Hexanes/EtOAc). [α]D25 +30.1 (c 1.0 , CH2Cl2).

Major

1

H NMR (400 MHz,

CDCl3) δ 2.39 (s, 3H), 3.53 (dd, J = 10.6, 5.5 Hz, 1H), 3.60 (dd, J = 10.6, 4.8 Hz, 1H), 4.15 (dd,
J = 5.5, 2.8 Hz, 1H), 4.37-4.51 (m, 6H), 4.59 (d, J = 11.8 Hz, 1H), 4.63 (d, J = 1.8 Hz, 1H), 4.74
(app. t, J = ~2.4 Hz, 1H), 7.20-7.32 (m, 17H), 7.57 (d, J = 8.1 Hz, 2H);

13

C NMR (100 MHz,

CDCl3) δ 21.5, 69.1, 71.9, 72.2, 73.3, 83.3, 83.9, 84.4, 102.0, 124.8, 127.7, 127.9, 128.0 (2
signals), 128.4 (2 signals), 128.5, 129.9, 137.3, 137.4, 137.9, 138.7, 141.8; HRMS (ESI) calcd
for C33H35O5S (M+H)+: 543.2160; obsd: 543.2206.
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(2.10)
Nα-tert-Butyloxycarbonyl-trans-4-hydroxy-4-O-[2,3,5-O-Benzyl-L-arabinofuranosyl]-L-proline
Allyl Ester (64). A solution of compounds 60 (1.17 g, 2.2 mmol, 1.0 equiv.) and 54 (0.688 g, 2.5
mmol, 1.1 equiv.) in dry CH2Cl2 (40 mL) was stirred with activated 4 Å molecular sieves (3.5 g)
under N2 for ~30 min at RT. The suspension was cooled to -78 °C (acetone/dry ice) and then
NIS (0.747 g, 3.2 mmol, 1.5 equiv.) and AgOTf (0.285 g, 0.55 mmol, 0.5 equiv.) were added.
The reaction was allowed to gradually reach 0 °C over 1.5 h, at which time it was quenched with
Et3N (3 mL) and filtered. The filtrate was diluted with EtOAc (150 mL) and washed with 10%
aqueous Na2S2O3 (2 x 200 mL) and brine (200 mL). The organic layer was filtered through
MgSO4 and concentrated. The residue, determined to be a 4:1 β:α ratio by NMR, was purified
by column chromatography, eluting with 3:1 Hex/EtOAc to afford 64β (the β-anomer) (0.732 g,
50%, 2:1 ratio of rotamers) as an orange oil. Rf 0.56 (1:1 Hexanes/EtOAc). [α]D25 +17.9 (c 1.0,
CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 1.37 (1.44)* (s, 9H),

1.96-2.07 (m, 1H), 2.27-2.37 (m,

1H), 3.44-3.67 (m, 4H), 4.03-4.12 (m, 3H), 4.25-4.71 (m, 10H), 4.96 (4.92) (d, J = 3.2 Hz, 1H),
5.20-5.34 (m, 2H), 5.86-5.91 (m, 1H), 7.28-7.33 (m, 15H);

13

C NMR (100 MHz, CDCl3) δ 28.3

(28.4), 37.4 (36.5), 50.7 (51.4), 58.1 (57.8), 65.6 (65.7), 72.0, 72.4, 73.3, 75.5, 80.1, 80.3, 82.7,
83.8, 83.9, 99.0 (99.9), 118.8 (118.4), 127.6, 127.8, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4,
128.5; 131.7 (131.9), 137.4, 137.9, 138.1, 153.7 (155.4), 172.7 (172.4). HRMS (ESI) calcd for
C39H48NO9 (M+H)+: 674.3324, obsd: 674.3343.
* values in parentheses signifiy a second signal due to a minor rotamer
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(2.11)
Nα-tert-Butyloxycarbonyl-trans-4-hydroxy-4-O-[2,3,5-O-Benzyl-L-arabinofuranosyl]-L-proline
Allyl Ester (64) – Sulfoxide method. A solution of compound 61 (133 mg, 0.25 mmol, 1.0 equiv.)
and 2,4,6-tri-tert-butyl pyridine (121 mg, 0.49 mmol, 2 equiv.) (TTBP) in dry CH2Cl2 (5 mL) was
stirred with activated 4Å molecular sieves (500 mg) under N2 for ~30 min at RT.

The

suspension was cooled to -78 °C (acetone/dry ice) and then triflic anhydride (49 µL, 82 mg, 0.29
mmol, 1.2 equiv.) was added, followed by compound 54 (66 mg, 0.24 mmol, 1.0 equiv.). The
reaction was allowed to gradually reach -30 °C over 2 h, at which time it was quenched with
Et3N (3 mL), filtered, and concentrated. The residue, determined to contain a 25:1 β:α ratio of
64 by NMR, was purified by column chromatography, eluting with 3:1 Hex/EtOAc to afford the βanomer 64β (84 mg, 51%) as an orange oil.
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2.5.2 Spectra
Compound 50 (Scheme 2.11) - 1H NMR spectrum
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Compound 50 (Scheme 2.11) – 13C NMR spectrum
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Compound 52 (Scheme 2.11) - 1H NMR spectrum
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Compound 52 (Scheme 2.11) – 13C NMR spectrum
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Compound 29 (Scheme 2.12) - 1H NMR spectrum
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Compound 29 (Scheme 2.12) – 13C NMR spectrum
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Compound 42a (Scheme 2.15) - 1H NMR spectrum
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Compound 42a (Scheme 2.15) – 13C NMR spectrum
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Compound 42b (Scheme 2.15) - 1H NMR spectrum
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Compound 42b (Scheme 2.15) – 13C NMR spectrum
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Compound 54 (Scheme 2.13) - 1H NMR spectrum
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Compound 54 (Scheme 2.13) – 13C NMR spectrum
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Compound 55β (Scheme 2.14) - 1H NMR spectrum
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Compound 55β (Scheme 2.14) – 13C NMR spectrum
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Compound 60 (Scheme 2.18) - 1H NMR spectrum
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Compound 60 (Scheme 2.18) – 13C NMR spectrum
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Compound 61 (Scheme 2.18) - 1H NMR spectrum
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Compound 61 (Scheme 2.18) – 13C NMR spectrum
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Compound 64β (Scheme 2.20) - 1H NMR spectrum
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Compound 64β (Scheme 2.20) – 13C NMR spectrum
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CHAPTER 3: SYNTHESIS OF OLIGOMERS OF 4-O-[β-L-ARABINOFURANOSYL]-(2S,4R)-4HYDROXYPROLINE
With the completion of the monomeric β-arabinoside of hydroxyproline in Chapter 2, we
moved forward with the assembly of its oligomers. We expected the peptide bond formations to
be increasingly difficult due to the gradual accumulation of size in the building blocks and the
associated increase in steric demands. We considered a variety of peptide coupling reagents
known for their efficiency in reactions involving prolyl amino components. There is an inherent
challenge in the coupling of a sterically hindered proline amino component. Fortunately, proline
carboxyl components are generally not expected to undergo racemization at C-α, which allowed
us to broaden our scope in coupling reagent selection.
3.1 Previous Syntheses of Glycoclusters
There is an abundance of literature detailing synthetic glycocluster peptides.63

A

glycocluster is an array of carbohydrate groups that are present in close proximity as a result of
primary sequence or backbone conformation. The “glycoside cluster effect” was introduced by
Lee’s group to describe the clustering effect that carbohydrate groups exhibit when interacting
with protein receptors.64 While many types of carbohydrate clusters exist, it is the contiguous Oglycosylated amino acid cluster that is the focus of the present work. From our perspective, the
most relevant solution phase synthesis of these glycoclusters has been in the area of mucins.
The mucin MUC1, a cancer biomarker, is a highly O-glycosylated molecule found on the
epithelial cells of the stomach, lungs, eyes, and other major organs. 65 In 1998, the Kunz group
reported the synthesis of a diglycohexapeptide and a diglycodecapeptide in the investigation of
the MUC1 core related glycopeptides (Figure 3.1).66

These glycopeptides represent two

sequences that are prominently found in MUC1 and which are repeated throughout the
molecule. Both glycopeptides feature adjacent serine and threonine residues O-glycosylated by
α-N-acetyl galactosamine.

The clustered glycopeptide fragment 69 was synthesized by
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fragment condensation of Fmoc-[O-(2-azido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl)]L-Ser-OH (67) and H-[O-(2-azido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl)]-L-Thr-AlaOHep

(68)

(Scheme

3.1).67

N-Hydroxybenzotriazole

(HOBt)

and

1-ethyl-3-(3-

dimethyllaminopropyl)carbodiimide hydrochloride (EDC) were employed to give the resulting
tripeptide in 48% yield.

Figure 3.1 MUC1 core related diglycohexapeptide and diglycodecapeptide

Scheme 3.1 Fragment condensation using HOBt and EDC
The Danishefsky group published a paper in 1998 detailing the synthesis of a
glycocluster in the TN and TF (Thomsen-Friedenreich) tumor-associated antigens (Figure 3.2)
where the N-acetyl galactosamine moiety is α-linked to a serine or threonine residue.68 The
glycosylated amino acids were each unmasked at the N- or C-terminus and condensed to
obtain the diglycodipeptide (74/75) and, subsequently, the triglycotripeptide cluster (78/79)
(Scheme 3.2).

The use of N-isobutyloxyl-carbonyl-2-isobutyloxy-1,3,-dihydroquinone (IIDQ)

gave great yields in the synthesis of the TN cluster. However, the bulkier residues, glycosylated
by disaccharides in the TF antigen, required the use of HATU/HOAt as the reactions were
reported as being “sluggish” with IIDQ.68

This observation was pertinent to us as the
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serine/threonine galactosides have the advantage of being primary amine nucleophiles, thus
providing steric advantages in peptide coupling relative to our hydroxyproline arabinosides. In
light of this precedent for addressing the steric challenges, we considered that HATU was a
strong candidate for the formation of our oligomers.

Figure 3.2 TN and TF antigen

Scheme 3.2 Synthesis of a triglycotripeptide cluster (TN only)
Contiguous O-glycosylated amino acid motifs have also been synthesized using solid
phase peptide synthesis (SPPS) by the Barany group to prepare mucin-like glycopeptides69 and
glycopeptide sequences from α-dystroglycan,70 an extracellular glycoprotein that controls
73

muscle function.

However, the most relevant SPPS study was reported by the Schweizer

group.71 Owens et al. investigated the conformational effects of contiguous O-galactosylation of
trans-L-hydroxyproline (details will be more closely examined in Chapter 4).

A per-

galactosylated nonapeptide (83) was prepared by solid phase synthesis using Fmoc-Rink
Amide resin; when the peptide is cleaved from the resin it affords a C-terminal amide (84)
(Scheme 3.3). The hydroxyproline galactoside donor was reportedly prepared in one step from
commercially available β-D-galactose pentaacetate (80) and Fmoc-Hyp-OH (81) giving the 1,2trans-glycoside as the only product. For each on-resin peptide coupling, three equivalents of
acid 82 was used in combination with four equivalents of O-(benzotriazol-1-yl)-N,N,N',N'tetramethyluronium tetrafluoroborate (TBTU) and eight equivalents of diisopropylethyl amine
(DIEA). The authors were able to prepare the nonaglycopeptide (84) for their structural studies.
However, no yields were reported.

Scheme 3.3 Solid phase peptide synthesis of a nonaglycopeptide
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We concluded at the outset that solid phase synthesis was not a realistic route for us
due to the high stoichiometry of monomer necessary to carry out each of the cycles. While the
galactose pentaacetate donor used by Schweitzer et al. is commercially available, our
arabinofuranoside donor is not.

The difficulty of synthesizing β-L-arabinosides of

hydroxyproline, as outlined in Chapter 2, rendered us unwilling to sacrifice the precious material
in these excess quantities. Our plan was to utilize the latest advances in solution phase peptide
coupling strategies in order to obtain these synthetically challenging glycopeptide clusters in
optimal yield and purity.
3.2 Dimer Synthesis
Retrosynthetically, it is obvious that we must derive the free carboxylic acid (86) and
prolyl amine (87) from our hydroxyproline arabinoside monomer for diglycodipeptide (85)
assembly (Scheme 3.4). Our choice of deprotection methods should look to leave the nontargeted protecting groups unaffected, as well as preserving the ever important O-glycosidic
linkage.

Scheme 3.4 Retrosynthetic analysis of dimer
Treatment of compound 64β (Scheme 3.5) with trifluoroacetic acid afforded the
secondary amine 87. When the reaction was carried out at room temperature, we isolated small
amounts of a prolyl species lacking the carbohydrate moiety. To minimize cleavage of the Oglycosidic linkage, we therefore removed the Boc-carbamate at 0 °C. While the amine salt is
typically not purified any further due to its high polarity, we found it beneficial to submit the
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residue to flash chromatography prior to the coupling reaction. Proton and

13

C NMR spectra of

compound 87 saw the disappearance of the second set of peaks present in the spectra of 64β
as a consequence of rotational isomerization, thus confirming that the two species observed in
the spectra of 64β were indeed assignable to carbamate rotamers.

Scheme 3.5 Boc deprotection of monomer
Our initial motivation to mask the acid as an allyl ester was the established ease of
deprotection under mild or neutral conditions (Scheme 3.6). Deallylation of the allyl ester with
10 mol % of palladium (0) and an allyl scavenger could be achieved in excellent yield as shown
by the groups of Zhang and Kunz.72 We chose tetrakis(triphenylphosphine)palladium(0) and
morpholine as the reaction conditions because the scavenger and its allylated counterpart could
be purified from the product through simple extraction using dilute HCl. The product, however,
could not be rendered free from residual catalyst, as evidenced by the distinct gold color which
carried into the dimeric product of coupling.

The high polarity of the free acid also made

purification by flash chromatography difficult. In search of an ester cleavage protocol free of
byproducts, we decided to try mild basic hydrolysis using aqueous tetrabutylammonium
hydroxide (TBAH) in THF (Scheme 3.7).73 The product of this reaction was colorless and was
not subjected to flash chromatography despite it being not completely free of byproducts.

Scheme 3.6 Known methods of allyl ester deprotection
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Scheme 3.7 Deallylation of monomer
We tried a variety of coupling reagents in the synthesis of the clustered diglycodipeptide.
We first looked at bromo-tris-pyrrolidinophosphoniumhexafluorophosphate (PyBrOP) for our
coupling due to its efficiency in the difficult coupling of the dipeptide of α-aminoisobutyric acid
(Aib) (88) (Scheme 3.8).74 Aib is a sterically hindered α-methylalanyl residue that can affect the
conformation75 of a peptide as well as its pharmacological activity. The coupling of Boc-Aib-OH
(89) and H2N-Aib-OMe (90) was carried out using PyBrOP and 4-dimethylaminopyridine
(DMAP) to give a 77% yield of the hindered dipeptide 88. Previous methods using pivaloyl
chloride and NMM, which constructed the dipeptide by way of a mixed anhydride, gave only
54% of product.76

Considering that both our nucleophile and carboxylate are also fairly

hindered, we chose PyBroP as our first coupling reagent.

Scheme 3.8 Difficult coupling of a dipeptide of aminoisobutyric acid
Coupling of acid 86 and amine 87 with PyBrOP (Scheme 3.9) yielded unsatisfactory
results. Thin layer chromatography (TLC) showed an array of products and the diglycodipeptide
(85) was isolated in only 11% yield. Unreacted amine and acid starting materials were evident
by TLC. Frerot et al. showed that addition of DMAP to peptide coupling reactions can improve
yields when used in combination with PyBrOP.74 PyBrOP is known to facilitate the formation of
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anhydrides77 while DMAP promotes the aminolysis of these anhydrides (Scheme 3.10).
Unfortunately, the isolated yields of 85 were not much better than coupling without DMAP.

Scheme 3.9 Fragment condensation of dimer with PyBrOP

Scheme 3.10 Mechanism of PyBrOP/DMAP mediated coupling
Given the inefficiency of PyBroP, we moved to a coupling reagent that would generate a
less sterically hindered activated species.

Carpino and coworkers published a paper in 1990

detailing a new peptide coupling strategy involving the use of stable amino acid fluorides (e.g.,
91) as key intermediates (Scheme 3.11).78 An amino acid fluoride has an advantage over its
chloride counterpart due to the smaller size of the leaving halide.

Moreover, amino acid

chlorides have shown lability in reactions involving acid side chains containing tert-butyl esters
wherein formation of the cyclic anhydride 94 and tert-butyl chloride (95) side products are
observed.79 This instability is not limited to tert-butyl esters, however, as β-1-adamantyl ester,
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NεBoc-lysine, and tert-butyl ethers of hydroxyl-bearing amino acids also undergo unwanted
transformations under coupling conditions involving acid chloride intermediates. Amino acid
fluorides do not undergo this process, most likely due to the stronger C-F bond character as
compared to its C-Cl counterpart,80 while being comparable in reactivity toward amine
nucleophiles.81

Scheme 3.11 Classical preparation of acid fluorides; acid chloride side reactions
Amino acid fluorides were classically synthesized using cyanuric fluoride in pyridine
(Scheme 3.11).82 More recently, tetramethylfluoroformamidinium hexafluorophosphate (TFFH)
(Scheme 3.12), a much milder reagent relative to cyanuric fluoride, was used to convert Fmoc
amino acids to acid fluorides.83

Acid fluorides can be generated by treatment of the

corresponding acid with TFFH within 15 minutes, with more hindered amino acids taking up to
two hours. While these compounds are stable enough to be isolated, peptide coupling reactions
can be subsequently carried out in one pot by adding the amine nucleophile and a hindered
amine base after formation of the acid fluoride.

Scheme 3.12 Preparation of TFFH
Initial use of TFFH in generating the acyl fluoride of our acid 86 for coupling with the
amine monomer 87 gave an increased yield when compared to coupling with PyBroP (Scheme
3.13).

Chemical yields ranging from 18-26% were obtained using TFFH.

Thin layer

chromatography showed that significant amounts of unreacted acid and amine monomers were
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present, in common with couplings using PyBrOP. This led us to believe that not all acid
monomer was converted to the acyl fluoride 96 or, perhaps once formed, the intermediate
underwent hydrolysis by adventitious water. While reaction with TFFH gave yields significantly
better than PyBrOP, the results were still unsatisfactory.

Scheme 3.13 Fragment condensation to produce dimer with TFFH
Peptide

coupling

reagent

O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate (HATU) has been widely used for amide formation in biologically
interesting, complex molecules.84 HATU has proven to be superior to its HBTU counterpart85
due to the neighboring group effect of the aromatic nitrogen (Figure 3.3b). 86 Carpino has shown
that the true form of HATU/HBTU to be the guanidinium salts (N-form) as opposed to the
uronium salts (O-form),87 which was previously believed to be the case. The O-isomers have
been shown to be more reactive than the N-form.

Figure 3.3 a) Guanidinium and uronium salts of HATU and HBTU, b) Neighboring group effect
Scheme 3.14 shows the possible pathways of peptide coupling using HATU. Initially,
the deprotonated acid nucleophile attacks the electrophilic carbon to form the O-acyl urea,
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which can immediately couple with the amine nucleophile to give the resulting peptide and urea
by-product. At least two other pathways can transpire after initial activation: 1) the O-acyl urea
can be displaced by another molecule of the carboxylate to form a symmetrical anhydride, 2)
formation of the activated ester.

The leaving group of either of the intermediates can be

displaced by the amine nucleophile to give the desired peptide product.

Scheme 3.14 Pathways of amide formation using HATU
Chemical yields of diglycodipeptide (85), obtained using HATU as the coupling reagent
(Scheme 3.15), were immediately better than any reagent we have used previously. Yields of
45-50% were achieved when the reaction was run at room temperature. When the reaction was
initiated in an ice bath, then allowing the mixture to warm to room temperature overnight as the
ice melted, the percent yield was reduced (~25%). This prompted us to investigate the effects
that increasing the temperature might have on this coupling reaction. Interestingly enough, mild
heating of the reaction vessel (30 °C) gave higher percent yields (50-60%). Further increase in
temperature did not show any improvement in chemical yield. Optimization of this reaction
condition has allowed us to obtain the dimer in amounts practical for the further synthesis of
larger oligomers. The diglycodipeptide has been fully characterized by mass spectrometry, 1H
and 13C NMR, and 2-D NMR experiments.

Structural studies will be elaborated in Chapter 4.
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Scheme 3.15 Fragment condensation to produce dimer using HATU
3.3 Oligomer Synthesis
In the preparation of the trimer 99, we were faced with two possible paths to reach the
glycopeptide: a [2+1] or a [1+2] coupling strategy. The [2+1] coupling would place the steric
bulk of an extra hydroxyproline arabinoside residue on the free acid 97 in favor of a less
sterically hindered amine nucleophile 87, while the [1+2] strategy would feature a bulkier prolyl
nucleophile 98 coupling to a less sterically hindered acid 86 (Scheme 3.16).

Scheme 3.16 [2+1] and [1+2] Trimer coupling strategy
Free acid 97 and amine 98 were prepared from diglycodipeptide 85 (Scheme 3.17).
Tetrabutylammonium hydroxide was again used to hydrolyze the allyl ester to avoid the need for
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chromatography as the polarity of free dimer acid 97 is higher than that of its monomer
counterpart. The heightened polarity likely also accounts for the less than quantitative yields as
the dimer acid has a higher affinity for the aqueous layer during work-up. The free amine 98
could still be obtained quantitatively with 50% TFA in dichloromethane at 0 °C.

Scheme 3.17 Preparation of dimer building blocks
The [2+1] coupling of dimer acid 97 and monomer amine 87 gave the triglycotripeptide
99 in ~35% yield (Scheme 3.18). Alternatively, the [1+2] coupling of monomer acid 86 and
dimer amine 98 gave a similar yield. In this instance, raising the temperature slightly did not
improve the yield in a noticeable fashion.

Scheme 3.18 Fragment condensation to produce trimer
Confronted with low yields for the construction of the triglycotripeptide, we chose not to
use it as a precursor to the tetramer. Instead, the alternate path of a [2+2] coupling, utilizing two
dimer building blocks which could be synthesized in reasonable quantities, was pursued. Thus,
free acid dimer 97 was coupled to dipeptide amine 98 to afford the glycotetrapeptide in 49%
83

yield (Scheme 3.19). Mass spectrometry, proton, and carbon NMR confirmed the formation of
the tetramer (100).

Scheme 3.19 Fragment condensation to produce tetramer
3.4 Oligomer End-Capping
With monomer, dimer, trimer, and tetramer in hand, we began preparations to “end-cap”
the glycopeptides. At this stage, the N- and C-termini were masked as a Boc carbamate and an
allyl ester respectively. In order to better mimic the extended peptide, we sought to cap both
termini as amides before committing to the global deprotection of the benzyl ethers of the
carbohydrate moieties (Scheme 3.20).

Scheme 3.20 End-capping of glycopeptides
Starting with monomer 64β, the carbamate was deprotected, as before, using TFA in
dichloromethane (Scheme 3.21).

Installation of the acetamide with acetic anhydride and

diisopropylethyl amine gave compound 101 in 69% yield over two steps.

Subsequent

deprotection of the allyl ester was carried out under the hydrolysis conditions described
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previously. The C-terminal methyl amide was formed using 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC)/HOBt and methylamine hydrochloride under basic conditions to afford the
fully end-capped monomer 102 in satisfactory yield.

Scheme 3.21 Monomer end-capping
Dimer 85 was treated in a similar fashion to form acetamide 103, albeit in slightly lower
yield, over two steps (Scheme 3.22). Upon deallylation of the free acid, however, we saw a
significant drop in yield when using EDC/HOBt as the coupling reagent in the formation of the Nmethyl amide (104). Furthermore, NMR showed that the products obtained were of much lower
purity. This problem was rectified by using HATU as the coupling reagent and acetonitrile as
the solvent. Quality fully end-capped dimer 104 could be obtained in 73% yield over two steps.

Scheme 3.22 Dimer end-capping
Installation of the N- and C-terminal amides on the trimer and tetramer proved not to be
trivial. Poor yields (trimer: 18% over 4 steps; tetramer: not obtained) forced us to modify our
strategy to include end-caps prior to peptide coupling and/or glycosylation. This strategy has
the potential to be more convergent, decreasing four linear steps in the overall oligomer
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synthesis.

This approach called for the preparation of oligomer-specific glycosidic building

blocks (Scheme 3.23, 105 and 106), as well as two new glycosyl acceptors (107 and 108).

Scheme 3.23 Oligomer-specific glycosidic building blocks
3.5 Pre-End-Capped Glycosides
Glycosyl acceptors 107 and 108 can both be constructed in one step from commercially
available

N-acetyl

trans-4-hydroxyproline

(109)

and

N-Boc-trans-4-hydroxyproline

(53)

respectively (Scheme 3.24). Treatment of Ac-Hyp-OH with dicyclohexylcarbodiimide (DCC) and
4-DMAP in methanol/dichloromethane affords acceptor 107 in 66% yield. The N-methyl amide
acceptor 108 could be obtained in quantitative yield using freshly recrystallized methylamine
hydrochloride, HATU, and triethylamine in acetonitrile (Scheme 3.24).

Scheme 3.24 Pre-end-capped glycosyl acceptors
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Glycosylation of Ac-Hyp-OMe (107) with thioarabinoside donor 60 proved to be highyielding relative to Boc-Hyp-OAll (Scheme 3.25). While the β:α ratio suffered slightly (3:1 as
opposed to 4:1), the overall yield of the target β-glycoside was significantly higher (83% vs
60%). The compromise in selectivity in lieu of percent yield did lead to a higher overall yield for
the β-glycoside.

Scheme 3.25 Preparation of pre-end-capped monomers
Glycosylation of Boc-Hyp-NHMe (108) with donor 60 under standard conditions gave the
methylamide building block 106 in 70 % yield, 2.7:1 β:α ratio. A huge drawback of this reaction
is the insufficient polarity differences between the α- and β-anomers. The Rf values of the two
diastereomers were nearly indistinguishable, which made separation by flash chromatography
all but impossible. We require these building blocks to be synthesized on gram-scale, thus the
tedious separation of the anomers by HPLC was impractical. Hence, for this particular building
block, we chose to install the methyl amide post-glycosylation on the β-monomer 86 (Scheme
3.26). This transformation can be carried out in two steps from 64β to give 106 in good yield.

Scheme 3.26 Alternate strategy for preparation of C-terminal amide glycoside
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Synthesis of the end-capped triglycotripeptide began with coupling of compound 110
and 87 to give the glycodipeptide building block 111 in 60% yield (Scheme 3.27). The allyl ester
of the diglycodipeptide was hydrolyzed to reveal the free acid dimer 112. The N-methyl amide
monomer 106 was cleaved of its Boc carbamate by TFA in dichloromethane to afford the endcapped free amine 113. Compounds 112 and 113 were coupled under standard conditions to
give the fully end-capped trimer 114 in 35% yield.

Scheme 3.27 Pre-end-capped trimer synthesis
For the synthesis of the fully end-capped tetramer, we chose again to pursue a [2+2]
route.

The N-terminus-capped dimer building block could be formed by the coupling of

compounds 86 and 113 under standard conditions (Scheme 3.28). The Boc carbamate (115) is
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subsequently removed to give the free amine 116) which is then coupled to free acid dimer 112
with HATU to give the fully end caped tetramer product 117.

Scheme 3.28 Pre-end-capped tetramer synthesis
3.6 Global Deprotection
Global debenzylation of all end-capped compounds was carried out using palladium on
carbon (Pd/C) and hydrogen gas in methanol (Scheme 3.29). This process gave quantitative
yields for all oligomers in an overnight reaction. For the larger oligomers, higher loadings of
Pd/C were useful. After filtering off the catalyst, small impurities could be washed away by
dissolving the highly polar products in water and extracting with immiscible organic solvents
(ethyl acetate, chloroform, dichloromethane).

Lyophilization of the aqueous layer overnight

afforded the end-capped glycopeptides with fully deprotected arabinoside domains as
amorphous solids.
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Scheme 3.29 Global debenzylation
3.7 Experimental Section
General methods: as stated in chapter 2.
3.7.1 Experimental procedures

(3.1)
Nα-tert-Butyloxycarbonyl-trans-4-hydroxy-4-O-[2,3,5-O-Benzyl-L-arabinofuranosyl]-L-proline
(86) A solution of compound 64β (662 mg, 1.0 mmol, 1.0 equiv.) in THF (8 mL) was treated
with 40% aqueous tetrabutylammonium hydroxide (2.0 mL, 796 mg, 3.0 mmol, 3.0 equiv.) and
stirred at RT for 1.5 h. The solvent was evaporated and the residue dissolved in EtOAc (45 mL)
and washed with 1M HCl (50 mL). The aqueous portion was back extracted with EtOAc (3 x 25
mL). Organic portions were combined, filtered through MgSO4, and concentrated. The crude
acid 86 (quantitative) was used in the next reaction without further purification.
trans-4-Hydroxy-4-O-[2,3,5-O-Benzyl-L-arabinofuranosyl]-L-proline

Allyl

Ester

(87).

Compound 64β (144 mg, .21 mmol, 1 equiv.) was dissolved in dry CH2Cl2 (2.5 mL) and stirred
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under N2. The mixture was cooled to 0 °C and treated with TFA (1 mL) and thioanisole (25 µL,
27 mg, 0.21 mmol, 1.0 equiv.). The mixture was stirred at 0 °C for 30 min, warmed to RT over
the next 2.5 h, and concentrated. The residue was purified by flash column chromatography,
starting with 2:1 EtOAc/Hex and flushing with 4:1 CH2Cl2/MeOH to give 87 as a light brown oil
(107 mg, 73%).
Diglycodipeptide (85). 87 (56 mg, .08 mmol, 1 equiv.) and 86 (62 mg, 0.10 mmol, 1.2 equiv.)
were suspended in dry CH2Cl2 (3 mL). The mixture was cooled to 0 °C and DIEA (53 µL, 40 mg,
0.30 mmol, 3.7 equiv.) and HATU (48 mg, 0.13 mmol, 1.5 equiv.) were added successively.
The reaction was heated to 30 °C while stirring under N2 overnight. Upon completion, the
mixture was diluted with CH2Cl2 to 25 mL total volume, washed with 1M HCl (2 x 20 mL), sat’d
NaHCO3 (20 mL), and brine (20 mL).

The organic layer was filtered through MgSO 4 and

concentrated. The residue was purified by flash column chromatography, eluting with 1.5:1
Hex/EtOAc  1.5:1 EtOAc/Hex to give title compound 85 as a light oil (58 mg, 60%). Rf 0.56
(2:1 EtOAc/Hex). [α]D25 +30.1 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 1.35 (1.30)* (s, 9H),
1.96-2.13 (m, 2H), 2.17-2.37 (m, 2H), 3.40-3.75 (m, 8H), 3.90-4.27 (m, 6H), 4.38-4.72 (m, 18H),
4.88 (5.08) (s {d, J = 4.0 Hz}, 1H), 4.99 (app. t, J = ~4.3 Hz, 1H), 5.20 (app. d, J = 10.4 Hz, 1H),
5.29 (app. d, J = 16.9 Hz, 1H), 5.82-5.91 (m, 1H), 7.25-7.33 (m, 30H);

13

C NMR (100 MHz,

CDCl3) δ t-Boc (28.4, 28.5)*, C-β (35.3, 35.5, 36.0, 36.6), C-δ (50.3, 51.0, 51.6, 51.7), C-α (56.6,
56.8, 57.8, 58.0), CH2CH=CH2 (65.7, 65.9), OCH2Ph (72.0-72.8, 73.4, 73.5), furanose C5 73.3,
C-γ (73.8, 74.3), (CH3)3C- (75.5, 76.8), furanose C2,3,4 (79.8-84.2), furanose C1 (98.5, 99.3,
98.9, 101.3), CH2CH=CH2 (118.4, 118.7), aromatic CH (127.7-128.6), CH2CH=CH2 (131.8,
131.9), aromatic -C- (137.4-138.2), NCOOR (153.7, 154.2), COR (171.4, 171.6, 171.4, 171.5);
HRMS (ESI) calcd C70H80N2O15Na for (M+Na)+: 1211.5456; obsd: 1211.5412.
*signals in parentheses signify pairs of rotamers.
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(3.2)
Dimer acid (97). A solution of compound 85(180 mg, 0.15 mmol, 1.0 equiv.) in THF (3 mL) was
treated with a 40% aq. solution of tetrabutylammonium hydroxide (296 µL, 160 mg, 0.45 mmol,
3.0 equiv.) and stirred at RT under N2 for 2 h.

The solvent was evaporated, the residue

dissolved in EtOAc (20 mL) and washed with 1M HCl (15 mL). The aqueous layer was backextracted with EtOAc (3 x 10 mL). The organic portions were combined, filtered through MgSO 4
and concentrated. The crude acid 97 was obtained in quantitative yield and submitted to the
next step without further purification.
Triglycotripeptide (99). Compounds 87 (48 mg, 0.07 mmol, 1.0 equiv.) and 97 (81 mg, 0.07
mmol, 1.0 equiv.) were suspended in dry CH2Cl2 (3 mL). Diisopropylethylamine (37 µL, 30 mg,
.21 mmol, 3.0 equiv.) and HATU (40 mg, 0.1 mmol, 1.5 equiv.) were added successively. The
reaction mixture was stirred for 21 h under N2. The mixture was diluted with CH2Cl2 to a total
volume of 25 mL, washed with 1M HCl (2 x 20 mL), sat’d NaHCO 3 (20 mL), and brine (20 mL).
The organic layer was filtered through MgSO4 and concentrated. The residue was purified by
flash column chromatography, eluting with 1.5:1 Hex/EtOAc  1.5:1 EtOAc/Hex  1:2
EtOAc/Hex to give the title compound 99 as a light oil (42 mg, 35%). Rf 0.62 (2:1 EtOAc/Hex).
[α]D25 42.6 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 1.34 (1.33)* (s, 9H), 1.75-1.80 (m, 1H),
1.90-2.00 (m, 1H), 2.04-2.34 (m, 4H), 3.06-3.67 (m, 8H), 3.84-4.13 (m, 12H), 4.38-4.72 (m,
27H), 4.84 (d, J = 4.2 Hz, 0.5H), 4.87 (d, J = 4.1Hz, 0.5H), 4.92 (d, J = 3.8, 0.5H), 5.09 (d, J =
2.8 Hz, 0.5H), 5.15 (d, J = 2.1 Hz, 0.5H), 5.16 (d, J = 4.0 Hz, 0.5H), 5.19-5.30 (m, 2H), 5.815.91 (m, 1H), 7.28-7.33 (m, 45H);
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C NMR (100 MHz, CDCl3) δ 28.5 (t-Boc CH3), (34.9, 35.1,
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35.5, 35.7, 36.0, 36.3) (C-β), (50.0, 50.1, 50.5, 50.7, 51.6, 51.9) (C-δ), (56.6, 56.8, 56.9, 57.0,
57.9, 58.1) (C-α), 65.7 (CH2CH=CH2), (72.0-72.7) (OCH2Ph), (73.1, 73.3) (furanose C5), (73.61,
73.7, 74.5) (C-γ), (79.6, 79.7) (Boc (CH3)3C-), (79.9-84.2) (furanose C2,3,4), (98.2, 98.6, 98.9,
101.0) (furanose C1), 118.4 (CH2CH=CH2), (127.8-128.4) (Ar 3° CH), 131.8 (CH2CH=CH2),
(137.5-138.2) (Ar 4° -C-), (153.8, 154.2) (NCOOtBu), (170.8, 170.8, 171.0, 171.1, 171.4, 171.5)
(COR); HRMS (ESI) calcd C101H112N3O21Na for (M+Na)+: 1726.7759; obsd: 1726.7750.
*Signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond

(3.3)
Dimer amine 98. Diglycodipeptide 85 (168 mg, .14 mmol, 1 equiv.) was dissolved in dry CH2Cl2
(3 mL) and stirred under N2. The mixture was cooled to 0 °C and treated with TFA (1.5 mL).
The mixture was stirred at 0 °C for 3 h and concentrated to give compound 98 in quantitative
yield. The residue was submitted to the next step without further purification.
Tetraglycotetrapeptide 100. Compounds 97 (145 mg, 0.13 mmol, 1 equiv.) and 98 (170 mg,
0.14 mmol, 1.1 equiv.) were suspended in dry CH2Cl2 (5 mL). HATU ( 50 mg, 0.13 mmol, 1.0
equiv.) and DIEA (110 µL, 82 mg, 0.63 mmol, 5.0 equiv.) were added successively. The mixture
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was stirred for 18 h under N2. Upon completion, the solvent was evaporated and the residue
diluted with EtoAc (30 mL), washed with 1M HCl (30 mL), sat’d NaHCO3 (30 mL), and brine (30
mL). The organic layer was filtered through MgSO4 and concentrated. The residue was purified
by flash column chromatography, eluting with 1.5:1 Hex/EtOAc  1:1 Hex/EtOAc  1:1.5
Hex/EtOAc  1:2 Hex/EtOAc to give the title compound 100 as a light oil (138 mg, 49%). Rf
0.80 (2:1 EtOAc/Hex). [α]D25 +42.2 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 1.30 [1.26]* (s,
9H), 1.70-2.30 (m, 8H), 3.08-3.66 (m, 16H), 3.76-4.20 (m, 15H), 4.23-4.67 (m, 31H), 4.76-5.10
(anomeric signals, 4H), 5.18 (d, J = 10.4 Hz, 1H), 5.27 (d, J = 17.3 Hz, 1H), 5.78-5.88 (m, 1H),
7.26-7.31 (m, 60H);

13

C NMR (100 MHz, CDCl3) δ (28.5, 29.7) (Boc CH3), (34.8, 35.0, 35.1,

35.3, 35.4, 35.9, 36.2) (C-β), (50.0, 50.1, 50.2, 50.4 50.5, 50.8, 51.6, 52.1) (C-δ), (56.7, 56.8,
57.0, 57.1, 57.2, 57.9) (C-α), (65.8) (CH2CH=CH2), (72.0-72.6) (OCH2Ph), (73.2, 73.3, 73.4)
(furanose C5), (73.8, 74.0, 74.1, 74.3) (C-γ), (79.6, 79.7) (Boc (CH3)3C-), (79.9-84.3) (furanose
C2,3,4), (98.0, 98.1, 98.3, 98.6, 98.9, 99.2, 99.4, 100.8) (furanose C1), (118.5, 118.6)
(CH2CH=CH2), (127.8-128.7) (Ar CH), 131.8 (CH2CH=CH2), (137.5-138.2) (Ar -C-), (153.9,
154.2) (NCOOtBu), (170.4, 170.5, 170.7, 170.9, 171.4) (COR); HRMS (ESI) calcd
C132H145N4O27Na for (M+Na)+: 2242.0067; obsd: 2243.0072.
*signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond.

(3.4)
N-Acety-L-trans-4-hydroxy-L-proline methyl ester (105).

Dicyclohexylcarbodiimide (119 mg,

0.58 mmol, 1.0 equiv.) and 4-DMAP (18 mg, 0.15 mmol, 0.25 equiv.) were added sequentially to
a suspension of Ac-Hyp-OH (109) (100 mg, 0.58 mmol, 1.0 equiv.) in dry MeOH (2 mL) and
CH2Cl2 (2 mL).

The mixture was stirred overnight under N2 after which the solvent was
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evaporated. The residue was triturated with CH2Cl2 and filtered to remove dicyclohexylurea.
The filtrate was concentrated and purified by flash column chromatography, eluting with
CH2Cl2/MeOH (14:1  10:1) to give compound 105 as an amorphous solid (71 mg, 66%). Rf
0.33 (10:1 CH2Cl2/MeOH). [α]D25 -89.9 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 2.03-2.10
(2.15-2.23) (m, 1H), 2.07 (1.96)* (s, 3H), 2.26-2.32 (2.41-2.47) (m, 1H), 3.51 (app. d, J = 11.2
Hz, 1H), 3.72 (3.77) (s, 3H), 3.74-3.79 (m, 1H), 4.52-4.57 (4.45) (m, 2H);
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C NMR (100 MHz,

CDCl3) δ 22.2 (21.6), 38.0 (39.7), 52.3 (52.7), 55.9 (54.5), 57.5 (58.8), 70.1 (68.5), 170.0
(170.7), 173.0 (172.7); HRMS (ESI) calcd for C8H14NO4 (M+H)+: 188.0917, obsdd: 188.0919.
*signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond.

(3.5)
N-Acetyl-trans-4-hydroxy-4-O-[2,3,5-O-benzyl-L-arabinofuranosyl]-L-proline Methyl Ester.

A

solution of compounds 60 (342 mg, 0.65 mmol, 1.0 equiv.) and 105 (124 mg, 0.66 mmol, 1.0
equiv.) in dry CH2Cl2 (40 mL) was stirred with activated powdered 4Å molecular sieves (1.0 g)
under N2 for ~30 min at RT. The suspension was cooled to -78 °C (acetone/dry ice) and then
NIS (231 mg, 1.0 mmol, 1.5 equiv.) and AgOTf (83 mg, 0.32 mmol, 0.5 equiv.) were added. The
reaction was allowed to gradually reach 0 °C over 1.5 h, at which time it was quenched with
Et3N (2 mL) and filtered. The filtrate was diluted with EtOAc (50 mL) and washed with 10%
aqueous Na2S2O3 (50 mL) and brine (50 mL). The organic layer was filtered through MgSO4
and concentrated. The residue, determined to be a 3:1 β:α ratio by NMR, was purified by
column chromatography, eluting with 3:1 Hex/EtOAc to afford 107 (317 mg, 83%) as an orange
oil. Rf 0.34 (8:1 EtOAc/Hex). [α]D25 39.2 (c 0.5, CH2Cl2).

1

H NMR (400 MHz, CDCl3) δ 2.02-

2.08 (2.10-2.17)* (m, 1H), 2.03 (1.84) (s, 3H), 2.31-2.40 (m, 1H), 3.41 (dd, J = 10.6, 3.6 Hz, 1H),
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3.49-3.52 (m, 2H), 3.71 (3.75) (s, 3H), 3.72-3.74 (m, 1H), 4.07-4.14 (m, 3H), 4.29-4.43 (m, 1H),
4.48-4.73 (m, 7H), 4.90 (4.98) (d, J = 3.6 (4.0) Hz, 1H), 7.27-7.36 (m, 15H); 13C NMR (100 MHz,
CDCl3) δ 22.3 (21.5), 36.0 (38.0), 52.3 (52.7), 52.8 (50.6), 57.5 (58.8), 71.9 (72.2), 72.5 (72.4),
72.7 (73.1), 73.4 (73.3), 76.3, 80.1, 82.4, 84.2 (83.9), 100.5 (99.1), 127.8, 127.9, 128.0, 128.1
(2c), 128.4, 128.5, 128.6, 137.6, 137.8 (137.9), 138.1 (2c), 169.3, 172.7 (172.6); HRMS (ESI)
calcd for C34H40NO8 (M+H)+: 590.2748, obsd: 590.2758.
*signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond

(3.6)
HATU (50 mg, 0.13 mmol, 1.5 equiv) and triethylamine (62 µL, 45 mg, 0.45 mmol, 5 equiv.)
were added to a solution of compounds 86 (56 mg, 0.09 mmol, 1 equiv.) and methylamine
hydrochloride (12 mg, 0.18 mmol, 2 equiv.) in acetonitrile under an atmosphere of N2. The
mixture was stirred for 18 h and the solvent evaporated. The residue was diluted with EtOAc
(30 mL), washed with 1 M HCl (30 mL) and aq. NaHCO3 (30 mL), filtered through MgSO4, and
concentrated.

The residue was purified by flash column chromatography, eluting with 8:1

EtOAc/Hex to give the amide product 108 as a light oil (40 mg, 70%). Rf 0.32 (8:1 EtOAc/Hex).
[α]D25 19.6 (c 1.0, CH2Cl2).

1

H NMR (400 MHz, CDCl3) δ 1.44 (1.38)* (s, 9H), 2.08 (br s, 1H),

2.43 (2.32) (br s, 1H), 2.78 (2.77) (s, 3H), 3.43-3.47 (3.75-3.78) (m, 2H), 3..52 (app d, J = 3.3
Hz, 2H), 4.06-4.31 (m, 5H), 4.50-4.70 (m, 6H), 4.97 (s, 1H), 6.57 (5.74) (s, 1H), 7.26-7.36 (m,
15H); HRMS (ESI) calcd for C37H46N2O8 (M+H)+: 647.3327, obsd: 647.3323.
*signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond.
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(3.7)
N-Acetyl-trans-4-hydroxy-4-O-[2,3,5-O-benzyl-L-arabinofuranosyl]-L-proline

Methyl

Amide

(102). A solution of compound 110 (121 mg, 0.21 mmol, 1.0 equiv.) in dry THF (4 mL) was
treated with a 40% aq. solution of tetrabutylammonium hydroxide (401 µL, 160 mg, 0.62 mmol,
3.0 equiv.) and stirred at RT under N2 for 1.5 h. The solvent was evaporated and the residue
dissolved in EtOAc (25 mL), washed with 1M HCl (25 mL). The aqueous layer was backextracted with EtOAc (10 mL). The organic portions were combined, filtered through MgSO 4
and concentrated. The crude acid was obtained in quantitative yield and submitted to next step
without further purification.
A suspension of the free acid (56 mg, 0.10 mmol, 1.0 equiv.) and methylamine hydrochloride (8
mg, 0.10 mmol, 1.0 equiv.) in dry CH2Cl2 was cooled to 0 °C while stirring under N2.
Diisopropylethylamine (19 μL, 14 mg, 0.11 mmol, 1.1 equiv.) was added, followed by EDC (21
mg, 0.11 mmol, 1.1 equiv.) and HOBt (17 mg, 0.13 mmol, 1.3 equiv.). The ice bath was then
removed and the reaction was left to stir overnight. The mixture was diluted with CH 2Cl2 (25
mL) and washed with 1 M HCl (25 mL), sat’d NaHCO3 (aq.) (25 mL), and brine (25 mL). The
organic layer was filtered through MgSO4 and concentrated. The residue was purified by flash
column chromatography, eluting with 19:1 CH2Cl2/MeOH to give compound 102 (35 mg, 61%)
as an oil. Rf 0.49 (10:1 CH2Cl2/MeOH). [α]D25 20.6 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ
2.02 (1.84)* (s, 3H), 2.04-2.07 (m, 1H), 2.53 (dt, J = 13.0, 5.1 Hz, 1H), 2.72 (2.77) (d, J = 4.8 Hz,
3H), 3.36 (3.43 ) (dd, J = 11.6 (12.7), 4.6 (4.1) Hz, 1H), 3.53-3.56 (m, 2H), 3.61 (dd, J = 10.7,
5.8 Hz, 1H), 4.07-4.11 (m, 3H), 4.39-4.44 (app. p, J = 5.4 Hz, 1H), 4.48-4.73 (m, 7H), 4.94
(4.99) (d, J = 3.8 Hz, 1H), 7.26-7.35 (m, 15H);

13

C NMR (100 MHz, CDCl3) δ 22.5, 26.2, 34.2,

52.9, 58.37, 72.1, 72.5, 72.7, 73.3, 76.3, 80.1, 82.7, 84.2, 127.7, 127.9, 128.0, 128.1, 128.4,
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128.5, 128.5, 137.6, 137.9, 138.1, 170.5, 171.4; HRMS (ESI) calcd for C34H41N2O7 (M+H)+:
589.2908, obsd: 589.2913.
*Signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond. Interestingly, the 13C spectrum only displayed signals for one species.

(3.8)
N-Acetyl-4-O-[L-arabinofuranosyl]-trans-4-hydroxy-L-proline Methyl Amide (118). Palladium on
carbon (10% w/w, 45 mg) was added to a solution of compound 102 (35 mg, 0.06 mmol) in
MeOH (2 mL). The suspension was stirred under an atmosphere of H2 gas for 18 h. Upon
completion, the mixture was filtered through Celite® and concentrated to give the triol 118 (19
mg, quantitative). [α]D25 25.6 (c 0.5, MeOH). 1H NMR (400 MHz, CD3OD) δ 2.08 (1.93)* (s, 3H),
2.03-2.10 (2.13-2.19) (m, 1H), 2.47-2.53 (2.59-2.64) (m, 1H), 2.73 (2.77) (s, 3H), 3.34 (s, 1H),
3.56 (dd, J = 11.6, 7.1 Hz, 1H), 3.68-3.78 (m, 3H), 3.85-3.91 (m, 1H), 3.96 (dd, J = 7.8, 4.6 Hz,
1H), 4.41 (4.51) (t, J = 8.0 (7.7) Hz, 1H), 4.45-4.47 (m, 1H), 4.99 (4.95) (d, J = 4.6 (4.5) Hz, 1H);
13

C NMR (100 MHz, CD3OD) δ 21.0 (20.2), 25.0 (25.1), 36.5 (38.4), 53.5 (51.7), 59.0 (60.1),

63.9 (63.8), 75.0 (74.4), 76.4, 77.2, 83.0, 101.2 (100.7), 171.2 (171.6), 173.7 (173.5); HRMS
(ESI) calcd for C13H23N2O7 (M+H)+: 319.1500, obsd: 319.1486.
*Signals in parentheses refer to the minor conformation arising from restricted rotation about the
prolyl peptide bond.
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(3.9)
Fully deprotected diglycodipeptide 104. The methyl amide 108 (199 mg, 0.31 mmol, 1 equiv.)
was dissolved in dry CH2Cl2 (5 mL) and cooled to 0

o

C under an atmosphere of N2.

Trifluoroacetic acid (1.6 mL) was then added and the mixture stirred for 3 h at 0 oC and
concentrated. The free amine was submitted to the next reaction without further purification.
The acid 110 (94 mg, 0.14 mmol, 1 equiv.) and amine 113 (104 mg, 0.14 mmol, 1 equiv.) were
dissolved in dry CH2Cl2 and stirred under N2. The coupling reagent HATU (93 mg, 0.21 mmol,
1.5 equiv.) was added and the reaction stirred for 15 min, after which DIEA (102 mg, 137 µL,
0.79 mmol, 5.5 equiv.) was added to the mixture. The reaction was (mildly) heated to 30 oC and
stirred for 18 h. The mixture was diluted with CH2Cl2 (25 mL), washed with 1 M HCl (25 mL) and
brine (25 mL), filtered through MgSO4, and concentrated. The residue was purified by flash
column chromatography, eluting with 14:1 CH2Cl2/MeOH to give the dimer 104 as a cloudy oil
(86 mg, 55%).
Palladium on carbon (20 mg, 10% w/w) was added to a solution of compound 104 (19 mg,
0.018 mmol) in MeOH (1 mL). The suspension was stirred under an atmosphere of H2 gas for
18 h. Upon completion, the mixture was filtered through Celite® washing well with MeOH, and
concentrated. The residue was dissolved in H2O (10 mL) and washed with CH2Cl2 (3 x 10mL) to
remove organic impurities. The aqueous layer was lyophilized to give the fully deprotected
dimer 119 (10 mg, quantitative) as an amorphous solid. [α]D25 +30.8 (c 0.5, MeOH).

1

H NMR

(400 MHz, CD3OD) δ 2.00-2.11 (m, 2H)*, 2.06 (s, 3H), 2.44-2.49 (m, 1H), 2.58-2.63 (m, 1H),
2.73 (s, 3H), 3.55-3.61(m, 2H), 3.69-3.78 (m, 7H), 3.89-3.99 (m, 4H), 4.12 (d, J = 11.1 Hz, 1H),
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4.46 (t, J = 8.1 Hz, 1H), 4.52 (br s, 1H), 4.76 (t, J = 8.1 Hz, 1H), 5.01 (d, J = 4.2 Hz, 1H), 5.04 (d,
J = 4.4 Hz, 1H);

13

C NMR (100 MHz, CD3OD) δ 20.8, 25.0, 35.6, 36.1, 52.4, 53.5, 56.9, 59.4,

74.9, 75.2, 76.2, 76.7, 77.3, 77.4, 83.0, 83.1, 100.9, 101.0, 170.7, 171.9, 173.4; HRMS (ESI+)
calcd for C23H38N3O13 (M+H)+: 564.2399, obsd: 564.2390.
*Product is predominantly a single species in solution thus minor rotamer not reported.

(3.10)
Fully deprotected triglycotripeptide 120. The acid 112 (156 mg, 0.14 mmol, 1.0 equiv.) and
amine 113 (94 mg, 0.14 mmol, 1.0 equiv.) were dissolved in dry CH2Cl2 (5 mL) and stirred under
N2. The coupling reagent HATU (82 mg, 0.22 mmol, 1.5 equiv.) was added and the reaction
stirred for 15 min, after which DIEA (124 µL, 92 mg, 0.71 mmol, 5.0 equiv.) was added to the
mixture. The reaction was stirred at rt for 21 h. The mixture was diluted with EtOAc (25 mL),
washed with 1 M HCl (25 mL), sat’d NaHCO3 (25 mL) and brine (25 mL), filtered through MgSO4
and concentrated. The residue was purified by flash column chromatography, eluting with 19:1
CH2Cl2/MeOH to give the protected trimer 114 as a light oil (81 mg, 35%).
Palladium on carbon (100 mg, 10% w/w) was added to a solution of compound 114 (11 mg, 6.8
µmol) in MeOH (1.5 mL). The suspension was stirred under an atmosphere of H2 gas for 24 h.
The mixture was filtered through Celite®, washing well with MeOH, and concentrated. The
residue was dissolved in H2O (10 mL) and washed with CH2Cl2 (3 x 10 mL) to remove organic
impurities.

The aqueous layer was lyophilized to give the fully deprotected trimer 120 in

quantitative yield (5.5 mg). [α]D25 -17.4 (c 0.1, MeOH). 1H NMR (400 MHz, CD3OD) δ 2.01-2.17
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(m, 3H), 2.11 (s, 3H), 2.47-2.66 (m, 3H), 2.75 (s, 3H), 3.58-3.66 (m, 3H), 3.69-3.78 (m, 10H),
3.86-4.01 (m, 6H), 4.15 (d, J = 11.5 Hz, 1H), 4.26 (d, J = 11.1 Hz, 1H), 4.48 (t, J = 8.5 Hz, 2H),
4.53 (br s, 2H), 4.60 (br s, 1H), 4.79 (t, J = 8.3 Hz, 1H), 5.02 (d, J = 4.4 Hz, 1H), 5.04 (app t, J =
4.8 Hz, 2H);

13

C NMR (100 MHz, CD3OD) δ 24.1, 28.6, 37.5, 37.7, 38.5, 55.4, 55.5, 56.4, 59.6,

60.2, 62.4, 63.2, 65.9, 65.9(5), 66.0, 72.5, 74.4, 77.1, 77.1(5), 77.2, 78.8, 78.8(2), 78.9, 79.0,
79.0(3), 79.3, 84.6, 84.6(7), 84.7, 102.7, 102.8, 102.9, 173.8, 174.6, 174.8, 175.5, 176.5; HRMS
(ESI+) calcd for C33H52N4O19 (M+H)+: 809.3299, obsd: 809.3314.
*Product is predominantly a single species in solution thus minor rotamer not reported.

(3.11)
Fully deprotected tetraglycotetrapeptide 1. The acid 112 (47 mg, 0.04 mmol, 1.0 equiv.) and
amine 116 (71 mg, 0.06 mmol, 1.4 equiv.) were dissolved in dry CH2Cl2 (1.75 mL) and stirred
under N2. The coupling reagent HATU (17 mg, 0.04 mmol, 1.0 equiv.) was added and the
reaction stirred for 15 min, after which DIEA (124 µL, 92 mg, 0.16 mmol, 4.0 equiv.) was added
to the mixture. The reaction was stirred at rt for 20 h. The mixture was diluted with EtOAc (25
mL), washed with 1 M HCl (25 mL) and brine (25 mL), filtered through MgSO4 and concentrated.
The residue was purified by flash column chromatography, eluting with 19:1 CH2Cl2/MeOH to
give the protected tetramer 117 as a light oil (14 mg, 15%).
Palladium on carbon (25 mg, 10% w/w) was added to a solution of compound 117 (3 mg, 1.4
µmol) in MeOH (0.6 mL). The suspension was stirred under an atmosphere of H2 gas for 24 h.
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The mixture was filtered through Celite®, washing well with MeOH, and concentrated. The
residue was dissolved in H2O (10 mL) and washed with CH2Cl2 (3 x 10mL) to remove organic
impurities.

The aqueous layer was lyophilized to give the fully deprotected tetramer 1 in

quantitative yield (1.5 mg). [α]D25 +60.8 (c 0.075, MeOH).

1

H NMR (400 MHz, CD3OD) δ 2.04-

2.19 (m, 4H), 2.09 (s, 3H), 2.47-2.67 (m, 4H), 2.76 (s, 3H), 3.59-3.65 (m, 4H), 3.73-3.79 (m,
12H), 3.86-4.01 (m, 8H), 4.15 (app d, J = 11.5 Hz, 3H), 4.50 (t, J = 8.0 Hz, 4H), 4.56 (br s, 4H),
5.04 (d, J = 4.5 Hz, 2H), 5.04 (d, J = 4.3 Hz, 4H); HRMS (ESI+) calcd for C43H67N5O25Na
(M+Na)+: 1076.4017, obsd: 1076.3992.
*Product is predominantly a single species in solution thus minor rotamer not reported.
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3.7.2 Spectra
Compound 85 (Scheme 3.15) - 1H NMR spectrum
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Compound 85 (Scheme 3.15) – 13C NMR spectrum
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Compound 99 (Scheme 3.18) - 1H NMR spectrum
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Compound 99 (Scheme 3.18) – 13C NMR spectrum
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Compound 100 (Scheme 3.19) - 1H NMR spectrum
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Compound 100 (Scheme 3.19) – 13C NMR spectrum
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Compound 105 (Scheme 3.24) - 1H NMR spectrum
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Compound 105 (Scheme 3.24) – 13C NMR spectrum
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Compound 107 (Scheme 3.25) - 1H NMR spectrum
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Compound 107 (Scheme 3.25) – 13C NMR spectrum
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Compound 108 (Scheme 3.25) - 1H NMR spectrum
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Compound 102 (Scheme 3.21) - 1H NMR spectrum
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Compound 102 (Scheme 3.21) – 13C NMR spectrum
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Compound 118 (Scheme 3.29) - 1H NMR spectrum
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Compound 118 (Scheme 3.29) – 1C NMR spectrum
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Compound 118 (Scheme 3.29) – Dept 135 NMR spectrum
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Compound 118 (Scheme 3.29) – COSY NMR spectrum
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Compound 118 (S cheme 3.29) - NOSEY spectrum
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Compound 118 (Scheme 3.29) - HSQC spectrum
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Compound 119 (Scheme 3.29) - 1H NMR spectrum
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Compound 119 (Scheme 3.29) – 1C NMR spectrum
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Compound 120 (Scheme 3.29) - 1H NMR spectrum
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Compound 120 (Scheme 3.29) – 13C NMR spectrum
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Compound 1 (Scheme 3.29) - 1H NMR spectrum
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Triglycotripeptide 99
1:1 EtOAc/Hex; 5 mL/min; 1 cm silica column

Tetraglycotetrapeptide 100
2:1 EtOAc/Hex; 5 mL/min; 1 cm silica column
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CHAPTER 4: STRUCTURAL STUDIES OF POLYPROLINE GLYCOSIDES
4.1 Circular Dichroism
4.1.1 Polyproline helices
Circular dichroism is a light absorption spectroscopy that gives information about the
secondary structure composition of polypeptides and proteins.88 One such secondary structure
found in proteins with recurring proline residues is the polyproline helix (Figure 4.1).

A

polyproline type I (PPI) helical conformation is a right handed helix having cis prolyl amide
bonds (ω = 0°). The PPI helix features 3.3 residues per turn with dihedral angles of Φ = -75°
and Ψ = +160° (Figure 4.2). A polyproline type II (PPII) helical conformation is a left handed
helix featuring all trans-amide bonds (ω = 180°) and three amino acid residues per turn. 89 Each
residue in the PPII helix has dihedral angles of Φ = -75° and Ψ = +145°.90

Figure 4.1 Polyproline type I and II helices
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Figure 4.2 Phi (Φ), psi (Ψ), and omega (ω) backbone dihedral angles of peptides
Twenty five percent of all residues in the PPII helix participate in nπ* interactions as
reported by Bartlett et al.91 The nπ* interaction arises when a lone pair of electrons on a
carbonyl oxygen (n) donates into the empty electrophilic π* orbital on the succeeding carbonyl
carbon (Figure 4.3). This electron delocalization event plays a crucial role in the conformational
stability of proteins. Proline is especially suited to be an acceptor in this interaction. The psi
angle of the PPII conformation is 145°, favorable for nπ* interaction (optimal Ψ = 150°).92
This nπ* interaction, coupled with the fact that the trans-amide bond conformation is lower in
energy compared to the cis, renders the PPII helix more commonplace than the PPI. Sreerama
and Woody estimated that 10% of all proteins may adopt the PPII conformation. 93 Circular
dichroism spectroscopy has demonstrated that the PPII conformation has its own distinct
elliptical shape (Figure 4.4).94

Figure 4.3 nπ* interaction in a proline tetramer.
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Figure 4.4 CD Spectrum of Ac-(Pro)7-Gly-Tyr-NH2 taken at 5 °C.95 Reprint with permission from
American Chemical Society.
The PPII structure plays a vital role in numerous biological processes. For example, in
the plant kingdom, hydroxyproline-rich glycopeptides (HPRG) are responsible for a plant’s
growth and defense, among other functions,96 and are known to adopt a PPII conformation in
the cell wall.97

In the animal kingdom, PPII helices are widely found in collagen, the main

component of connective tissues found in vertebrates.98

Interestingly, through use of

computational protein modeling, Himly and coworkers predicted that the carboxyl terminal
domain of Art v 1 would exhibit a left handed helical structure resembling collagen.17 Dedic et
al. later confirmed that the CD spectra of Art v 1 was indeed similar to those of polyproline
helices,99 although no (further) details of the spectra were provided.
Proline-rich regions of peptides often contain many nonproline residues adjacent to one
another.100 Kelly et al. conducted a “host-guest” study on the effect a non-proline residue has
on the CD spectra of short polyproline compounds.95 “Guest” residues were inserted into a host
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peptide known to adopt a PPII helix. Alanine was employed due to its inclination to be in a PPII
helical conformation. The CD spectra of PPP, PAP, and PAAP were taken at 5 °C (Figure 4.5).
The decrease in PPII helical content was found to be three percent between PPP and PAP and
nine percent between PAP and PAAP.

The nonlinearity of the decreasing helical content

suggests that a more pronounced decrease in PPII helical content may be detected in stretches
with three or even four non-proline residues in a proline rich region. Despite this decrease, it is
apparent from the CD spectra that PAAP still
showed significant PPII character.

Figure 4.5 Host PPII helix sequence with insertion of guest amino acids. Reprint with permission
from American Chemical Society

Figure 4.6 shows the circular dichroism spectra of various H-(Pro)n-OH peptides as
reported by Rothe et al.101 Synthetic oligomers of up to 40 unmodified proline residues were
investigated.

The authors note that three consecutive Pro residues are required for PPII

characteristics to be observed. Moreover, the intensity of the maxima, namely the negative
maxima at 206 nm, generally increased with the number of Pro residues.
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Figure 4.6 CD spectra of synthetic polyproline peptides H-(Pro)n-OH101
4.1.2 Effect of pH on peptide conformation
The pH of a solution can be highly influential in the cis/trans isomerization of X-Pro
bonds where there are ionic functional groups.102

The cis conformation allows for an

electrostatic interaction between amino and carboxylate groups in the zwitterion (Figure 4.7),
while the trans conformation is favored in acidic medium due to hydrogen bonding. Thus, the
impact of pH on the conformation of peptides having free termini would be measurable for short
peptides (<3 residues) being that the two types of polyproline helices favor differing
conformations of proline.103
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Figure 4.7 Cis/Trans isomerization of Alanylproline
This effect of pH, however, is not a factor with neutral glycopeptides that are end-capped
with terminal amides. We hypothesized that the CD spectra of our monomer and dimer would
demonstrate little or no secondary structure. Helbecque et al., in their investigation of H-Gly(Pro)n-OH peptides, also noted that three proline residues were required for the PPII
conformation (n = 3).103 Thus, the emergence of helical character started with the tetrapeptide
(H-Gly-(Pro)3-OH). However, examination of the CD spectrum of their trimer (H-Gly-(Pro)2-OH,
Figure 4.8) shows some characteristics of the PPII elliptical curve, although not as intense as
the larger oligomers. Hence, we might expect some PPII helical content in our own trimer (Ac[(β-L-Araf)Hyp]3-NHMe) as all of our amino acids involved are prolyl amides and PPII helical
formation is a local folding event.104 Being that the PPII conformation arises from the restricted
set of the dihedral angles of an amino acid by the succeeding proline residue, 105 we therefore
fully expect the tetramer to exhibit PPII helical character.

Figure 4.8 CD Spectra of H-Gly-(Pro)2-OH. Reprint with permission from John Wiley and Sons.
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4.1.3 Glycosylated oligomers of proline
The Schweizer group published a paper in 2010 detailing the conformation of contiguous
β-O-galactosylated trans-4-hydroxyproline through analysis of far-ultraviolet circular dichroism
spectra.71 As described in Chapter 3, model polyproline peptides were synthesized by solid
phase peptide synthesis (Scheme 3.3). Far-ultraviolet circular dichroism spectra of peptides Ac(Pro)9-NH2, Ac-(Hyp)9-NH2, and Ac-[(β-D-Gal)Hyp]9-NH2 (121-123) were recorded at 25 °C in
water (Figure 4.9). All peptides exhibited spectra characteristic of the PPII conformation,106 viz.
positive maxima at 220-230 nm and negative maxima at 200-210 nm.94

The hydroxylated

nonamer 122 had a more accentuated positive maxima and a depreciated negative maxima
relative to the proline nonamer 121. The glycosylated nonamer 123 exhibited both a weaker
positive and weaker negative band compared to its hydroxyproline counterpart 122. Owens et
al. speculated that while the lowered positive and negative maxima of compound 123 may be
attributed to a possible distortion of the PPII conformation, much like the PAAP model peptide,
glycopeptide 123 was still considered to have significant PPII character.

Figure 4.9 CD spectra of model peptides. Reprinted with permission from American Chemical
Society.
The relative band strength (ρ) is defined as the ratio of the maximum positive ellipticity to
the maximum negative ellipticity.107

Pysh attributed the increase or decrease in ρ to

conformational differences or changes to solvent and carbonyl backbone interactions.106
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Calculations show that a decreasing ρ value corresponds to an increasing solvent-carbonyl
interaction.

Owens reported the ρ values of Ac-(Pro)9-NH2, Ac-(Hyp)9-NH2, and Ac-[(β-D-

Gal)Hyp]9-NH2 to be 0.06, 0.21, and 0.29 respectively.71 The consistent increase in ρ through
the series of model peptides can be attributed to a decreasing solvation of the amide backbone.
While the increase in ρ values can also indicate a destabilization of the PPII conformation, the
authors hypothesized that hydration differences, or shielding of the amide carbonyl groups, was
the primary reason for the significant differences in ρ values.
Naziga et al., working in conjunction with the Schweizer group, recently reported that the
conformation of glycosylated oligoprolines is highly influenced by solvent interactions. 108
Examining the same model peptides as Owens et al. (Figure 4.9, 121, 122, and 123),71 Naziga
and coworkers used molecular modeling techniques to investigate the increase in thermal
stability of glycosylated oligoprolines and the effect of temperature on the polyproline
conformation.

Thermal melting experiments gave T m values of 22, 38, and 70 °C for

compounds 121, 122, and 123

respectively.71

While increased stability of the Hyp and

glycosylated Hyp oligomers relative to the unmodified proline oligomer can be attributed to a
higher population of the trans isomer,109 it did not explain the Tm difference in Ac-(Hyp)9-NH2 and
Ac-[(β-D-Gal)Hyp]9-NH2 as trans stabilization was not observed upon glycosylation of Ac-HypNHMe as a model compound. Using molecular dynamics simulations, Naziga et al. reported
that while sugar-sugar and sugar-backbone interactions may contribute to the stability of the
PPII conformation, it was the interaction between the sugar and water molecules that was
paramount to the increased stability of the glycosylated oligoprolines.108

The free energy

difference between the Hyp and glycosylated Hyp oligomers was found to be 26 kcal mol-1 in
explicit solvent (c.f., no estimated difference in implicit solvent where hydrogen bonding is not
accounted for).
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4.1.4 CD Spectra of Ara-Hyp glycopeptides
Circular dichroism spectra of the monomer 118, dimer 119, trimer 120, and tetramer (1)
were taken in the far-ultraviolet region of the spectrum (190-240 nm). The aqueous solutions of
monomer, dimer, trimer, and tetramer showed a pH reading of 6.80, 7.38, 8.79, and 9.48
respectively. Circular dichroism data was recorded in water at 20 °C at a concentration of ~0.4
mM.
Examination of the CD spectrum of our monomer showed that this compound is largely
unordered, as we had expected (Figure 4.10). While there seems to be a negative maxima at
200 nm ([θ] = -3967 deg cm2 dmol-1), there is no defined maxima. A PPII helix would feature a
positive maxima around 220-230 nm, whereas the spectrum of the monomer never rises above
zero deg cm2 dmol-1. The CD spectrum of the monomer is akin to that of an unmodified proline
dimer (Figure 4.9, n = 2) where H-(Pro)2-OH exhibits a negative maxima at around 210 nm but
no positive maxima.101 This is consistent with previous work reporting that peptides with less
than three residues do not exhibit the PPII conformation.101
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Figure 4.10 CD spectrum of Ac-([β-L-Araf]Hyp)-NHMe
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230

240

We fully expected that the CD spectrum of the dimer would be similar to that of the
unordered monomer. Surprisingly, a cursory glance at Figure 4.11 shows that the dimer does
indeed exhibit order in its elliptical curve. The peptide Ac-([β-L-Araf]Hyp)2-NHMe displayed both
a positive band (λmax = 220 nm, [θ] = 2905 deg cm2 dmol-1) and a negative band (λmin = 199 nm,
[θ] = -10423 deg cm2 dmol-1) that is characteristic of the PPII conformation.94 This is significant
as previous studies on short polyproline peptides have shown that formation of the PPII helix
began at three proline residues (H-Pro3-OH) (Figure 4.9, n = 3).101 It is tempting to suggest that
this difference is due to the carbohydrate residues acting as a restrictive medium, thus giving
more order to the prolyl component of the molecule. Considering that polyproline helices are
stabilized by the steric constraint of their pyrrolidine rings, we believe that the added bulk of the
sugars might very well be contributing to their heightened structure.
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Figure 4.11 CD spectrum of Ac-([β-L-Araf]Hyp)2-NHMe
The CD spectra of both trimer and tetramer showed typical PPII-type helical structure
(Figure 4.12). Peptide Ac-([β-L-Araf]Hyp)3-NHMe showed a positive band at 222 nm ([θ] = 4207
deg cm2 dmol-1) and a negative maxima at 203 nm ([θ] = -13352 deg cm2 dmol-1). Peptide Ac-
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([β-L-Araf]Hyp)4-NHMe exhibited a positive band at 220 nm ([θ] = 3704 deg cm 2 dmol-1) and a
negative maxima at 200 nm ([θ] = -13816 deg cm2 dmol-1).
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Figure 4.12 CD spectrum of Ac-([β-L-Araf]Hyp)3-NHMe and Ac-([β-L-Araf]Hyp)4-NHMe
Figure 4.13 shows an overlay of the CD spectra of all four synthetic glycopeptides
relative to one another. Using the monomer as a baseline value, we can see that the intensity
of the negative maxima increases with the length of the glycopeptide. This is consistent with the
findings of Rothe.101 The trimer and tetramer, as expected, showed the most intense positive
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and negative bands.

This is likely due to the fact that the larger oligomers possess the

necessary number of residues to form a proper PPII helix.
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Figure 4.13 CD Spectra of all four synthetic glycopeptides
The relative band strength (ρ value) of dimer, trimer, and tetramer are 0.28, 0.30, and
0.27 respectively. While we anticipated a decrease in relative band strength with increasing
residue count, this was not the case. Instead, the ρ value increased slightly from dimer to
trimer, with tetramer having the lowest ρ value of all three peptides. However, we do not believe
the differences in these values are significant. The discrepancies in the ρ values are most likely
due to common experimental error and it is probable that the PPII helical content of the three
compounds are quite comparable to one another. These values are also in agreement with the
ρ value of the galactosylated hydroxyproline nonamer reported by Owens (ρ = 0.29).71
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4.2 Nuclear Magnetic Resonance Spectroscopy
4.2.1 Characterization of Ara-Hyp glycopeptides of nArt v 1 by Leonard et al.
Nuclear magnetic resonance spectroscopy was conducted on α-arabinosidase-treated
nArt v 1. Tables 4.1 and 4.2 show the chemical shifts for Hyp and β-Ara residues as reported
by Leonard and coworkers.22 Three types of β-arabinoside residues were found for which
distinct anomeric proton signals could be discerned around 5.10-5.12 ppm (Table 4.2). This is
consistent with the occurrence of three residues per turn in the PPII helix. The

13

C NMR signal

for the anomeric carbon, which could not be differentiated for the three types, was found at
100.9 ppm. For comparison, the C1 signal for α-Ara residues of nArt v 1 were found at 107-109
ppm. Typically, when substitutents on C1 and C2 are cis to one another, as is the case for βarabinosides, the C1 resonances can be found between 100 to 105 ppm.110 The

13

C chemical

shifts are also in agreement with literature values reported from naturally occurring
polysaccharide arabinans containing the β-Ara motif.111

Nuclear Overhauser effect (nOe)

correlations between the anomeric proton of β-Ara and the γ-proton of Hyp support the linkage
of the arabinoside.

Leonard et al. had reported the first 1H and

13

C characterization of

contiguous mono-β-arabinosides of hydroxyproline found in the carbohydrate region of nArt v 1.
Table 4.1 NMR resonances of Hyp in Art v 1 22
Chemical Shift (ppm)
Hyp
α

β1

β2

γ

δ1

δ2

H

4.837

2.547

2.000

4.581

4.035

3.729

H

4.844

2.552

2.005

4.574

4.012

3.758

H

4.831

2.531

2.001

4.580

4.028

3.722

C

58.6

Type 1

1

Type 2

1

Type 3

1

13

35.7
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77.5

53.8

Table 4.2 NMR resonances of β-Ara in Art v 122
Chemical Shift (ppm)
β-Ara
1

2

3

4

5a

5b

5.120

4.10

4.012

3.848

3.744

3.600

5.108

4.069

3.991

3.840

3.734

3.577

H

5.105

4.089

3.972

3.840

3.734

3.572

C

100.9

77.2

75.3

82.8

Type 1

1

Type 2

1

Type 3

1

H
H

13

64.1

4.2.2 Characterization of synthetic Ara-Hyp glycopeptides
Various 1H,

13

C, and 2-D NMR spectra of Ac-([β-L-Araf]Hyp)-NHMe (118) in CD3OD

were acquired. Due to the rotational isomerization of the prolyl acetamide, an approximate 4:1
ratio of rotamers is detected. Examination of the NOESY spectrum (Figure 4.14) shows a
correlation between the acetamide CH3 signal (2.08 ppm) of the major rotamer to the δ protons
(3.73 ppm) of hydroxyproline, signifying that the preferred isomer is in the trans conformation.
There is also correlation of the minor acetamide CH3 signal (1.93 ppm) to the minor α proton
(4.52 ppm) of the prolyl ring. For simplicity’s sake, we will assign only the major rotamer from
here forth.
The resonances at 4.99 ppm could be readily assigned to the anomeric proton of the
arabinose residue, close to the ~5.11 ppm reported by Leonard,22 with the disparity between
the numbers most likely due to the differing solvent used. The

13

C-1H correlation spectrum

(Figure 4.15, HSQC) revealed that the anomeric proton was attached to a

13

C resonance at

101.2 ppm, indicating the substitutents at C1 and C2 are cis.110 The J coupling constant of the
anomeric signal was 4.6 Hz which is typical for β-arabinosides (c.f., J = 0-2 Hz for αarabinosides). The COSY spectrum (Figure 4.16, p 144) shows a correlation of the anomeric
141

proton signal to a doublet of doublets at 3.96 ppm which we label H2. Resonances at 3.88 and
3.76 can be readily assigned to H3 and H4 respectively. Two signals correlate to H4, which the
HSQC spectrum reveals to be attached to the same carbon at 63.9 ppm (c.f., 64.1 ppm as
assigned by Leonard in Art v 1), and is assigned as the diastereotopic H5 protons of the
arabinose ring.

Figure 4.14 NOESY spectrum of Ac-([β-L-Araf]Hyp)-NHMe

142

Figure 4.15 HSQC spectrum of Ac-([β-L-Araf]Hyp)-NHMe
Multiplets at 2.06 and 2.50 ppm can be assigned to a pair of diastereotopic protons
attached to a carbon that resonates at 36.5 ppm as seen in the HSQC spectrum. These were
assigned to Hβ of the proline ring, consistent with their chemical shifts. The Hβ signals show
correlations with two other signals in the COSY spectrum. The first of the two signals was
assigned to Hα (4.41 ppm), as evidence by its splitting into a triplet. The second of these
signals is Hγ (4.46 ppm) which was split into a multiplet as expected from its environment. The
Hγ resonance showed further correlation with a pair of diastereotopic protons at 3.72 ppm which
are the Hδ signals.

Finally, the glycosidic linkage of hydroxyproline and arabinose was

confirmed by an nOe between Hγ of Hyp (4.46 ppm) and the anomeric proton of β-Araf (4.99
ppm).
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Figure 4.16 COSY spectrum of Ac-([β-L-Araf]Hyp)-NHMe
Nuclear magnetic resonance spectra were acquired for the oligomers.
shows a comparison of the

1

H NMR spectra of the four compounds.

characterized the monomer and dimer using 1H,

Figure 4.17

We have fully

13

C, and 2D NMR experiments. With each

additional (β-L-Araf)Hyp residue added, however, the NMR spectra became increasingly more
complex. The spectral assignments of trimer and tetramer were made with only 1-D NMR
experiments and by extrapolation from spectral assignments of monomer and dimer.
To validate the number of residues, we compared the integration of C-terminal methyl
amide (#H = 3 for all compounds, ~2.75 ppm) to the anomeric signal (#H = 1-4 for monomer,
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dimer, trimer and tetramer, ~5.00 ppm). The N-terminal acetamide could also be employed for
this comparison, albeit some overlap with Hβ signal made this less straightforward than using
the methyl amide. Although the integration of the combined anomeric signals increased by one
unit per added residue, additional anomeric peaks were not detected, signifying that all sugar
residues are in a similar environment and conformation. In the larger oligomers, rotational
isomeric signals were less prominent than that of the monomer. This is in contrast to the fully
benzylated Boc-([β-L-Araf]Hyp)n-OAll peptides where each additional residue gave rise to a new
pair of rotational isomeric signals, resulting in up to eight

13

C signals for C1 in the fully protected

tetramer (100, Scheme 3.19). Our findings on the protected oligomers are in agreement with
previous work on oligoprolines.112 It is possible that the carbohydrate residues are contributing
to the reduced number of species of these larger compounds in solution. Figure 4.17 shows the
1

H NMR spectra of 118, 119, 120, and 1 in CD3OD at 400 MHz (Next Page).
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Figure 4.17 1H NMR of all four synthetic glycopeptides
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4.3 Enzyme Linked Immunosorbent Assays
In the spring of 2011, the first two synthetic glycopeptides were sent to the Altmann
Group at BOKU in Vienna, Austria. Ten milligrams each of monomer 117 and dimer 118 were
provided by the Taylor Group for biological testing against antibodies specific for the
carbohydrate region of Art v 1. Enzyme linked immunosorbent assay (ELISA) experiments,
used extensively for the detection of antibodies/antigens in serum samples, were employed to
confirm the existence of glycan epitopes. The Altmann group conducted cross-inhibition ELISA
experiments, also known as competitive ELISA, to determine the IgG binding properties of the
synthetic glycopeptides.
First, various concentrations of monomer 117 and dimer 118 were incubated with rabbit
serum containing only the anti-glycan IgGs. This serum was then added to a microtiter plate
bound with natural Art v 1 to allow for possible competitive binding to the antibody. The plate
was washed so that any unbound antibody was washed away.

The amount of remaining

antigen still bound to the surface of the plate correlates directly to the binding capacity of the
synthetic glycopeptides to the antibody generated against the carbohydrate region of the natural
allergen. The higher the percentage of antigen still present in the wells signifies a higher
percentage of the synthetic glycopeptides binding to the antibody.
In order to measure this displacement, the remaining bound anti-glycan IgGs were
treated with an alkaline phosphatase-conjugated goat anti-rabbit IgG that is specific for the
bound antigen.

The plate was washed again to remove any unbound antibody-enzyme

conjugate. Upon activation of the enzyme with 0.1% p-nitrophenyl phosphate (Scheme 4.1), a
chromogenic substrate, and a 0.1 M diethanolamine (pH 9.8) buffer, the plate was read
immediately at 405/620 nm with an SLT-spectra plate reader to obtain quantitative results on
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the amount of antigen remaining. Figure 4.18 shows the initial results of the ELISA inhibition
experiment with the synthetic glycopeptides at millimolar concentration.

Scheme 4.1 Activation of ALP with p-nitrophenyl phosphate

Figure 4.18 ELISA inhibition experiments of synthetic glycopeptides
At the highest of concentrations (2 mM), the % inhibition for both the monomer and
dimer were similar to one another, reaching 80% at ~0.5 mM; these initial results were
encouraging.

Unfortunately, subsequent repeated assays with diluted samples showed

inconsistencies (Figure 4.19).

The inhibition potency of monomer and dimer varied in the

experiments for unexplained reasons.

However, in all three experiments presented here,

monomer and dimer inhibit Art v 1 binding to a similar extent. The results reported herein are
unpublished work from the Altmann Group.113
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Figure 4.19 Varied concentrations of synthetic glycopeptides in inhibition experiments
4.4 Summary
It was the goal of this dissertation to find the minimal carbohydrate epitope of the Art v 1
allergen. A key intermediate in the assembly of relevant oligomers was a β-arabinoside of
hydroxyproline, a 1,2-cis glycoside that is a challenge to synthetic organic chemistry. Towards
the synthesis of this intermediate, we prepared N-tert-butoxycarbonyl-trans-4-hydroxy-L-proline
allyl ester (54) for glycosylation with p-cresyl 2-O-benzyl-3,5-O-(di-tert-butylsilylene)-1-thio-α-Larabinofuranoside (42). Unfortunately, use of this conformationally restricted bicyclic donor 60
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resulted in low yields and complex mixtures. Instead, we employed p-cresyl 2,3,5-O-benzyl-1thio-α-L-arabinofuranoside (60), for glycosylation of hydroxyproline. Using careful temperature
control, we were able obtain the Ara-Hyp glycoside 64 with 4:1 β:α ratio in 60% yield. Flash
column chromatography could be used to separate the anomers.

Scheme 4.2 Glycosylation of Boc-Hyp-OAll by sulfide donor
In preparing the oligomers of hydroxyproline arabinosides, we unmasked the N- and Ctermini of Boc-([β-L-Araf]Hyp)-OAll in independent experiments. Coupling of the free acid and
amine with HATU gave the Boc-([β-L-Araf]Hyp)2-OAll dimer (85) in 60% yield. The trimer 99
could be assembled by the coupling of Boc-([β-L-Araf]Hyp)-OH with H-([β-L-Araf]Hyp)2-OAll
[1+2] or Boc-([β-L-Araf]Hyp)2-OH with H-([β-L-Araf]Hyp)-OAll [2+1], with each strategy affording
chemical yields of ~35%. Coupling of a Boc-([β-L-Araf]Hyp)2-OH and H-([β-L-Araf]Hyp)2-OAll
gave the tetramer 100 in 49%.

Figure 4.20 Protected oligomers
Installation of amide end-caps on Boc-([β-L-Araf]Hyp)-OAll gave Ac-([β-L-Araf]Hyp)NHMe in 42% yield over 4 steps. Switching to a more convergent and higher yielding route, we
chose to utilize pre-endcapped glycosidic building blocks for the preparation of end-capped
oligomers. Position-specific glycosidic building blocks Ac-([β-L-Araf]Hyp)-OMe (N-terminal) and
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Boc-([β-L-Araf]Hyp)-NHMe (C-terminal) were prepared.

With this strategy, fragment

condensation of end-capped building blocks afforded dimer 104, trimer 114, and tetramer 117 in
48%, 35%, and 15% respectively. Global debenzylation of the end-capped glycopeptides gave
the four deprotected compounds in quantitative yield.

Scheme 4.3 Global debenzylation
Circular dichroism data were obtained for the synthetic glycopeptides. The monomer
spectrum showed it to be unordered as expected. Analysis of the CD spectra showed that the
glycosylated proline oligomers exhibited characteristic polyproline II helical conformation.
However, to our surprise, the dimer displayed order in its elliptical curve (λmax = 220 nm, λmin =
199 nm). The trimer (λmax = 222 nm, λmin = 203 nm) and tetramer (λmax = 220 nm, λmin = 200 nm)
both exhibited significant PPII helical conformation.
Nuclear magnetic resonance spectroscopy was used to characterize all target
glycopeptides.

1

H,

13

C, and various 2-D NMR were used to identify key resonances in the

comparison of the synthetic glycopeptides with glycoprotein isolated from the natural allergen.
In closing, the synthesis and oligomers described herein enable the further study of this
important class of compounds. Our homogeneous compounds, characterized with the rigor of
organic chemistry, lay the foundation for unambiguous biological studies that were not possible
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with the trace amount of heterogeneous material available from degradation of the native Art v 1
protein.
4.5 Future Work
The obvious next step in the project is to conduct ELISA experiments on trimer and
tetramer in varying concentrations. With the completion of the CD experiments, trimer and
tetramer are ready to be sent to Vienna. Despite reproducibility issues, the fact that monomer
and dimer have behaved similarly may suggest that the large oligomers will as well.
direction of the project thereafter will be conditional upon those results.

The

In any event, we

propose herein a plan for the continuation of the investigation of the carbohydrate epitope of Art
v 1.
4.5.1 Incorporation of the β-Ara-Hyp motif into longer pepitides
While we have synthesized the tetraproline component of the tail section of Art v 1, we
do not yet know whether or not this is optimal, vis-à-vis biological response.

While the

monomer and dimer seemed to be at least partially effective, it is possible that increasing the
length of the peptide chain may be beneficial to the activity of the glycopeptides. Table 4.3
shows the amino acid sequence of the carbohydrate domain of

Art v 1. Note that the proline

residues typically follow a serine or alanine residue. In fact, the amino acid sequence SPP is
found thrice in this sequence and SPPPP twice. The sequences APP and APPP are also
found. It is interesting as to whether or not an extended glycopeptide sequence, synthesized to
include these serine and alanine residues, and perhaps more than one glycocluster, would have
an effect on antibody binding. If so, will an even longer sequence of the tail section of Art v 1 be
worth investigating?
Table 4.3 Amino acid sequence in the polyproline domain
56-60
SPPGA

61-70
TPAPPGAAPP

71-80
PAAGGSPSPP

81-90
ADGGSPPPA
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91-100
DGGSPPVDGG

100-108
SPPPPSTH

4.5.2 Antibody generation
Glycosylated proteins have been known to have antigenic properties.114 Advances in
carbohydrate research have further illuminated their potential as vaccines.115 However, the low
immunogenicity of carbohydrate antigens continues to prove problematic. Polysaccharides are
T-cell independent, meaning they do not induce immunological memory. To this end,
carbohydrate

antigens

have

been

coupled

to

carrier

proteins

to

heighten

their

immunogenicity.116
Avery and Goebel first introduced the technique to enhance the immunogenicity of
polysaccharide antigens.117 More recently, this hapten-carrier protein conjugate strategy has
been regularly employed for bacterial carbohydrates.118

The covalent linkage of the

polysaccharide and the carrier protein has been achieved by various techniques (i.e.,
carbodiimide coupling, reductive amination, etc).119
Covalent linkages to our synthetic glycopeptides can be made by N-terminal
conjugation. The free amine will be modified for attachment via a spacer unit bearing a
carboxylic acid which permits conjugation (Figure 4.21). The glycoprotein conjugate will then be
used to raise a rabbit antiserum specific against the homogeneous, synthetic β-Ara-Hyp
epitope. Monoclonal antibodies generated using the glycoprotein conjugate can potentially be
useful in screening for cross-reactivity in other plant allergens.

Finally, the glycoprotein

conjugates can be used to determine binding affinities for rabbit and human IgG and IgE.

Figure 4.21 Proposed conjugation of synthetic glycopeptides to carrier proteins
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4.5.3 Effect of glycosylation on oligoproline conformation
The Taylor group has made fundamental contributions to conformational determinates in
proline-containing peptides.57, 120 This dissertation opens the door to studies on consecutive
proline residues as well as modified proline oligomers. Molecular dynamics studies have shown
the predominant conformation of end-capped oligoprolines to be trans,121 which indicates a PPII
helix.

Utilizing NMR and circular dichroism spectroscopy, investigation of the twelve

compounds in Table 4.4 would allow us to see the changes in their conformation with regards to
number of proline residues and degree of post-translational modification.

This would give

greater context to the results described in Section 4.14.
Table 4.4 Target oligoproline compounds

n
R

124 125 126 127
1
2
3
4
H

128 129 130 131
1
2
3
4
OH

118 119 120 1
1
2
3
4
O-β-L-Araf

4.5.4 Synthetic glycopeptides as diagnostic tools
The development of modern diagnostic tools has been paramount in the identification of
allergies.122 Two of the most commonly used screening methods are the skin prick test (SPT)
and allergy blood tests. In order to pinpoint the exact source of the allergen, investigations have
focused on identifying cross-reactive pollens of the Asteraceae family.123 Pollen from ragweed,
chrysanthemum, and dandelion may share similar epitopes (β-Ara-Hyp) with mugwort pollen.
Further related plants such as feverfew and sunflower may also contain the β-Ara-Hyp epitope
as these species all produce a homolog of Art v 1. Most notably, the allergen of ragweed, Amb
a 4, has 50% homology to Art v 1 and was found to contain small amounts of β-Ara-Hyp.31
Furthermore, natural Art v 1 was found to inhibit IgE binding of Amb a 4. In order to evaluate
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the relevance of the β-Ara-Hyp epitope, we propose that a specific anti-β-Ara-Hyp serum be
generated in order to screen a wide array of plant pollens.
4.6 Experimental Section
4.6.1 Circular dichroism spectroscopy
Sample compounds were lyophilized for 24 h prior to dilution to a concentration of 0.4
mM with water. The pH of the samples was determined at rt and found to be 6.80, 7.38, 8.79,
and 9.48 for compounds 118, 119, 120, and 1 respectively.

Circular

dichroism

measurements were carried out using a JASCO J-815 spectrometer. For analysis, 175 µL of
the sample was loaded into a quartz cell with a path length of 0.1 cm. The CD spectra were
recorded at a scan rate of 20 nm per min, data pitch of 1.0 nm, and bandwith of 2.0 nm. The
accumulation of three scans was averaged for each sample, after which a blank of the solvent
was subtracted. The CD signal was converted to molar ellipticity per mean residue ([θ]) and the
data was smoothed by application of the Savitzky-Golay algorithm.
4.6.2 NMR spectroscopy
NMR spectra were obtained using a Bruker AV-400 or Varian 700 MHz spectrometer.
Proton NMR data is reported in ppm downfield from TMS as an internal standard. Disodium 3trimethylsilyl-1-propane-sulfonate (DSS) was used to reference 1H NMR spectra run in D2O.
Minor rotational isomers are reported in parentheses when significant amount exist.

155

REFERENCES
1.
Timmer, M. S. M.; Stocker, B. L.; Seeberger, P. H., Probing glycomics. Current Opinion
in Chemical Biology 2007, 11, 59-65.
2.
Sairam, M. R., Role of carbohydrates in glycoprotein hormone signal transduction.
Faseb Journal 1989, 3, 1915-1926.
3.
Avci, F. Y.; Kasper, D. L., How bacterial carbohydrates influence the adaptive immune
system. Annual Review of Immunology, Vol 28 2010, 28, 107-130.
4.
Bishop, J. R.; Schuksz, M.; Esko, J. D., Heparan sulphate proteoglycans fine-tune
mammalian physiology. Nature 2007, 446, 1030-1037.
5.
(a) Zachara, N. E.; Hart, G. W., Cell signaling, the essential role of O-GlcNAc!
Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 2006, 1761, 599-617; (b)
Love, D. C.; Hanover, J. A., The hexosamine signaling pathway: deciphering the "O-GlcNAc
code". Sci STKE 2005, 2005, re13.
6.
Hart, G. W.; Housley, M. P.; Slawson, C., Cycling of O-linked beta-N-acetylglucosamine
on nucleocytoplasmic proteins. Nature 2007, 446, 1017-1022.
7.
Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Hart, G. W.; Gong, C. X., O-GlcNAcylation regulates
phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proceedings of the
National Academy of Sciences of the United States of America 2004, 101, 10804-10809.
8.
Oppenheimer, S. B.; Alvarez, M.; Nnoli, J., Carbohydrate-based experimental
therapeutics for cancer, HIV/AIDS and other diseases. Acta Histochemica 2008, 110, 6-13.
9.
Helling, F.; Shang, A.; Calves, M.; Zhang, S. L.; Ren, S. L.; Yu, R. K.; Oettgen, H. F.;
Livingston, P. O., G(D3) Vaccines for melanoma - superior immunogenicity of Keyhole Limpet
Hemocyanin conjugate vaccines. Cancer Research 1994, 54, 197-203.
10.
Ada, G.; Isaacs, D., Carbohydrate-protein conjugate vaccines. Clin Microbiol Infec 2003,
9, 79-85.
11.
Seeberger, P. H.; Werz, D. B., Synthesis and medical applications of oligosaccharides.
Nature 2007, 446, 1046-1051.
12.

World malaria situation 1990. World health statistics quarterly 1992, 45, 257-266.

13.
Schofield, L.; Hewitt, M. C.; Evans, K.; Siomos, M. A.; Seeberger, P. H., Synthetic GPI
as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418, 785-789.
14.
Lamport, D. T. A.; Clark, L., The isolation and partial characterization of hydroxyprolinerich glycopeptides obtained by enzymic degradation of primary cell walls. Biochemistry-Us
1969, 8, 1155-1163.
15.
Sommer-Knudsen, J.; Bacic, A.; Clarke, A. E., Hydroxyproline-rich plant glycoproteins.
Phytochemistry 1998, 47, 483-497.
156

16.
Deepak, S.; Shailasree, S.; Kini, R. K.; Muck, A.; Mithofer, A.; Shetty, S. H.,
Hydroxyproline-rich Glycoproteins and Plant Defence. Journal of Phytopathology 2010, 158,
585-593.
17.
Himly, M.; Jahn-Schmid, B.; Dedic, A.; Kelemen, P.; Wopfner, N.; Altmann, F.; van Ree,
R.; Briza, P.; Richter, K.; Ebner, C.; Ferreira, F., Art v 1, the major allergen of mugwort pollen, is
a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB 2002, 16,
106-108.
18.
Spieksma, F. T. M.; Charpin, H.; Nolard, N.; Stix, E., City Spore Concentrations in the
European Economic-Community (Eec) .4. Summer Weed Pollen(Rumex, Plantago,
Chenopodiaceae, Artemisia), 1976 and 1977. Clinical Allergy 1980, 10, 319-329.
19.
Beasley, R.; Keil, U.; von Mutius, E.; Pearce, N.; Ait-Khaled, N.; Anabwani, G.;
Anderson, H. R.; Asher, M. I.; Bjorkstein, B.; Burr, M. L.; Clayton, T. O.; Crane, J.; Ellwood, P.;
Lai, C. K. W.; Mallol, J.; Martinez, F. D.; Mitchell, E. A.; Montefort, S.; Robertson, C. F.; Shah, J.
R.; Sibbald, B.; Stewart, A. W.; Strachan, D. P.; Weiland, S. K.; Williams, H. C.; Childhood, I. S.
A. A., Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and
atopic eczema: ISAAC. Lancet 1998, 351, 1225-1232.
20.
Gadermaier, G.; Jahn-Schmid, B.; Vogel, L.; Egger, M.; Himly, M.; Briza, P.; Ebner, C.;
Vieths, S.; Bohle, B.; Ferreira, F., Targeting the cysteine-stabilized fold of Art v 1 for
immunotherapy of Artemisia pollen allergy. Molecular Immunology 2010, 47, 1292-1298.
21.
Razzera, G.; Gadermaier, G.; de Paula, V.; Almeida, M. S.; Egger, M.; Jahn-Schmid, B.;
Almeida, F. C. L.; Ferreira, F.; Valente, A. P., Mapping the interactions between a major pollen
allergen and human IgE antibodies. Structure 2010, 18, 1011-1021.
22.
Leonard, R.; Petersen, B. O.; Himly, M.; Kaar, W.; Wopfner, N.; Kolarich, D.; van Ree,
R.; Ebner, C.; Duus, J. O.; Ferreira, F.; Altmann, F., Two novel types of O-glycans on the
mugwort pollen allergen Art v 1 and their role in antibody binding. J Biol Chem 2005, 280, 79327940.
23.
Clarke, A. E.; Anderson, R. L.; Stone, B. A., Form and function of arabinogalactans and
arabinogalactan-proteins. Phytochemistry 1979, 18, 521-540.
24.
Anderson, R. L.; Clarke, A. E.; Jermyn, M. A.; Knox, R. B.; Stone, B. A., Carbohydratebinding arabinogalactan-protein from liquid suspension cultures of endosperm from Lollium
multiflorum Australian Journal of Plant Physiology 1977, 4, 143-158.
25.
(a) Anderson, M. A.; Sandrin, M. S.; Clarke, A. E., A High proportion of hybridomas
raised to a plant extract secrete antibody to arabinose or galactose. Plant Physiology 1984, 75,
1013-1016; (b) Willats, W. G. T.; Marcus, S. E.; Knox, J. P., Generation of a monoclonal
antibody specific to (1→5)-α-l-arabinan. Carbohyd Res 1998, 308 (1–2), 149-152.
26.
(a) Haavik, S.; Paulsen, B. S.; Wold, J. K., Glycoprotein allergens in pollen of Timothy 4.
Structural studies of a basic glycoprotein allergen. International Archives of Allergy and Applied
Immunology 1987, 83, 225-230; (b) Haavik, S.; Paulsen, B. S.; Wold, J. K., Glycoprotein
allergens in pollen of Timothy 5. Significance of the carbohydrate moiety for the immunological
activity of a basic glycoprotein allergen. International Archives of Allergy and Applied
Immunology 1987, 83, 231-237.
157

27.
Oberhuber, C.; Ma, Y.; Wopfner, N.; Gadermaier, G.; Dedic, A.; Niggemann, B.;
Maderegger, B.; Gruber, P.; Ferreira, F.; Scheiner, O.; Hoffmann-Sommergruber, K.,
Prevalence of IgE-binding to Art v1, Art v4 and Amb a1 in mugwort-allergic patients.
International Archives of Allergy and Immunology 2008, 145, 94-101.
28.
Jahn-Schmid, B.; Kelemen, P.; Himly, M.; Bohle, B.; Fischer, G.; Ferreira, F.; Ebner, C.,
The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope.
Journal of Immunology 2002, 169, 6005-6011.
29.
Jahn-Schmid, B.; Fischer, G. F.; Bohle, B.; Fae, I.; Gadermaier, G.; Dedic, A.; Ferreira,
F.; Ebner, C., Antigen presentation of the immunodominant T-cell epitope of the major mugwort
pollen allergen, Art v 1, is associated with the expression of HLA-DRB1*01. Journal of Allergy
and Clinical Immunology 2005, 115, 399-404.
30.
Schmid-Grendelmeier, P.; Holzmann, D.; Himly, M.; Weichel, M.; Tresch, S.; Ruckert, B.;
Menz, G.; Ferreira, F.; Blaser, K.; Wuthrich, B.; Crameri, R., Native Art v 1 and recombinant Art
v 1 are able to induce humoral and T cell-mediated in vitro and in vivo responses in mugwort
allergy. Journal of Allergy and Clinical Immunology 2003, 111, 1328-1336.
31.
Leonard, R.; Wopfner, N.; Pabst, M.; Stadlmann, J.; Petersen, B. O.; Duus, J. O.; Himly,
M.; Radauer, C.; Gadermaier, G.; Razzazi-Fazeli, E.; Ferreira, F.; Altmann, F., A new allergen
from ragweed (Ambrosia artemisiifolia) with homology to Art v 1 from mugwort. Journal of
Biological Chemistry 2010, 285, 27192-27200.
32.
Ohyama, K.; Shinohara, H.; Ogawa-Ohnishi, M.; Matsubayashi, Y., A glycopeptide
regulating stem cell fate in Arabidopsis thaliana. Nature Chemical Biology 2009, 5, 578-580.
33.
Fletcher, J. C.; Meyerowitz, E. M., Cell signaling within the shoot meristem. Current
Opinion in Plant Biology 2000, 3, 23-30.
34.
Shinohara, H.; Matsubayashi, Y., Chemical synthesis of Arabidopsis CLV3 glycopeptide
reveals the impact of hydroxyproline arabinosylation on peptide conformation and activity. Plant
and Cell Physiology 2013, 54, 369-374.
35.
Chatterjee, D., The mycobacterial cell wall: structure, biosynthesis and sites of drug
action. Curr. Opn. Chem. Biol. 1997, 1, 579-588.
36.
(a) Wende, G.; Fry, S. C., 2-O-beta-D-xylopyranosyl-(5-O-feruloyl)-L-arabinose, a
widespread component of grass cell walls. Phytochemistry 1997, 44, 1019-1030; (b) Montes, R.
A. C.; Ranocha, P.; Martinez, Y.; Minic, Z.; Jouanin, L.; Marquis, M.; Saulnier, L.; Fulton, L. M.;
Cobbett, C. S.; Bitton, F.; Renou, J. P.; Jauneau, A.; Goffner, D., Cell wall modifications in
Arabidopsis plants with altered alpha-L-arabinofuranosidase activity. Plant Physiology 2008,
147, 63-77.
37.
Lowary, T. L., Synthesis and conformational analysis of arabinofuranosides,
galactofuranosides and fructofuranosides. Curr. Opn. Chem. Biol. 2003, 7, 749-756.
38.
Taylor, C. M.; Weir, C. A.; Jorgensen, C. G., Synthesis of D-galactopyranosides of trans4-hydroxy-L-proline utilizing the sulfoxide glycosylation method. Australian Journal of Chemistry
2002, 55, 135-140.
158

39.
Ellervik, U.; Magnusson, G., Anomeric Effect in Furanosides. Experimental Evidence
from Conformationally Restricted Compounds. J. Am. Chem. Soc. 1994, 116, 2340-2347.
40.
Houseknecht, J. B.; Lowary, T. L.; Hadad, C. M., Improved Karplus equations for
3JC1,H4 in aldopentofuranosides: Application to the conformational preferences of the methyl
aldopentofuranosides. Journal of Physical Chemistry A 2003, 107, 372-378.
41.
Glaudemans, C. P. J.; Fletcher, H. G. J., Syntheses with partially benzylated sugars. III.
A simple pathway to a cis-nucleoside, 9-beta-D-arabinofuranosyladenine (Spongoadenosine).
Journal of Organic Chemistry 1963, 28, 3004-3006.
42.
Glaudemans, C. P. J.; Fletcher, H. G. J., The methanolysis of some D-arabinofuranosyl
halides having a nonparticipating group at carbon 2. Journal of the American Chemical Society
1965, 87, 2456-2461.
43.
Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraserreid, B., Armed and Disarmed NPentenyl Glycosides in Saccharide Couplings Leading to Oligosaccharides. J. Am. Chem. Soc.
1988, 110 (16), 5583-5584.
44.
Glaudemans, C. P. J.; Fletcher, H. G. J., Long-range effects of acyl groups in solvolysis
of glycofuranosyl halides . synthesis of 2,3-di-O-benzyl-5-O-P-nitrobenzoyl-alpha-Darabinofuranosyl chloride and of 2-O-benzyl-3,5-di-O-P-nitrobenzoyl-alpha-D-arabinofuranosyl
chloride. Journal of the American Chemical Society 1965, 87, 4636-4641.
45.
(a) Sanchez, S.; Bamhaoud, T.; Prandi, J., A comprehensive glycosylation system for
the elaboration of oilgoarabinofuranosides. Tetrahedron Lett 2000, 41, 7447-7452; (b)
Bamhaoud, T.; Sanchez, S.; Prandi, J., 1,2,5-ortho esters of D-arabinose as versatile
arabinofuranosidic building blocks. Concise synthesis of the tetrasaccharidic cap of the
lipoarabinomannan of Mycobacterium tuberculosis. Chemical Communications (Cambridge,
United Kingdom) 2000, 659-660.
46.
(a) Gadikota, R. R.; Callam, C. S.; Lowary, T. L., Stereocontrolled synthesis of 2,3anhydro-beta-D-lyxofuranosyl glycosides. Org. Lett. 2001, 3, 607-610; (b) Gadikota, R. R.;
Callam, C. S.; Wagner, T.; Del Fraino, B.; Lowary, T. L., 2,3-anhydro sugars in glycoside bond
synthesis. Highly stereoselective syntheses of oligosaccharides containing alpha- and betaarabinofuranosyl linkages. J. Am. Chem. Soc. 2003, 125, 4155-4165; (c) Callam, C. S.;
Gadikota, R. R.; Krein, D. M.; Lowary, T. L., 2,3-anhydrosugars in glycoside bond synthesis.
NMR and computational investigations into the mechanism of glycosylations with 2,3anhydrofuranosyl glycosyl sulfoxides. Journal of the American Chemical Society 2003, 125,
13112-13119.
47.
Zhu, X.; Kawatkar, S.; Rao, Y.; Boons, G. J., Practical approach for the stereoselective
introduction of beta-arabinofuranosides. Journal of the American Chemical Society 2006, 128,
11948-11957.
48.
(a) Crich, D.; Sun, S. X., Formation of beta-mannopyranosides of primary alcohols using
the sulfoxide method. J. Org. chem. 1996, 61, 4506-4507; (b) Crich, D.; Sun, S. X., Direct
chemical synthesis of beta-mannopyranosides and other glycosides via glycosyl triflates.
Tetrahedron 1998, 54, 8321-8348.

159

49.
Crich, D.; Pedersen, C. M.; Bowers, A. A.; Wink, D. J., On the use of 3,5-O-benzylidene
and 3,5-O-(di-tert-butylsilylene)-2-O-benzylarabinothiofuranosides and their sulfoxides as
glycosyl donors for the synthesis of beta-arabinofuranosides: Importance of the activation
method. J. Org. Chem. 2007, 72, 1553-1565.
50.
Crich, D.; Li, H., Direct stereoselective synthesis of beta-thiomannoside. J. Org. Chem.
2000, 65, 801-805.
51.
Crich, D.; Lim, L. B. L., Glycosylation with sulfoxides and sulfinates as donors or
promoters. Org. React. 2004, (64).
52.
Nacario, R. C.; Lowary, T. L.; McDonald, R., p-Tolyl 2-O-benzyl-3,5-O-(di-tertbutylsilanediyl)-1-thio-alpha-D-arabinofuranoside. Acta Crystallographica Section E-Structure
Reports Online 2007, 63, O498-O500.
53.
Wang, Y. X.; Maguire-Boyle, S.; Dere, R. T.; Zhu, X., Synthesis of beta-Darabinofuranosides: stereochemical differentiation between D- and L-enantiomers. Carbohyd
Res 2008, 343, 3100-3106.
54.
Guthrie, R. D.; Smith, S. C., An Improved Preparation of 1,2,3,5-Tetra-O-Acetyl-Beta-DRibofuranose. Chemistry & Industry 1968, 547-548.
55.
Kam, B. L.; Barascut, J. L.; Imbach, J. L., General Method of Synthesis and Isolation,
and an Nmr-Spectroscopic Study, of "Tetra-O-Acetyl-D-Aldopentofuranoses. Carbohydr Res
1979, 69, 135-142.
56.
Friedrich-Bochnitschek, S.; Waldmann, H.; Kunz, H., Allyl esters as carboxy protecting
groups in the synthesis of O-glycopeptides. J. Org. Chem. 1989, 54, 751-756.
57.
Taylor, C. M.; Hardre, R.; Edwards, P. J. B., The impact of pyrrolidine hydroxylation on
the conformation of proline-containing peptides. J. Org. Chem. 2005, 70, 1306-1315.
58.
Alabugin, I. V.; Zeidan, T. A., Stereoelectronic Effects and General Trends in
Hyperconjugative Acceptor Ability of σ Bonds. J. Am. Chem. Soc. 2002, 124, 3175-3185.
59.
Kahne, D.; Walker, S.; Cheng, Y.; Vanengen, D., Glycosylation of Unreactive
Substrates. J. Am. Chem. Soc. 1989, 111, 6881-6882.
60.
Ishiwata, A.; Munemura, Y.; Ito, Y., NAP ether mediated intramolecular aglycon delivery:
A unified strategy for 1,2-cis-glycosylation. Eur J Org Chem 2008, 4250-4263.
61.
Ishiwata, A.; Akao, H.; Ito, Y., Stereoselective synthesis of a fragment of mycobacterial
arabinan. Org. Lett. 2006, 8, 5525-5528.
62.
(a) D'Souza, F. W.; Lowary, T. L., The first total synthesis of a highly branched
arabinofuranosyl hexasaccharide found at the nonreducing termini of mycobacterial
arabinogalactan and lipoarabinomannan. Org. Lett. 2000, 2, 1493-1495; (b) Yin, H. F.; D'Souza,
F. W.; Lowary, T. L., Arabinofuranosides from mycobacteria: Synthesis of a highly branched
hexasaccharide and related fragments containing beta-axabinofuranosyl residues. J. Org.
Chem. 2002, 67, 892-903.
160

63.
(a) Sato, K.; Hada, N.; Takeda, T., Syntheses of new peptidic glycoclusters derived from
beta-alanine: di- and trimerized glycoclusters and glycocluster-clusters. Carbohydr Res 2006,
341, 836-845; (b) Shaikh, H. A.; Sonnichsen, F. D.; Lindhorst, T. K., Synthesis of glycocluster
peptides. Carbohydr Res 2008, 343, 1665-1674; (c) Bossu, I.; Sulc, M.; Krenek, K.; Dufour, E.;
Garcia, J.; Berthet, N.; Dumy, P.; Kren, V.; Renaudet, O., Dendri-RAFTs: a second generation
of cyclopeptide-based glycoclusters. Org Biomol Chem 2011, 9, 1948-1959.
64.
(a) Lee, R. T.; Lee, Y. C., Affinity enhancement by multivalent lectin-carbohydrate
interaction. Glycoconjugate Journal 2000, 17, 543-551; (b) Vargas-Berenguel, A.; OrtegaCaballero, F.; Casas-Solvas, J. M., Supramolecular chemistry of carbohydrate clusters with
cores having guest binding abilities. Mini-Reviews in Organic Chemistry 2007, 4, 1-14.
65.
Hollingsworth, M. A.; Swanson, B. J., Mucins in cancer: protection and control of the cell
surface. Nat Rev Cancer 2004, 4, 45-60.
66.
Braun, P.; Davies, G. M.; Price, M. R.; Williams, P. M.; Tendler, S. J. B.; Kunz, H.,
Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1.
Bioorgan Med Chem 1998, 6, 1531-1545.
67.
Braum, G.; Braun, P.; Kowalczyk, D.; Kunz, H., Enzymatic-hydrolysis of hydrophilic
esters by lipases - carboxy deblocking of peptides and glycopeptides. Tet Lett 1993, 34, 31113114.
68.
Kuduk, S. D.; Schwarz, J. B.; Chen, X. T.; Glunz, P. W.; Sames, D.; Ragupathi, G.;
Livingston, P. O.; Danishefsky, S. J., Synthetic and immunological studies on clustered modes
of mucin-related Tn and TF O-linked antigens: the preparation of a glycopeptide-based vaccine
for clinical trials against prostate cancer. Journal of the American Chemical Society 1998, 120,
12474-12485.
69.
Liu, M.; Barany, G.; Live, D., Parallel solid-phase synthesis of mucin-like glycopeptides.
Carbohyd Res 2005, 340, 2111-2122.
70.
Liu, M. A.; Borgert, A.; Barany, G.; Live, D., Conformational consequences of protein
glycosylation: preparation of O-mannosyl serine and threonine building blocks, and their
incorporation into glycopeptide sequences derived from alpha-dystroglycan. Biopolymers 2008,
90, 358-368.
71.
Owens, N. W.; Stetefeld, J.; Lattova, E.; Schweizer, F., Contiguous O-galactosylation of
4(R)-hydroxy-L-proline residues forms very stable polyproline II helices. Journal of the American
Chemical Society 2010, 132, 5036-5042.
72.
(a) Friedrichbochnitschek, S.; Waldmann, H.; Kunz, H., Allyl esters as carboxy protecting
groups in the synthesis of O-glycopeptides. Journal of Organic Chemistry 1989, 54, 751-756; (b)
Zhang, H. X.; Guibe, F.; Balavoine, G., Selective palladium-catalyzed deprotection of the allyl
and allyloxycarbonyl groups in phosphate chemistry and in the presence of propargyl and
propargyloxycarbonyl groups. Tet Lett 1988, 29, 623-626.
73.
Abdel-Magid, A. F.; Cohen, J. H.; Maryanoff, C. A.; Shah, R. D.; Villani, F. J.; Zhang, F.,
Hydrolysis of polypeptide esters with tetrabutylammonium hydroxide. Tetrahedron Lett 1998, 39,
3391-3394.
161

74.
Frerot, E.; Coste, J.; Pantaloni, A.; Dufour, M. N.; Jouin, P., Pybop and Pybrop - 2
reagents for the difficult coupling of the alpha,alpha-dialkyl amino-acid, Aib. Tetrahedron 1991,
47, 259-270.
75.
Valle, G.; Crisma, M.; Toniolo, C.; Beisswenger, R.; Rieker, A.; Jung, G., 1st observation
of a helical peptide containing a chiral residue without a preferred screw sense. Journal of the
American Chemical Society 1989, 111, 6828-6833.
76.
Schmitt, H.; Jung, G., Total synthesis of the alpha-helical eicosapeptide antibiotic
alamethicin. Liebigs Ann Chem 1985, 321-344.
77.
Castro, B.; Dormoy, J. R., Reaction of trisdimethylamino(pseudo)halophosphonium salts
with carboxylic-acids. Tetrahedron Lett 1973, 3243-3246.
78.
Carpino, L. A.; Cohen, B. J.; Stephens, K. E.; Sadataalaee, S. Y.; Tien, J. H.; Langridge,
D. C., ((9-Fluorenylmethyl)oxy)carbonyl (Fmoc) amino-acid chlorides - synthesis,
characterization, and application to the rapid synthesis of short peptide segments. Journal of
Organic Chemistry 1986, 51, 3732-3734.
79.
Carpino, L. A.; Sadataalaee, D.; Chao, H. G.; Deselms, R. H., ((9Fluorenylmethyl)oxy)carbonyl (Fmoc) amino-acid fluorides - convenient new peptide coupling
reagents applicable to the Fmoc/tert-butyl strategy for solution and solid-phase syntheses.
Journal of the American Chemical Society 1990, 112, 9651-9652.
80.
Swain, C. G.; Scott, C. B., Rates of solvolysis of some alkyl fluorides and chlorides.
Journal of the American Chemical Society 1953, 75, 246-248.
81.
Bender, M. L.; Jones, J. M., Nucleophilic reactions of morpholine with benzoyl halides.
The presence of an element effect. Journal of Organic Chemistry 1962, 27, 3771-3774.
82.
Olah, G. A.; Nojima, M.; Kerekes, I., Synthetic methods and reactions. 4. Fluorination of
carboxylic-acids with cyanuric fluoride. Synthesis-Stuttgart 1973, 487-488.
83.
Carpino, L. A.; Elfaham, A., Tetramethylfluoroformamidinium hexafluorophosphate - a
rapid-acting peptide coupling reagent for solution and solid-phase peptide-synthesis. Journal of
the American Chemical Society 1995, 117, 5401-5402.
84.
(a) Jou, G.; Gonzalez, I.; Albericio, F.; LloydWilliams, P.; Giralt, E., Total synthesis of
dehydrodidemnin B. Use of uronium and phosphonium salt coupling reagents in peptide
synthesis in solution. Journal of Organic Chemistry 1997, 62, 354-366; (b) Ehrlich, A.; Heyne, H.
U.; Winter, R.; Beyermann, M.; Haber, H.; Carpino, L. A.; Bienert, M., Cyclization of all-Lpentapeptides by means of 1-hydroxy-7-azabenzotriazole-derived uronium and phosphonium
reagents. Journal of Organic Chemistry 1996, 61, 8831-8838; (c) El Haddadi, M.; Cavelier, F.;
Vives, E.; Azmani, A.; Verducci, J.; Martinez, J., All-L-Leu-Pro-Leu-Pro: A challenging
cyclization. J Pept Sci 2000, 6, 560-570; (d) Kamenecka, T. M.; Danishefsky, S. J., Discovery
through total synthesis: A retrospective on the himastatin problem. Chem-Eur J 2001, 7, 41-63.
85.
Carpino, L. A.; Elfaham, A.; Minor, C. A.; Albericio, F., Advantageous applications of
azabenzotriazole (triazolopyridine)-based coupling reagents to solid-phase peptide-synthesis. J
Chem Soc Chem Comm 1994, 201-203.
162

86.
Carpino, L. A., 1-Hydroxy-7-azabenzotriazole - an efficient peptide coupling additive.
Journal of the American Chemical Society 1993, 115, 4397-4398.
87.
Carpino, L. A.; Imazumi, H.; El-Faham, A.; Ferrer, F. J.; Zhang, C. W.; Lee, Y. S.;
Foxman, B. M.; Henklein, P.; Hanay, C.; Mugge, C.; Wenschuh, H.; Klose, K.; Beyermann, M.;
Bienert, M., The uronium/guanidinium peptide coupling reagents: finally the true uronium salts.
Angewandte Chemie-International Edition 2002, 41, 442-445.
88.
(a) Woody, R. W.; Sreerama, N., Circular Dichroism 2000, Wiley-VCH, New York, N.Y.,
601-620; (b) Kelly, S. M.; Jess, T. J.; Price, N. C., How to study proteins by circular dichroism.
BBA-Proteins Proteomics 2005, 1751, 119-139; (c) Johnson, W. C., Analyzing protein circular
dichroism spectra for accurate secondary structures. Proteins: Structure, Function, and
Bioinformatics 1999, 35, 307-312.
89.

Cowan, P. M.; McGavin, S., Structure of Poly-L-Proline. Nature 1955, 176, 501-503.

90.
Adzhubei, A. A.; Sternberg, M. J. E., Left-handed Polyproline II Helices Commonly
Occur in Globular Proteins. Journal of Molecular Biology 1993, 229, 472-493.
91.
Bartlett, G. J.; Choudhary, A.; Raines, R. T.; Woolfson, D. N., n ->pi* Interactions in
proteins. Nature Chemical Biology 2010, 6, 615-620.
92.
Hinderaker, M. P.; Raines, R. T., An electronic effect on protein structure. Protein Sci
2003, 12, 1188-1194.
93.
Sreerama, N.; Woody, R. W., Poly(Pro)II Helices in Globular-Proteins - Identification and
Circular Dichroic Analysis. Biochemistry-Us 1994, 33, 10022-10025.
94.
Ronish, E. W.; Krimm, S., The calculated circular dichroism of polyproline II in the
polarizability approximation. Biopolymers 1974, 13, 1635-1651.
95.
Kelly, M. A.; Chellgren, B. W.; Rucker, A. L.; Troutman, J. M.; Fried, M. G.; Miller, A.-F.;
Creamer, T. P., Host−Guest Study of Left-Handed Polyproline II Helix Formation. BiochemistryUs 2001, 40, 14376-14383.
96.
Taylor, C. M.; Karunaratne, C. V.; Xie, N., Glycosides of hydroxyproline: Some recent,
unusual discoveries. Glycobiology 2012, 22, 757-767.
97.
Ferris, P. J.; Woessner, J. P.; Waffenschmidt, S.; Kilz, S.; Drees, J.; Goodenough, U.
W., Glycosylated Polyproline II Rods with Kinks as a Structural Motif in Plant HydroxyprolineRich Glycoproteins. Biochemistry-Us 2001, 40, 2978-2987.
98.
Pauling, L.; Corey, R. B., Structure of fibrous proteins of the collagen-gelatin group. Proc
Nat Acad Sci USA 1951, 37, 272-281.
99.
Dedic, A.; Gadermaier, G.; Vogel, L.; Ebner, C.; Vieths, S.; Ferreira, F.; Egger, M.,
Immune recognition of novel isoforms and domains of the mugwort pollen major allergen Art v 1.
Molecular Immunology 2009, 46, 416-421.
100. Williamson, M. P., The structure and function of proline-rich regions in protein.
Biochemical Journal 1994, 297, 249-260.
163

101. Rothe, M.; Rott, M.; Mazanek, J., Solid phase synthesis and conformation of
monodisperse high molecular weight oligo-L-prolines. Editions de l'Universite de Bruxelles:
Brussels, 1976.
102. (a) Thomas, W. A.; Williams, M. K., C-13 NUCLEAR MAGNETIC-RESONANCE
SPECTROSCOPY AND CIS-TRANS ISOMERISM IN DIPEPTIDES CONTAINING PROLINE. J
Chem Soc Chem Comm 1972, (17), 994; (b) Evans, C. A.; Rabenste.Dl, NUCLEAR
MAGNETIC-RESONANCE STUDIES OF ACID-BASE CHEMISTRY OF AMINO-ACIDS AND
PEPTIDES .2. DEPENDENCE OF ACIDITY OF C-TERMINAL CARBOXYL GROUP ON
CONFORMATION OF C-TERMINAL PEPTIDE-BOND. Journal of the American Chemical
Society 1974, 96 (23), 7312-7317; (c) Grathwohl, C.; Wüthrich, K., The X-Pro peptide bond as
an nmr probe for conformational studies of flexible linear peptides. Biopolymers 1976, 15 (10),
2025-2041; (d) Bedford, G. R.; Sadler, P. J., 13C magnetic resonance study of the ionization of
N-acetyl-dl-proline in aqueous solution. Biochimica et Biophysica Acta (BBA) - General Subjects
1974, 343, 656-662.
103. Helbecque, N.; Loucheux-Lefebvre, M. H., Critical chain length for polyproline-II
structure formation in H-Gly-(Pro)n-OH. International Journal of Peptide and Protein Research
1982, 19, 94-101.
104. Creamer, T. P., Left-handed polyproline II helix formation is (very) locally driven.
Proteins-Structure Function and Genetics 1998, 33, 218-226.
105. MacArthur, M. W.; Thornton, J. M., Influence of proline residues on protein conformation.
Journal of Molecular Biology 1991, 218, 397-412.
106. Pysh, E. S., Random phase calculation of poly-L-proline II circular dichroism.
Biopolymers 1974, 13, 1563-1571.
107. Brahmachari, S. K.; Bansal, M.; Ananthanarayanan, V. S.; Sasisekharan, V., Structural
investigations on poly(4-hydroxy-L-proline) 2. Physiochemical studies. Macromolecules 1979,
12, 23-28.
108. Naziga, E. B.; Schweizer, F.; Wetmore, S. D., Solvent Interactions Stabilize the
Polyproline II Conformation of Glycosylated Oligoprolines. Journal of Physical Chemistry B
2013, 117, 2671-2681.
109. Owens, N. W.; Lee, A.; Marat, K.; Schweizer, F., The Implications of (2S,4S)Hydroxyproline 4-O-Glycosylation for Prolyl Amide Isomerization. Chem-Eur J 2009, 15, 1064910657.
110. Imamura, A.; Lowary, T., Chemical Synthesis of Furanose Glycosides. Trends in
Glycoscience and Glycotechnology 2011, 23, 134-152.
111. Cardoso, S. M.; Silva, A. M. S.; Coimbra, M. A., Structural characterisation of the olive
pomace pectic polysaccharide arabinan side chains. Carbohydr Res 2002, 337, 917-924.
112. Deber, C. M.; Bovey, F. A.; Carver, J. P.; Blout, E. R., Nuclear magnetic resonance
evidence for cis-peptide bonds in proline oligomers. Journal of the American Chemical Society
1970, 92, 6191-6198.
164

113. Svehla, E., The influence of weed pollen glycosylation on IgG-binding. Master thesis at
the University of Natural Resources and Life Sciences Vienna, Austria 2013.
114. Lisowska, E., The role of glycosylation in protein antigenic properties. Cellular and
Molecular Life Sciences 2002, 59, 445-455.
115. Jones, C., Vaccines based on the cell surface carbohydrates of pathogenic bacteria.
Anais Da Academia Brasileira De Ciencias 2005, 77, 293-324.
116. Wilson, I. B. H.; Harthill, J. E.; Mullin, N. P.; Ashford, D. A.; Altmann, F., Core alpha 1,3fucose is a key part of the epitope recognized by antibodies reacting against plant N-linked
oligosaccharides and is present in a wide variety of plant extracts. Glycobiology 1998, 8, 651661.
117. Avery, O. T.; Goebel, W. F., Chemo-immunological studies on conjugated carbohydrate
proteins. V. Immunological specificity of an antigen prepared by combining the capsular
polysaccharide of type III pneumonococcus with foreign protein. J Exp Med 1931, 54, 437-447.
118. (a) Schneerson, R.; Barrera, O.; Sutton, A.; Robbins, J. B., Preparation, characterization,
and immunogenicity of Hemophilus-Influenzae type-B polysaccharide-protein conjugates. J Exp
Med 1980, 152, 361-376; (b) Beuvery, E. C.; Leussink, A. B.; Vandelft, R. W.; Tiesjema, R. H.;
Nagel, J., Immunoglobulin M and G antibody responses and persistence of these antibodies in
adults after vaccination with a combined meningococcal group A and group C polysaccharide
vaccine. Infection and Immunity 1982, 37, 579-585; (c) Beuvery, E. C.; Vanrossum, F.; Nagel,
J., Comparison of the induction of immunoglobulin M and G antibodies in mice with purified
pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates.
Infection and Immunity 1982, 37, 15-22.
119. (a) Gray, G. R., DIRECT COUPLING OF OLIGOSACCHARIDES TO PROTEINS AND
DERIVATIZED GELS. Archives of Biochemistry and Biophysics 1974, 163 (1), 426-428; (b)
Roy, R.; Laferriere, C. A., Michael addition as the key step in the syntheses of
sialyloligosaccharide-protein conjugates from N-acryloylated glycopyranosylamines. J Chem
Soc Chem Comm 1990, 1709-1711.
120. Taylor, C. M.; Hardré, R.; Edwards, P. J. B.; Park, J. H., Factors Affecting Conformation
in Proline-Containing Peptides. Organic Letters 2003, 5, 4413-4416.
121. (a) Kang, Y. K.; Jhon, J. S.; Park, H. S., Conformational Preferences of Proline
Oligopeptides. The Journal of Physical Chemistry B 2006, 110, 17645-17655; (b) Moradi, M.;
Babin, V.; Roland, C.; Sagui, C., A classical molecular dynamics investigation of the free energy
and structure of short polyproline conformers. Journal of Chemical Physics 2010, 133, 125104.
122. Weber, R. W., Cross-reactivity of pollen allergens: impact on allergen immunotherapy.
Annals of Allergy, Asthma & Immunology 2007, 99, 203-212.
123. Lee, Y. W.; Choi, S. Y.; Lee, E. K.; Sohn, J. H.; Park, J.-W.; Hong, C.-S., Crossallergenicity of pollens from the Compositae family: Artemisia vulgaris, Dendranthema
grandiflorum, and Taraxacum officinale. Annals of Allergy, Asthma & Immunology 2007, 99,
526-533.

165

APPENDIX: LETTERS OF PERMISSION
Figure 1.6 – Page 17

To whom it may concern,
It is the policy of the American Society for Biochemistry and Molecular Biology to allow reuse of
any material published in its journals (the Journal of Biological Chemistry, Molecular & Cellular
Proteomics and the Journal of Lipid Research) in a thesis or dissertation at no cost and with no
explicit permission needed. Please see our copyright permissions page on the journal site for more
information.
Best wishes,
Sarah Crespi
American Society for Biochemistry and Molecular Biology
11200 Rockville Pike, Rockville, MD
Suite 302
240-283-6616
JBC | MCP | JLR
Tel:

ELSEVIER LICENSE
TERMS AND CONDITIONS
Jun 12, 2013

166

Figure 1.11 – Page 13
This is a License Agreement between Ning Xie ("You") and Elsevier ("Elsevier") provided
by Copyright Clearance Center ("CCC"). The license consists of your order details, the
terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
Elsevier Limited
Supplier
The Boulevard,Langford Lane
Kidlington,Oxford,OX5 1GB,UK
Registered Company Number 1982084
Customer name
Ning Xie
Customer address
9430 Langham Dr
Baton Rouge, LA 70810
License number
3130920906580
License date
Apr 16, 2013
Licensed content publisher
Elsevier
Licensed content publication Structure
Mapping the Interactions between a Major Pollen Allergen
Licensed content title
and Human IgE Antibodies
Guilherme Razzera,Gabriele Gadermaier,Viviane de
Paula,Marcius S. Almeida,Matthias Egger,Beatrice JahnLicensed content author
Schmid,Fabio C.L. Almeida,Fatima Ferreira,Ana Paula
Valente
Licensed content date
11 August 2010
Licensed content volume
18
number
Licensed content issue
8
number
Number of pages
11
Start Page
1011
End Page
1021
Type of Use
reuse in a thesis/dissertation
Portion
figures/tables/illustrations
Number of
1
figures/tables/illustrations
Format
both print and electronic
Are you the author of this
No
Elsevier article?
Will you be translating?
No
Order reference number
167

Title of your
thesis/dissertation
Expected completion date
Estimated size (number of
pages)
Elsevier VAT number
Permissions price
VAT/Local Sales Tax
Total
Terms and Conditions

Oligomers of Beta-L-Arabinosides of Hydroxyproline:
Synthesis of the Carbohydrate Epitope of the Art v 1
Allergen
Aug 2013
150
GB 494 6272 12
0.00 USD
0.0 USD / 0.0 GBP
0.00 USD

168

Figure 2.5 – Page 26
Permission is hereby granted, on behalf of the IUCr, for you
to reproduce the material specified below, subject to the following
conditions:
1. Reproduction is intended in a primary journal, secondary journal,
CD-ROM, book or thesis.
2. The original article in which the material appeared is cited.
3. IUCr's copyright permission is indicated next to the
Figure in print. In electronic form, this acknowledgement
must be visible at the same time as the Figure, and
must be hyperlinked to the article
(http://dx.doi.org/10.1107/S1600536806054729).

With best wishes,
Gillian
--------------------------------------------------------------------------Dr Gillian Holmes (Managing Editor, Acta Crystallographica Section E)
International Union of Crystallography
5 Abbey Square, Chester, CH1 2HU, England

169

Figure 4.4 – Page 131; Figure 4.5 – Page 132

Host−Guest Study of LeftHanded Polyproline II Helix
Formation†
Author:
Melissa A. Kelly et al.
Publication: Biochemistry
Publisher: American Chemical Society
Date:
Dec 1, 2001
Copyright © 2001, American Chemical
Society
Title:

Logged in as:
Ning Xie
Account #:
3000646924

PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:







Permission is granted for your request in both print and electronic formats, and
translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate
school.
Appropriate credit for the requested material should be given as follows: "Reprinted
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright
(YEAR) American Chemical Society." Insert appropriate information in place of the
capitalized words.
One-time permission is granted only for the use specified in your request. No additional
uses are granted (such as derivative works or other editions). For any other uses, please
submit a new request.

If credit is given to another source for the material you requested, permission must be obtained
from that source.

170

Figure 4.8 - Page 134

Title:

Critical chain length for
polyproline-II structure
formation in H-Gly-(Pro)n-OH
Author:
N. HELBECQUE,M.H.
LOUCHEUX-LEFEBVRE
Publication: Chemical Biology & Drug
Design
Publisher: John Wiley and Sons
Date:
Jan 12, 2009
© 1982 Munksgaard International
Publishers Ltd.

Logged in as:
Ning Xie
Account #:
3000646924

Order Completed
Thank you very much for your order.
This is a License Agreement between Ning Xie ("You") and John Wiley and Sons ("John Wiley
and Sons"). The license consists of your order details, the terms and conditions provided by John
Wiley and Sons, and the payment terms and conditions.
Get the printable license.
License Number
3166670470667
License date
Jun 12, 2013
Licensed content publisher
John Wiley and Sons
Licensed content publication
Chemical Biology & Drug Design
Critical chain length for polyproline-II structure formation in
Licensed content title
H-Gly-(Pro)n-OH
Licensed copyright line
© 1982 Munksgaard International Publishers Ltd.
Licensed content author
N. HELBECQUE,M.H. LOUCHEUX-LEFEBVRE
Licensed content date
Jan 12, 2009
Start page
94
End page
101
Type of use
Dissertation/Thesis
Requestor type
University/Academic
Format
Print and electronic
Portion
Figure/table
Number of figures/tables
1
Original Wiley figure/table
Figure 2
number(s)
Will you be translating?
No
Total
0.00 USD
171

Figure 4.9 – Page 135

Title:

Contiguous O-Galactosylation
of 4(R)-Hydroxy-l-proline
Residues Forms Very Stable
Polyproline II Helices
Author:
Neil W. Owens, Jörg Stetefeld,
Erika Lattová, and Frank
Schweizer
Publication: Journal of the American
Chemical Society
Publisher: American Chemical Society
Date:
Apr 1, 2010
Copyright © 2010, American Chemical
Society

Logged in as:
Ning Xie
Account #:
3000646924

PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:







Permission is granted for your request in both print and electronic formats, and
translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate
school.
Appropriate credit for the requested material should be given as follows: "Reprinted
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright
(YEAR) American Chemical Society." Insert appropriate information in place of the
capitalized words.
One-time permission is granted only for the use specified in your request. No additional
uses are granted (such as derivative works or other editions). For any other uses, please
submit a new request.

If credit is given to another source for the material you requested, permission must be obtained
from that source.

172

VITA

Ning Xie was born in Yangzhou, China, where he lived and attended school up until the
3rd grade. Two months before his 8th birthday, Ning came to Baton Rouge, Louisiana, to join his
father, who was currently a doctoral candidate at Louisiana State University under Professor
Milton C. Rush, and mother. He would live in Baton Rouge for the better part of his life, along
with a short stint in Crowley, Louisiana.
Ning Xie received his Bachelor of Science degree in Chemistry in 2007 from LSU. He
performed organic chemistry experiments as an undergraduate in the laboratory of Professor
Robert Hammer where he first conducted peptide chemistry. In the fall of 2007, Ning was
accepted into the doctoral program in the chemistry department at LSU where he is currently a
doctoral candidate in organic chemistry working under the tutelage of Professor Carol M. Taylor.
His graduate dissertation work involved the synthesis of oligomers of arabinosylated
hydroxyproline and the investigation of their allergenic potential. Ning is a member of the
American Chemical Society.

173

